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Motivational symptoms such as fatigue, anergia, and amotivation are seen in depression,
Parkinson’s disease, schizophrenia, and other disorders. These symptoms are often left untreated
by the most frequently prescribed antidepressants, which typically block serotonin transport.
Considerable evidence implicates brain dopamine (DA) in the regulation of behavioral activation
and effort-related aspects of motivation. Animal studies of effort-based choice are being used to
provide formal models of motivational dysfunctions in humans. Drugs that block DA transport
(DAT) are able to reverse the effort-related effects of the vesicular monoamine transport
inhibitor tetrabenazine, a drug that blocks DA storage and depletes DA. Many of the existing
DAT inhibitor drugs are either classic DA blockers such as cocaine, or drugs that also stimulate
release of DA. These drugs can produce a number of undesirable side effects, including
psychotic symptoms and abuse liability. Thus, there is a need to develop and characterize novel
atypical DAT inhibitors that are relatively selective and have unique binding profiles. The
completed studies discussed here focus on the behavioral and neurochemical characterization of
several recently synthesized atypical DAT inhibitors, with the aim of identifying a novel family
of drugs that may be useful for the treatment of motivational dysfunctions in humans, and the
development of physiological markers of the selection of high-effort instrumental behavior. In
recent years, human imaging and neurophysiological studies have had sought to identify the
neural processes involved in motivation, psychomotor retardation, anergia, and lassitude in
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depression and other disorders. Human studies have suggested that there is frontal
electroencephalography (EEG) asymmetry in depressed patients, but physiological correlates of
effort-related motivational dysfunction have not been identified in animals. To complement the
investigation of effort-related impairments using pharmacological approaches, the final
experiment involved the measurement of frontal cortex EEG activity of animals under
pharmacological manipulation of DA transmission. Ultimately, the development of a
physiological marker of effort-related dysfunction in a preclinical model may be critical for
identifying the brain circuits involved in regulating these behaviors that can be readily translated
to human studies. Together, results from these experiments may contribute to the identification
of novel treatment options for motivational dysfunctions.
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Chapter 1: Background
Role of Dopamine (DA) in Motivated Behaviors
Motivation has been defined as the process that allows organisms to regulate their
internal and external environment, and control the probability, proximity, and availability of
stimuli (Salamone et al. 2017). On a day to day basis, organisms continually make effort-related
decisions based upon cost/benefit analyses of reinforcement preference vs. response costs such
as effort requirements. Central dopamine (DA) has been identified as a significant regulator of
motivated behaviors in both animal and human studies. Behavioral paradigms such as the Tmaze barrier and operant lever pressing tasks have been designed in order to measure effortrelated decision making in rodents. These tasks are useful for assessing the activational aspects
of motivation, described as the speed, vigor, and persistence of motivated behavior (Salamone
and Correa 2002; Salamone et al. 2016a), and for characterizing how those functions can be
manipulated under different experimental conditions, such as depletion or antagonism of DA.
Behavioral activation in these tasks is regularly driven by incentives and cost/benefit strategies
that assess the perceived benefits to be gained by exerting effort to obtain a highly valued
stimulus. When DA transmission is reduced, the typical patterns of behavior are altered, and
animals tend to select options with lower physical effort requirements. It has been suggested that
these behavioral effects resemble symptoms associated with human depression such as anergia
and fatigue (Salamone et al. 2016a).
Considerable evidence supports the role of DA in modulating the exertion of effort in
rodents performing instrumental actions. For instance, interference with ventral striatal (i.e.,
accumbens) DA transmission preferentially affects high-effort instrumental activities elicited or
supported by conditioned stimuli, whereas consummatory behaviors, low-effort instrumental
1

behaviors, and reinforcer preference remain intact (Aberman and Salamone 1999; Salamone and
Correa, 2012). Drugs that can reliably reverse the low-effort bias induced by DA antagonists or
depletions, such as DA transport (DAT) inhibitors, act to increase extracellular DA in the
nucleus accumbens, which supports the notion that mesolimbic DA plays a direct role in
activational or effort-related aspects of motivated behaviors.

Motivational Aspects of Depression
Major depressive disorder (MDD) is a psychiatric illness that affects over 300 million
people worldwide (WHO, 2018). This number has increased steadily over the past several
decades, and has been accompanied by a dramatic increase in the number of antidepressants that
are being prescribed. The most widely recognized symptoms of major depression are emotional
and cognitive in nature, but patients also exhibit lassitude, lack of self-reported energy, fatigue,
psychomotor retardation, and motivational dysfunction (Stahl, 2006; Treadway and Zald, 2011;
Fava et al. 2014; Salamone et al. 2016a), which are often the most difficult symptoms to treat.
The most commonly prescribed medications for MDD are selective serotonin reuptake inhibitors
(SSRIs), which tend to improve mood and reduce rumination and anxiety, but have little to no
effect on symptoms of motivational dysfunction and fatigue (Papakostas et al., 2006; Pae et al.,
2007; Cooper et al., 2014; Fava et al., 2014; Rothschild et al., 2014). Thus, these symptoms are
often left untreated and can be severely debilitating.
Patients with depression, as well as Parkinson’s disease and schizophrenia, show a loweffort bias when tested on effort-related choice procedures (Treadway et al. 2012; Yang et al.
2014; Chong et al. 2016; Barch et al. 2017), and it has been shown that the risk of depression in
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individuals who report fatigue is two-fold greater compared to non-fatigued individuals (Corfield
et al. 2016). These symptoms that involve amotivation and reductions in exertion of physical
effort are commonly accompanied by elevated levels of pro-inflammatory cytokines such as IL6, IL-1β, IFN-alpha, and TFN-α (Raison et al., 2006; Dantzer et al., 2008; Dowlati et al. 2010;
Cattaneo et al. 2013), and several of these cytokines are upregulated as a result of exposure to
chronic stress in animals (Miller et al. 2009; Lopresti et al. 2012). Rodent studies of effort-based
choice have paralleled results from human research on motivational dysfunction, underlining
their utility as animal models useful in determining possible treatment strategies for these
symptoms (Dantzer et al. 2008; Nunes et al. 2014; Yohn et al. 2016b,d). These rodent studies
focusing on modeling of effort-related motivation symptoms are consistent with the NIMH
Research Domain Criteria (RDoC) approach, which emphasizes the importance of characterizing
the neural processes that underlie the development of specific psychiatric symptoms.

Pharmacological Models of Fatigue and Anergia in Rats
Pharmacological agents that reduce DA transmission are used to treat symptoms of
disorders such as schizophrenia and Huntington’s disease, however, they have been shown to
produce several undesirable side effects. For example, chronic treatment with DA antagonists
such as haloperidol and other first-generation antipsychotics in schizophrenic patients is
generally unsuccessful at treating negative symptoms such as lack of energy, fatigue, and
amotivation (Harvey et al. 2016). In fact, drugs such as haloperidol can induce negative
symptoms in healthy volunteers (Artaloytia et al. 2006). In addition, it has been reported that
Huntington’s disease patients treated with tetrabenazine (TBZ), a VMAT-2 inhibitor which
depletes brain DA, tend to exhibit depressive symptoms including fatigue (Frank 2009, 2010;
3

Guay, 2010; Chen et al. 2012). When animals are administered TBZ in tasks measuring effortrelated choice, high-effort baseline behavior is shifted towards a low-effort bias (Nunes et al.
2013; Randall et al. 2012, 2014; Yohn et al. 2015a,b). These effects are not dependent upon
changes in food intake or preference, or discrimination of reinforcement magnitude, and do not
resemble the effects of reinforcer devaluation or appetite suppressant drugs (Nunes et al. 2013;
Yohn et al. 2015b; Randall et al. 2012, 2014). Rodent studies have also shown that a low-effort
bias can be induced by inflammatory challenges (Nunes et al. 2014; Yohn et al. 2016d). The
most commonly prescribed antidepressants, which inhibit the transport of serotonin (SSRIs or
SERT inhibitors), do not reverse the effects of TBZ when co-administered, and actually tend to
worsen them (Yohn et al. 2016a,b). However, administration of DAT inhibitors such as
bupropion, GBR12909, lisdexamfetamine, and methylphenidate are able to reverse the effects of
TBZ (Nunes et al. 2013, Yohn et al. 2016a,b; Salamone et al. 2016b) and of pro-inflammatory
cytokines (Yohn et al. 2016c). These findings emphasize the need to identify and characterize a
group of atypical DAT inhibitor compounds that are able to reverse the effects of DA
antagonists/depletions or pro-inflammatory cytokines.

Classical vs. Atypical Dopamine Transport Inhibitors
Several drugs that inhibit DA uptake, such as bupropion, amphetamines,
methylphenidate, and modafinil, have demonstrated the ability to partially reverse motivational
dysfunctions in human studies of depression and other psychiatric disorders (Stotz et al. 1999;
Hanna et al. 2006; Pae et al. 2007; Papakostas et al. 2006; Cooper et al., 2014). However, many
of the existing drugs that are labeled as DAT inhibitors are either classical DA uptake blockers
such as cocaine, or drugs that also stimulate release of DA, which can produce undesirable side
4

effects such as psychotic symptoms and abuse liability (Wilcox et al. 2002; Todtenkopf and
Carlezon 2006; Ostlund et al. 2014; Dong et al. 2017). Psychomotor stimulants such as
amphetamines and cocaine are categorized as “classical” DAT inhibitors due to their action at
the DAT and their substantial effects on extracellular DA levels (Ferris et al. 2011; Schmitt et al.
2013; Tanda et al. 2013). When administered to rodents, both cocaine and amphetamine induce
effects associated with recreational use and abuse liability, such as place conditioning (Tanda et
al. 2013), conditioned DA release during self-administration (Phillips et al. 2003; Willuhn et al.
2010; Ostlund et al. 2014), and cue-induced craving (Dong et al. 2017). Taken together, this
evidence suggests that while yielding positive effects in some studies focusing on motivational
symptoms, there is probably a limited therapeutic utility in psychiatry for most classical DAT
inhibitors. This highlights the importance of investigating the effort-related motivational effects
of drugs that inhibit the uptake of DA, but may not be as likely to promote abuse and
dependence.
A relatively new group of DA uptake inhibitors, known as atypical DAT inhibitors, has
emerged over the last several years as a class of drugs that demonstrate distinct binding
characteristics and different behavioral profiles from classical DAT inhibitors. These compounds
are neither classified as cocaine-like DAT inhibitors nor amphetamine-like substrates and
releasing agents due to their unique binding site and subsequent functional changes within the
cell, resulting in a lack of cocaine-like subjective effects that result from binding (Schmitt et al.
2008; Schmitt et al. 2013; Kohut et al. 2014). The behavioral assessment of atypical DAT
inhibitors such as benztropine, modafinil, and vanoxerine (GBR12909), has led to the discovery
that not all inhibitors of DA uptake show signs of abuse liability to the same extent as the
classical DAT inhibitors that are psychostimulants (Sogaard et al. 1990; Preti 2000; Woolverton

5

et al. 2001; Loland et al. 2008; Schmitt et al. 2008; Tanda et al. 2013). For example, while
modafinil inhibits DAT (Schmitt and Reith 2011), and elevates extracellular DA as measured by
microdialysis (Mereu et al. 2017) and human imaging studies (Volkow et al. 2009), this drug in
humans does not induce a powerful euphoria or ‘high’ at doses that increase motivation and
enhance task engagement (Muller et al. 2013). Some evidence indicates that modafinil binds to
the DAT with different characteristics than cocaine (Schmitt and Reith 2011). However, the
neurochemical bases for these different functional outcomes are still not completely understood.
Based upon all the studies reviewed above, it has become evident that there is a need to
develop novel therapeutic strategies to treat motivational dysfunctions in humans. In order to be
useful clinically, the behavioral and neurochemical profiles of novel drug targets need to be
elucidated. The body of literature cited above outlines a class of drugs, known as atypical DAT
inhibitors, which are currently being assessed for their ability to reverse motivational deficits
induced by DA antagonists or depletions, and by pro-inflammatory cytokine challenges.

Development of Physiological Measures of Effort-Related Aspects of Motivation
Though the neural bases of the effort-related dysfunctions in psychopathology are still
being characterized, considerable evidence indicates that the ability to exert effort and select
high-effort options is dependent upon the functional integrity of forebrain circuits that involve
mesolimbic DA inputs to nucleus accumbens, as well as the ventral pallidum, amygdala, and
prefrontal cortex (Salamone et al. 1991, 1994; 2007, 2016a,b, 2018; Walton et al. 2003; Floresco
and Ghods-Sharifi 2007; Mingote et al. 2008; Farrar et al. 2008, 2010; Winstanley and Floresco
2016). Systemic injections or local intra-accumbens infusions of drugs that block DA D1 or D2
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family receptors can induce a low-effort bias in rats tested on effort-based choice procedures
(Cousins et al. 1994; Nowend et al. 2001; Salamone et al. 2002; Sink et al. 2008; Warden et al.
2009; Nunes et al. 2010; Randall et al. 2014; Yohn et al. 2015b). While pharmacological
manipulation of neural function remains an important tool in behavioral neuroscience, advances
in molecular biology have led to the development of methods that allow for the silencing or
activation of specific types of neurons, such as optogenetics and chemogenetics. Considerable
evidence indicates that D1 and D2 receptors are predominantly localized on separate populations
of neostriatal and accumbens medium spiny projection neurons, containing different peptide
markers and distinct projection targets. Our laboratory has a long-range plan to investigate the
role of accumbens neurons that express D1 and D2 receptors in effort-related function. Based
upon circuitry models of basal ganglia, and the known signal transduction effects of stimulating
D1 and D2 receptors (Mingote et al. 2008; Salamone et al. 2010; Farrar et al. 2010; Santerre et al.
2012; Nunes et al. 2013; Pardo-Garcia et al. 2019; Carvalho Poyraz et al. 2016), it is
hypothesized that chemogenetic inactivation of accumbens neurons that express DA D 1 receptors
will induce a low effort bias similar to that induced by TBZ.
As discussed above, pharmacological conditions that induce a low-effort bias in humans
can alter effort-related choice in rats, and bias animals towards low-effort options (Salamone et
al. 2016a,b,c; Yohn et al. 2016a,b,c), and these effects can be reversed by co-administration of
several drugs that facilitate DA transmission. What is missing from this body of animal studies is
the identification of a physiological marker that can be readily translatable to human clinical
research. Recent studies have demonstrated that there are electroencephalographic (EEG)
markers of frontal cortex activity that are characteristic of engagement in motivated behavior and
anticipation of reinforcement, and that these markers are reduced in depressed people (Nelson et
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al. 2018; Gheza et al. 2019). Moreover, these effects are associated with clinically rated lassitude
in depressed individuals (Nelson et al. 2018). Generally speaking, these studies have implicated
striatal and frontal cortical processes in approach motivation and effort-based decision making,
which is consistent with animal studies in this area (Winstanley and Floresco 2016). Therefore,
there is a need to employ EEG methods to aid in the development of physiological markers
associated with altered DA transmission and effort-related dysfunction in preclinical animal
models that can be readily translated to human studies.

Present Work
The following set of experiments was undertaken to investigate the behavioral and
neurochemical evidence of motivational dysfunctions in rats, to uncover potential treatments for
the effort-related motivational symptoms of depression and other disorders. The experiments
discussed in Chapter 2 aimed to evaluate the effects of the DA D2 receptor antagonist
haloperidol, chronically administered via subdermal minipump, in rats tested on effort-related
procedures. Several experiments in this dissertation employed the vesicular monoamine transport
(VMAT-2) inhibitor tetrabenazine to induce effort-related motivational impairments in rats
(Chapters 3-6). Experiments described in Chapters 3-5 aimed to characterize the effort-related
and neurochemical effects of three recently synthesized atypical DA transport inhibitors. A
critical goal of the final experiments in this dissertation (Chapters 6-7) was to employ a novel
operant lever pressing task and EEG methods to aid in the development of physiological markers
associated with altered DA transmission and effort-related dysfunction in preclinical animal
models that can be readily translated to human studies. Appendices 1-3 provide the results from
studies involving compounds that do not act directly on DA transmission (i.e., serotonin and
8

kappa opioid receptors). Results from these studies will contribute to the development and
discovery of novel treatments for treating anergia, fatigue, and motivational symptoms of
depression, Parkinson’s disease, and other disorders.

9

Chapter 2: Evaluation of the effort-related effects of chronic administration of the DA D2
receptor antagonist haloperidol via subcutaneous minipumps.

2.1 Introduction
Motivational/psychomotor symptoms such as response slowing, apathy, fatigue, and
reduced exertion of effort are critical and debilitating features of major depressive disorder (Stahl
2002; Demyttenaere et al. 2005; Salamone et al. 2006; Treadway and Zald 2011; Fava et al.
2014). These symptoms, often classified as negative symptoms, are present in diverse psychiatric
disorders in addition to depression, including schizophrenia, Parkinson’s disease, and bipolar
disorder (Caligiuri and Ellwanger 2000; Salamone et al. 2006, 2010; Friedman et al. 2007; Horan
et al. 2015; Reddy et al. 2015; Fervaha et al. 2015; Treadway et al. 2015). Chronic treatment
with DA antagonists such as haloperidol and other first-generation antipsychotics in
schizophrenic patients is generally unsuccessful at treating negative symptoms such as lack of
energy, fatigue, and amotivation (Kelley et al. 1999; Harvey et al. 2016). In fact, drugs such as
haloperidol can induce negative symptoms in healthy volunteers (Artaloytia et al. 2006), and
thus it has been hypothesized that a subset of the most common negative symptoms might be
induced, at least partially, by chronic exposure to antipsychotic treatments.
In addition to physical symptoms of fatigue and amotivation, clinical reports indicate that
chronic exposure to antipsychotics is often associated with adverse side effects such as dystonia,
extrapyramidal symptoms, and sedation (Chouinard et al. 1993; Emsley et al. 2008; Essali et al.
2019). Drug tolerance or sensitivity have been commonly reported as effects of chronic
antipsychotic use, yet these characteristics remain difficult to predict and to regulate due to
myriad neurobiological factors (Li 2016). Treatment compliance issues are at the forefront of
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schizophrenia and other psychiatric disorders due to undesirable side effects, impaired cognition,
and/or a general lack of insight, which may ultimately lead to severe negative consequences
(Xiao et al. 2015; Bitter et al. 2015; Phan 2016). For these reasons, it has become increasingly
common for clinicians to prescribe long-acting injectable antipsychotics, including haloperidol
decanoate, which is a depot formulation of the DA D2 antagonist (Eklund and Forsman 1991;
McEvoy et al. 2014; Brissos et al. 2015). Although long-acting depot formulations eliminate
some of the medication adherence issues and decrease relapse rates (Brissos et al. 2015), the
secondary negative effects of prolonged antipsychotic delivery can be debilitating and can
severely impact daily functioning.
Fatigue and amotivation have been documented in rodents through the use of acute
administration of DA D2 antagonists in effort-related choice paradigms (Salamone et al. 1991;
Salamone and Correa 2002, 2012a); however, the effects of chronic steady-state antipsychotic
administration on effort-related processes are still unknown. Thus, assessing the behavioral
changes that take place as a result of chronic DA D2 antagonist administration in rats could
provide insight regarding the development of secondary negative symptoms and the development
of drug tolerance in schizophrenic patients (Gold et al. 2013; Fervaha et al. 2013; Barnes et al.
2013; Kring and Barch 2014; Barch et al. 2014; Reddy et al. 2015). The use of programmable
infusion pumps has allowed researchers to implement continuous and controlled drug delivery
which closely resembles long-acting and slow-release formulations of clinical drug therapies
(Abe et al. 2010; Tan et al. 2011). The studies discussed below assessed the effects of chronic
DA D2 receptor blockade via subdermal haloperidol infusions on effort-related choice behavior,
and the possible development of drug tolerance, or substantial carryover into the washout period.
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2.2 Materials and Methods
Animals
Adult male Sprague Dawley rats (Envigo Sprague Dawley, Indianapolis, IN, USA;
weights 275-299 g upon arrival) were pair-housed in a colony maintained at 23°C, with a 12-h
light/dark cycle (lights on 07:00). Rats were food deprived to 85% of their free-feeding body
weight for operant training and were fed supplemental chow as needed, allowing modest growth
throughout the experiment. Water was available ad libitum in home cages. Animal protocols
were approved by the University of Connecticut Institutional Animal Care and Use Committee,
and the studies were conducted according to National Institutes of Health (NIH) guidelines.

Behavioral Procedures
Behavioral sessions were conducted in operant chambers (28 x 23 x 23 cm3; Med
Associates, Fairfax, VT) with 30 minute sessions 5 days/week. Rats were initially trained to
lever press on a continuous reinforcement FR1 schedule (high-carbohydrate 45 mg pellets, BioServ, Frenchtown, NJ) and then shifted to the FR5 schedule. Rats in Exp 2.1 (n=15) remained on
the FR5 schedule for four to five weeks, until a stable baseline was reached. Rats in Exp 2.2
(n=17) underwent the same initial training, and after four weeks of FR5, were shifted to the
concurrent FR5/chow feeding choice procedure for up to four additional weeks. Weighed
amounts of laboratory chow (Laboratory Diet, 5P00 Prolab RMH 3000, Purina Mills, St. Louis,
MO; typically 15-20 g) were concurrently available on the floor of the chamber during the
FR5/chow feeding choice task sessions. At the end of each 30 minute session, rats were
immediately removed from the chambers, number of lever presses was recorded, and the amount
12

of chow consumed was determined by weighing the remaining food (including spillage from a
tray beneath the floor of the chamber). On baseline and drug treatment days, rats consumed all of
the operant pellets that were delivered during each session. After a stable baseline was reached
on the FR5 or FR5/chow procedure, rats in both experiments underwent a surgical procedure.

Surgeries
All rats underwent a surgical procedure for implantation of iPRECIO infusion pumps
(iPRECIO SMP-200, Alzet). Pumps were stored at 45°C for 36 h prior to the surgery in a heating
cabinet. On the day of surgery, the temperature was reduced to 37°C. Antiseptic technique was
used and all instruments were cleaned and autoclaved prior to the procedure. Anesthesia was
induced with 4-5% isoflurane in oxygen (and maintained in 2-3% isoflurane). The desired
incision site was shaved, and betadine solution was used to disinfect the shaved area. Local
analgesia (topical lidocaine) was applied at the incision site. Using a size 10 scalpel blade, a 4cm midline incision was made approximately 8 cm from the top of the head. Blunt dissection
was used, creating a pouch under the skin from the point of incision to the caudal area on the
rat’s right side, by separating the skin from the underlying tissue with hemostats. The pump was
then removed from the heating cabinet, filled with sterile 0.9% saline, and the outlet tube was cut
to 4 cm prior to being placed within the pocket. Non-absorbable nylon sutures (5-0) were used to
attach the pump to the muscle layer. A blunt scissor was used to form a small tunnel for the
outlet tube between the muscle and skin layers in the rostral direction. The tube was then sutured
to the muscle ~1 cm from the tip. The skin incision was closed using 5-0 non-absorbable suture
with 5-8 simple interrupted stitches or metal wound clips. After surgery, the rats were singlehoused for a recovery period of at least seven days.
13

Behavioral Pharmacology Experiments
These experiments assessed the effects of continuous infusion of haloperidol vs. vehicle
on performance on effort-related choice behavior. After a seven day recovery period, rats were
retrained on their respective behavioral tasks to reestablish their baseline responding rates.
Pumps were pre-programmed to initiate an infusion rate of 3 µl/hour twelve days after surgery.
As soon as animals reached stable baseline responding, pumps were filled with haloperidol (2.0
mg/ml or 1.0 mg/ml) or 0.3% tartaric acid vehicle through a subcutaneous port. Infusion of
haloperidol or vehicle occurred for four weeks, which was referred to as the ‘drug exposure’
phase, followed by a four-week ‘washout phase’. During both the drug exposure and washout
phases, behavioral testing was conducted 5 days/week (19 days of data collection in each phase).

Statistical Analysis
The data for this experiment were analyzed in SPSS using a 3 × 4 factorial analysis of
variance (ANOVA) with treatment group as the between-groups factor and week as the withingroups factor. In the case of a significant interaction, simple effects of treatment group were
assessed by computing between groups ANOVAs at each week. Dunnett’s tests using the error
term from the between-subjects analysis were used to assess differences between each drug
treatment and vehicle at each time point (weeks 1-4). A p value of <0.05 was considered
statistically significant for all analyses.
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2.3 Results
Experiment 2.1: Ability of chronic DA D2 receptor antagonism by continuous subdermal
infusion of haloperidol to suppress lever pressing on the FR5 operant procedure.
Fifteen rats were treated with one of two doses of haloperidol (1.0 mg/ml or 2.0 mg/ml)
or vehicle for four weeks and tested on the FR5 lever pressing task daily. At baseline, prior to
drug exposure, there were no significant differences in lever pressing between the three groups
according to one-way ANOVA (p=n.s.). During the drug exposure phase, repeated measures
factorial ANOVA indicated a significant overall effect of treatment group [F(2,12)=36.172,
p<0.001] and week [F(3,36)=3.434, p<0.05] on lever pressing (Figure 2.1). No week by
treatment interaction was found (p=n.s.), but a linear trend for week approached significance
[F(1,12)=3.617, p=0.08]. To make specific comparisons of the effects of each dose of
haloperidol and assess effect size of treatments on lever pressing, factorial ANOVAs were
performed comparing the vehicle vs. high dose group, and vehicle vs. low dose group. Treatment
had a significant effect on high dose group lever pressing [F(1,9)=150.137, p<0.001] with a large
effect size (ηp2 = 0.943). The low dose treatment did not have a significant effect on lever
presses [F(1,8)=4.739, p>0.05] and the effect size for this analysis was relatively low (ηp2 =
0.372).
In the washout phase, factorial ANOVA revealed a significant effect of week
[F(3,36)=18.255, p<0.001] and a significant week by treatment interaction [F(6,36)=6.073,
p<0.001], and no significant overall effect of treatment on lever pressing during the washout
phase (p=n.s.). Because of a significant week by treatment interaction, between groups overall
ANOVAs were computed at each time point and post-hoc two-tailed Dunnett’s tests were
performed to assess differences between individual groups. An overall significant difference in
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lever presses was found only at week 1 [F(2,14)=4.297, p<0.05], and a Dunnett’s test revealed a
significant difference only between the vehicle and high dose groups (p<0.05). No significant
differences in lever pressing were seen in the remaining weeks of washout. In addition, a
significant linear trend for week [F(1,12)=40.368, p<0.001], and for week by treatment
interaction [F(2,12)=11.957, p<0.001] were found during washout. Thus, in summary, the high
dose of haloperidol suppressed FR5 lever pressing, the lack of significant dose x treatment
interaction indicates that there were no substantial signs of sensitization or tolerance during
chronic drug treatment, and there was rapid return to pre-drug lever pressing during washout
(Fig. 2.1).
Experiment 2.2: Ability of chronic DA D2 receptor antagonism by continuous subdermal
infusion of haloperidol to induce motivational impairments on the FR5/chow feeding choice
procedure.
Figure 2.2 shows the effects of chronic haloperidol treatment on lever pressing and chow
intake on the FR5/chow feeding choice task in rats (n=17). During the drug exposure phase,
there was a significant overall effect of treatment on lever presses [F(2,14)=20.498, p<0.001]
(Fig. 2.2A) and chow intake [F(2,14)=18.574, p<0.001] (Fig. 2.2B), but no effect of week or
week by treatment interaction for either lever presses or chow intake (p=n.s.). As with Exp 2.1,
separate factorial ANOVAs were computed to assess the effect of treatment on lever pressing in
the vehicle vs. high dose group and vehicle vs. low dose group. Significant effects of treatment
on lever presses were found when comparing vehicle vs. high dose [F(1,9)=39.845, p<0.001; ηp2
= 0.816], and vehicle vs. low dose [F(1,7)=20.359, p<0.01; ηp2 = 0.744], with large effect sizes
between drug treatment and lever presses for both doses.
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The total number of subjects was reduced to n=7 in the washout phase. Repeated
measures ANOVA revealed a significant effect of week on lever presses [F(3,12)=11.088,
p=0.001] and chow intake [F(3,12)=8.813, p<0.01]. The week by treatment interaction
approached significance for lever presses (0.05<p<0.1), and was statistically significant for chow
intake [F(6,12)=3.194, p<0.05]. Treatment did not have a significant overall main effect on lever
presses or chow intake during the washout phase (p=n.s.).
In summary, both the low and high doses of haloperidol shifted choice behavior,
suppressing FR5 lever pressing while significantly and substantially increasing chow intake. As
seen in the FR5 alone experiment, there was a lack of significant dose x treatment interaction
during chronic drug treatment, indicating that there were no substantial signs of sensitization or
tolerance. Although the n was very low during the washout period due to the COVID shutdown,
it is evident that there was a rapid return to pre-baseline levels of lever pressing during the
washout, though the chow data were more variable (Fig. 2.2).
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2.4 Figures

Figure 2.1. The effect of chronic haloperidol (HAL) administration on lever pressing on an FR5
feeding task in rats (n=15). Mean (± SEM) number of lever presses during a 30-minute session.
**p<0.001, significant between groups effect of treatment on lever presses between HAL 2.0
mg/ml vehicle during drug exposure phase. *p<0.05, lever presses significantly differed between
HAL 2.0 mg/ml and vehicle at week 1 of washout. Dashed vertical lines represent treatment
phase transitions.
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Figure 2.2. The effect of chronic haloperidol (HAL) administration on lever pressing and chow
intake in rats (n=17) performing on an FR5/chow feeding choice task. (A) Mean (± SEM)
number of lever presses in a 30-minute session. **p<0.001, significant between groups effect of
treatment on lever presses between HAL 2.0 mg/ml and vehicle, *p<0.01 significant between
groups effect of treatment on lever presses between HAL 1.0 mg/ml and vehicle during drug
exposure phase. (B) Mean (± SEM) gram quantity of chow intake during a 30-minute session.
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**p<0.001, significant between groups effect of treatment on chow intake between HAL 2.0
mg/ml and vehicle, *p<0.01 significant between groups effect of treatment on chow intake
between HAL 1.0 mg/ml and vehicle during drug exposure phase. There was a significant effect
of week (p<0.01) and a significant week by treatment interaction (p<0.05) only during the
washout phase. Dashed vertical lines represent treatment phase transitions.
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Chapter 3: The novel atypical dopamine uptake inhibitor (S)-CE-123 partially reverses the
effort-related effects of the dopamine depleting agent tetrabenazine and increases
progressive ratio responding.
Published; Rotolo et al. 2019, Frontiers in Pharmacology

3.1 Introduction
Motivational symptoms such as fatigue, anergia, and psychomotor slowing are seen in
depression, Parkinson’s disease, and other disorders. These symptoms are often debilitating, and
can severely limit long-term functional outcomes (Demyttenaere et al. 2005; Friedman et al.
2007; Fava et al. 2014; Rothschild et al. 2014; Chong et al. 2015; Salamone et al. 2006,
2016a,b,c, 2017). Moreover, motivational symptoms can be highly resistant to treatment with
common antidepressants such as serotonin transporter (SERT) blockers (Cooper et al. 2014;
Fava et al. 2014; Rothschild et al. 2014). The catecholamine uptake inhibitor bupropion has
shown some success in treating motivational symptoms in depressed people (Papakostas et al.
2006; Pae et al. 2006; Cooper et al. 2014), and reports indicate that treatment with drugs that
inhibit dopamine transporter (DAT), such as d-amphetamine and methylphenidate, can improve
motivational function (Stotz et al. 1999). However, psychomotor stimulants that block DAT also
can have undesirable effects, such as abuse liability and induction of psychotic symptoms. For
these reasons, it is important to develop and assess drugs that are highly selective for DAT, but
show atypical neurochemical characteristics that may lower the side effect profile.
A recently synthesized and chromatographically separated analog of modafinil, (S)-CE123 (Fig. 3.1) is a highly selective atypical inhibitor of DAT which has been shown to enhance
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cognitive flexibility and reduce impulsivity in rats (Nikiforuk et al., 2017). The present paper
describes the enantioselective synthesis and initial characterization of (S)-CE-123. In addition,
(S)-CE-123 was assessed for its effects on effort-related aspects of motivation in rats. These
behavioral pharmacology studies evaluated the motivational effects of (S)-CE-123 in rats using
well characterized tests of effort-based choice behavior, the concurrent fixed ratio 5 (FR5)/chow
feeding choice task, and the concurrent progressive ratio (PROG)/chow feeding choice task.
Effort-related choice is studied using procedures that offer high effort options leading to highly
valued reinforcers vs. low effort/low reward options (Salamone and Correa 2012; Salamone et al.
2016a,b,c, 2017, 2018; Hart et al. 2017). Considerable research has implicated dopamine (DA)
transmission, particularly in nucleus accumbens core, in the regulation of effort-based choice;
animals with impaired DA transmission (i.e., DA antagonism or depletion) show a shift from the
high-effort option to the low effort option, while enhancement of DA transmission reverses those
effects (Sokolowski and Salamone 1998; Salamone et al. 2002, 2007, 2016a,b,c; Farrar et al.
2010; Mai et al. 2012; Hosking et al. 2015). It has been suggested that animal models employing
tests of effort-based decision making can be used to study functions that are related to aspects of
human motivational dysfunction (Salamone et al. 2006, 2016a,b,c, 2018). This strategy has been
validated by clinical research showing that patients with major depression, Parkinson’s disease,
and other disorders show a low-effort bias when tested on effort-related choice procedures
(Treadway et al. 2012; Yang et al. 2014; Chong et al. 2015; Barch et al. 2017).
Studies have shown that a low-effort bias can be induced in rats by several conditions
associated with depressive symptoms, including stress (Shafiei et al. 2012; Bryce and Floresco
2016), inflammatory challenge (Nunes et al. 2014; Yohn et al. 2016e), withdrawal from
methamphetamine (Hart et al. 2018), and injections of the vesicular monoamine transporter type-
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2 (VMAT-2) inhibitor tetrabenazine (TBZ; Nunes et al. 2013; Randall et al. 2014; Yohn et al.
2015a,b). TBZ induces depressive symptoms in people (Frank 2009, 2010; Guay, 2010), and has
been used in classical animal models of depression (Tadano et al., 2000; Wang et al., 2010). By
virtue of inhibiting VMAT-2, TBZ blocks DA storage, depletes brain DA, and reduces postsynaptic DA receptor signaling (Nunes et al. 2013). Across a variety of behavioral tests, TBZ
shifts choice behavior and induces a low-effort bias, and the reallocation of behavior from high
to low-effort options that is produced by TBZ is not due to alterations in food preference or
hedonic taste reactivity, reduced appetite, or impairments in reference memory (Randall et al.
2012, 2014; Nunes et al. 2013; Correa et al. 2015; Pardo et al. 2015; Yohn et al. 2015a). On
operant behavior tests that give animals the choice between lever pressing on a FR5 or PROG
schedule for a preferred food vs. approaching and consuming a less preferred lab chow (Nunes et
al. 2013; Randall et al. 2014; Yohn et al. 2016a,b,c) TBZ reliably decreases working for food by
lever pressing, but actually increases consumption of the concurrently available chow. TBZ in
this dose range does not reduce consumption of either type of food that is used in these studies,
nor does it affect preference as measured in free-feeding preference tests (Nunes et al. 2013).
Also, the effects of TBZ on operant choice procedures differ substantially from the effects of
reinforcer devaluation, as well as appetite suppressant drugs (Randall et al. 2013, 2014). These
effects of TBZ are not reversed by the SERT blockers fluoxetine and citalopram, or by the
norepinephrine transporter (NET) inhibitor desipramine (Yohn et al. 2016a,b), but they are
attenuated by several drugs that block DAT, including bupropion, GBR12909, lisdexamfetamine,
methylphenidate and modafinil (Nunes et al. 2013; Randall et al. 2014; Yohn et al. 2016a,b,c;
Salamone et al. 2016a,b). Drugs that inhibit DAT, such as bupropion, lisdexamfetamine, and
PRX-14040, also have been shown to increase the motivation to work for food reinforcers in
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more highly demanding behavioral tasks, such as the PROG/chow feeding choice task (Randall
et al. 2015; Yohn et al. 2016b,c,d). In view of these results, the present studies investigated the
ability of (S)-CE-123 to attenuate the effort-related effects of TBZ in rats tested on the
concurrent FR5/chow feeding choice task, and to enhance exertion of effort in rats assessed with
the PROG/chow feeding choice task. An additional experiment studied the effects of the
behaviorally effective dose of (S)-CE-123 (24.0 mg/kg) on extracellular DA in nucleus
accumbens using microdialysis methods.

3.2 Materials and Methods
Synthesis of (S)-CE-123
Refer to Rotolo et al. 2019 for details regarding synthesis and chemical structure (see Fig. 3.1).
Synthesis was performed by the laboratory of Dr. Gert Lubec.

In Vivo Behavioral Pharmacology
Animals:
For the behavioral pharmacology experiments, adult male Sprague Dawley rats (Envigo
Sprague Dawley, Indianapolis, IN, USA; weights 275-299 g upon arrival) were pair-housed in a
colony maintained at 23°C, with a 12-h light/dark cycle (lights on 07:00). Rats were food
deprived to 85% of their free-feeding body weight for operant training and allowed modest
growth throughout the experiment. Water was available ad libitum in the home cages. Animal
protocols were approved by the University of Connecticut Institutional Animal Care and Use
Committee, and the studies were conducted according to National Institutes of Health (NIH)
guidelines. For the in vivo microdialysis experiment, adult male Sprague Dawley rats (Harlan
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Italy; weights 275-300 g upon arrival) were used. Rats were housed 4 per cage, in standard
plastic cages with wood chip bedding, maintained at 22 ± 2 °C and 60% humidity with a 12-h
light/dark cycle (lights on 07:00). Water and standard laboratory rodent chow (Mucedola,
Settimo Milanese, Italy) were provided ad libitum in the home cage. All animal experiments
were carried out in accordance with the Guidelines for the Care and Use of Mammals in
Neuroscience and Behavioral Research according to Italian (D.L. 116/92 and 152/06) and
European Council (609/86 and 63/2010) directives and in compliance with the approved animal
policies by the Ethical Committee for Animal Experiments (CESA, University of Cagliari) and
the Italian Ministry of Health (Aut. N. 162/2016- PR). All efforts were taken to minimize pain
and suffering, and to reduce the number of animals used.

Behavioral Procedures
FR5/Chow Feding Choice Task:
Behavioral sessions were conducted in operant chambers (28 x 23 x 23 cm3; Med
Associates, Fairfax, VT) with 30 minute sessions 5 days/week. Rats were initially trained to
lever press on a continuous reinforcement FR1 schedule (high-carbohydrate 45 mg pellets, BioServ, Frenchtown, NJ) and then shifted to the FR5 schedule. After 5 weeks of training on the
FR5 schedule, chow was introduced. Weighed amounts of laboratory chow (Laboratory Diet,
5P00 Prolab RMH 3000, Purina Mills, St. Louis, MO; typically 15-20 g) were concurrently
available on the floor of the chamber during the FR5/chow feeding choice task sessions. At the
start of each session, it was confirmed that the pieces of weighed chow were larger than the
spaces between the bars that make up the floor of the chamber, so they could not fall through. At
the end of each 30 minute session, rats were immediately removed from the chambers, number
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of lever presses was recorded, and the amount of chow consumed was determined by weighing
the remaining food (including spillage from a tray beneath the floor of the chamber). Rats were
trained on the FR5/chow feeding choice procedure for 5 weeks, after which drug testing began.
On baseline and drug treatment days, rats consumed all of the operant pellets that were delivered
during each session.

PROG/Chow Feeding Choice Task:
Behavioral sessions were conducted in operant chambers with 30 minute sessions 5
days/week. Rats were initially trained to lever press on a continuous reinforcement FR1 schedule
(high-carbohydrate 45 mg pellets, Bio-Serv) and then shifted to the PROG schedule (Randall et
al. 2012, 2014, 2015). For PROG sessions, the ratio started at FR1 and was increased by 1
additional response every time 15 reinforcements were obtained (FR1×15, FR2×15, etc.). A
“time-out” feature deactivated the response lever for the rest of the session whenever 2 minutes
elapsed without a completed ratio. After 9 weeks of training on the PROG schedule, chow was
introduced. Weighed amounts of laboratory chow (Laboratory Diet, 5P00 Prolab RMH 3000,
Purina Mills; typically 15-20 g) were concurrently available on the floor of the chamber during
the PROG/chow feeding choice task sessions. At the end of each 30 minute session, rats were
immediately removed from the chambers, number of lever presses was recorded, and the amount
of chow consumed was determined by weighing the remaining food (including spillage from a
tray beneath the floor of the chamber). Rats were trained on the PROG/chow feeding choice
procedure for 5 weeks, after which drug testing began. On baseline and drug treatment days, rats
consumed all of the operant pellets that were delivered during each session.
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Drug Treatments and Dose Selection
(S)-CE-123 ((S)-5-((benzhydrylsulfinyl)methyl)thiazole) was obtained from the Lubec
Laboratory (University of Vienna, Austria) and dissolved in dimethyl sulfoxide (DMSO) (10%),
Tween 80 (15%), and 0.9% saline (75%). The DMSO/Tween 80/saline solution was
administered as the vehicle control. TBZ (9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7, 11b
hexahydrobenzo[a]quinolizin-2-one) was obtained from Tocris Bioscience (Ellisville, MO) and
was dissolved in DMSO (20%), 0.9% saline (80%), and was titrated with microliter quantities of
1.0 N HCl until the solid drug was in solution at a pH of 4.0-4.5. The DMSO/saline solution was
administered as the vehicle control. The dose of 1.0 mg/kg TBZ was based on extensive piloting
in our laboratory. The doses of (S)-CE-123 were selected based on extensive pilot studies and
information about its relative affinity for DAT.

Behavioral Pharmacology Experiments
Trained rats (n=8) were administered either TBZ (1.0 mg/kg) or vehicle, and (S)-CE-123
(6.0, 12.0, and 24.0 mg/kg) or vehicle, via intraperitoneal (IP) injections on drug testing days.
Rats received TBZ or vehicle 120 minutes before testing and (S)-CE-123 or vehicle 30 minutes
before testing. The experiment used a within-groups design, with each rat receiving each drug
treatment in a randomly varied order (one treatment per week, with none of the treatment
sequences repeated across different animals). Sample size was determined based on information
obtained from pilot studies done in our laboratory. Experimenter blinding was not necessary due
to the objective nature of the data collection. The following five treatment combinations were
given: TBZ vehicle + (S)-CE-123 vehicle; 1.0 mg/kg TBZ + (S)-CE-123 vehicle; 1/0 mg/kg TBZ
+ 6.0 mg/kg (S)-CE-123; 1.0 mg/kg TBZ + 12.0 mg/kg (S)-CE-123; 1.0 mg/kg TBZ + 24.0
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mg/kg (S)-CE-123. The endpoint of the experiment was marked by the completion of the last
scheduled drug treatments for each rat, after having received each drug treatment in a randomly
varied order.
Following the initial behavioral experiment, (S)-CE-123 was tested on a different group
of rats (n=7) to assess whether it had a behavioral effect when administered alone. Rats were
trained on the FR5/chow feeding choice task as described previously. Thirty minutes prior to the
testing session, rats were administered either vehicle or 24.0 mg/kg (S)-CE-123. One week later,
rats received either vehicle or 24.0 mg/kg (S)-CE-123 so that the treatment orders were
counterbalanced. Only the highest dose of (S)-CE-123 (24.0 mg/kg) was chosen for testing in
this paradigm.
A third behavioral experiment was conducted to determine if (S)-CE-123 had an effect on
rats’ behavior on the PROG/chow feeding choice task when administered alone. Thirty minutes
prior to the testing session, trained rats (n=15) were administered either vehicle or 6.0, 12.0, or
24.0 mg/kg (S)-CE-123. This experiment used a within-groups design, with each rat receiving
each drug treatment in a randomly varied order. Treatments were administered once per week
over the course of four weeks.

In Vivo Microdialysis
Surgery:
Male Sprague Dawley rats (275-300 g; Harlan, Italy) were anaesthetized with fentanyl
(0.06 mg/kg IP), placed in a stereotaxic apparatus, and implanted with vertical dialysis probes
prepared as previously described (De Luca et al., 2016) with 1.5 mm dialyzing portion.
According to the rat brain atlas of Paxinos and Watson (1998), unilateral probes were implanted
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in the nucleus accumbens shell (A +2.2, L +1.0 from bregma, V -7.8 from dura; n=10) or nucleus
accumbens core (A +1.4; L +1.6 from bregma, V -7.6 from dura; n=7).

Analytical Procedure:
On the day following surgery, animals were connected to an infusion pump and probes
were perfused with Ringer's solution (147 mM NaCl, 4 mM KCl, 2.2 mM CaCl2) at a constant
rate of 1 µl/min. After rinsing for at least 1 h, dialysate samples (20 µl) were collected every 20
minutes and injected into an HPLC equipped with a reverse phase column (C8 3.5 µm, Waters,
USA) and a coulometric detector (ESA, Coulochem II) to quantify DA. The electrodes of the
analytical cell were set at +125 mV (oxidation) and −175 mV (reduction) to detect dopamine.
The mobile phase composition was: 50 mM NaH2PO4, 0.1mM Na2EDTA, 0.5 mM n-octylsulfate
and 15% (v/v) methanol. The sensitivity of the assay for DA was 5 fmol/sample. When the DA
did not differ more than 10% in three consecutive samples, the average value was considered as
the basal level of DA. The animals were treated with vehicle or (S)-CE-123 24.0 mg/kg IP, and
monoamine levels were monitored for 3 h from the start of the treatment.

Histology:
At the end of the experiment, animals were sacrificed and brains were removed and
stored in formalin (8%). Brains were sliced and stained with Nissl stain for histological
examination in order to verify the correct placement of the microdialysis probes. Histology work
was performed by the laboratory of Dr. Marco Pistis.

29

Statistical Analysis
Behavioral Pharmacology Experiments:
Total number of lever presses and gram quantity of chow intake from the 30 minute
sessions were analyzed using repeated measures ANOVA. A statistical program (SPSS, Version
25) was used to perform all analyses. Since there were significant overall F values for the three
behavioral measures being used, nonorthogonal planned comparisons were performed, using the
overall error term to assess differences between each treatment and the control condition. The
number of comparisons was restricted to the number of treatments minus one (Keppel, 1991).
Statistical outliers were predefined as any point that is more than two standard deviations from
the mean. No data from this study were excluded as outliers. Microdialysis data were expressed
as percent of the last 3 baseline samples, and were analyzed by a 4 group x 12 sample factorial
analysis of variance (ANOVA) with repeated measures on the sample factor. Since there was a
significant group x sample interaction, so subsequent analysis of simple main effects examined
the effect of the sample factor for each of the 4 groups. Results from treatments showing
significant overall changes were subjected to Tukey’s tests for post hoc comparisons, with
significance at p<0.05.

3.3 Results
FR5/Chow Feeding Choice task
Figure 3.2 shows the results of the FR5/chow feeding choice experiment. TBZ shifted
effort-based choice, decreasing lever pressing and increasing chow intake. Repeated measures
ANOVA revealed that there was an overall significant effect of drug treatment on lever pressing
[F(4,28)=34.625, p<0.001] (Fig. 3.2A). Planned comparisons showed that TBZ significantly
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decreased lever pressing compared to vehicle treatment (TBZ/Veh vs. Veh/Veh [F(1,28) =
105.87, p<0.001]). There also was a significant overall effects of drug treatment on chow intake
[F(4,28)=27.280, p<0.001], and TBZ alone significantly increased chow intake relative to
vehicle treatment (TBZ/Veh vs. Veh/Veh [F(1,28) = 66.625, p<0.001]) (Fig. 3.2B). Additional
planned comparisons revealed that co-administration of the dose of 24.0 mg/kg (S)-CE-123 with
TBZ significantly attenuated the effects of TBZ on lever pressing (TBZ plus 24.0 mg/kg vs.
TBZ/Veh [F(1,28) = 13.2866, p<0.01]) and chow intake (TBZ plus 24.0 mg/kg vs. TBZ/Veh
[F(1,28) = 61.014, p<0.001]).
As shown in Figure 3, there was no effect of drug treatment relative to vehicle on lever
pressing or chow intake on the FR5/chow feeding choice task when 24.0 mg/kg (S)-CE-123 was
administered alone prior to testing. Repeated measures ANOVA indicated no significant
difference between rats treated with 24.0 mg/kg (S)-CE-123 and vehicle-treated rats on lever
pressing [F(1,6)=0.012, p=n.s.] (Fig. 3.3A) or chow intake [F(1,6)=0.030, p=n.s.] (Fig. 3.3B).

PROG/Chow Feeding Choice Task
(S)-CE-123 was tested for its behavioral effect on the PROG/chow feeding choice task
when administered alone (i.e., in the absence of TBZ). Repeated measures ANOVA revealed an
overall main effect of drug treatment on lever pressing [F(3,42)=3.165, p<0.05], and planned
comparisons demonstrated that lever presses were significantly increased at 24.0 mg/kg (S)-CE123 compared to vehicle treatment (Veh vs. 24.0 mg/kg (S)-CE-123 [F(1,42)=4.061, p<0.05]
(Fig. 4.4A). Drug treatment with (S)-CE-123 also had a significant effect on chow intake during
the PROG/chow session, indicated by a repeated measures ANOVA [F(3,42)=13.771, p<0.001],
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with a significant reduction in chow intake at the 24.0 mg/kg dose compared to vehicle (Veh vs.
24.0 mg/kg (S)-CE-123 [F(1,42)=28.107, p<0.001] (Fig. 3.4B).

Microdialysis
One-way ANOVA revealed no differences in basal DA levels between nucleus
accumbens shell vehicle (Mean 130.46 fmoles DA/20 µl; SEM 19.01) and nucleus accumbens
shell 24.0 mg/kg (S)-CE-123 (Mean 90.65 fmoles DA/20 µl; SEM 12.17) conditions
[F(1,9)=2.411, p=n.s.], or nucleus accumbens core vehicle (Mean 91.28 fmoles DA/20 µl; SEM
27.37) and nucleus accumbens core 24.0 mg/kg (S)-CE-123 (Mean 90.25 fmoles DA/20 µl; SEM
17.12) conditions [F(1,6)=0.001, p=n.s.]. A repeated measures factorial ANOVA revealed a
significant overall effect of treatment group [F(3,13)=29.680, p<0.001], a significant effect of
sample [F(11,143)=6.756, p<0.001], and a significant treatment x sample interaction
[F(33,143)=8.019, p<0.001] (Fig. 3.5). Analysis of simple effects in which each condition was
analyzed separately showed that there was a significant increase in extracellular DA in the
nucleus accumbens core in the group that received 24.0 mg/kg (S)-CE-123 [F(11,33)=11.950,
p<0.001]. Tukey tests indicated that 24.0 mg/kg (S)-CE-123 administration increased nucleus
accumbens core DA significantly from baseline at samples taken 40-180 minutes after injection
(p<0.05). Analysis of simple effects also showed that there was a significant difference in
extracellular DA in the nucleus accumbens shell in the group treated with 24.0 mg/kg (S)-CE123 [F(11,33)=7.049, p<0.001] from baseline, and a Tukey test indicated a significant reduction
at 100 minutes after injection (p<0.05). Injections of vehicle had no significant effect on
extracellular DA levels in either nucleus accumbens core or shell (Fig. 3.5).
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3.4 Figures

Figure 3.1. Structure of the novel atypical dopamine reuptake inhibitor
(S)-CE-123 ((S)-5-((benzhydrylsulfinyl)methyl)thiazole).
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Figure 3.2. The effects of the DAT blocker (S)-CE-123 on TBZ-induced changes in
performance on the concurrent lever pressing/chow-feeding choice procedure. (A) TBZ plus
vehicle significantly differed from vehicle plus vehicle (#p<0.001); TBZ plus 24.0 mg/kg (S)CE-123 significantly differed from TBZ plus vehicle (*p< 0.01). (B) TBZ plus vehicle
significantly differed from vehicle plus vehicle (#p<0.001); TBZ plus 24.0 mg/kg (S)-CE-123
significantly differed from TBZ plus vehicle (**p< 0.001).
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Figure 3.3. The effects of 24.0 mg/kg (S)-CE-123 or vehicle on performance on the concurrent
FR5/chow feeding choice task. There was no effect of drug treatment on lever pressing or chow
intake on the FR5/chow feeding choice task when rats (n=7) were administered (S)-CE-123 or
vehicle prior to testing. Repeated measures ANOVA indicated no significant difference between
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rats treated with 24 mg/kg (S)-CE-123 and vehicle-treated rats on lever pressing [F(1,6)=0.012,
p=n.s.] (Fig. 3.3A) or chow intake [F(1,6)=0.030, p=n.s.] (Fig. 3.3B).
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Figure 3.4. The effects of the DAT blocker (S)-CE-123 on performance on the concurrent
PROG/chow feeding choice procedure. Rats (n=15) received intraperitoneal injections of vehicle
(Veh), 6.0, 12.0, or 24.0 mg/kg doses of (S)-CE-123. (A) 24.0 mg/kg (S)-CE-123 significantly
differed from vehicle (*p<0.05). (B) 24.0 mg/kg (S)-CE-123 significantly differed from vehicle
(**p<0.001)

Figure 3.5. Effect of vehicle or 24.0 mg/kg (S)-CE-123 on extracellular DA in the nucleus
accumbens core and shell measured by microdialysis. Mean (±SEM) extracellular DA (expressed
as percent baseline) in 20 minute samples across 180 minutes. Three baseline samples were
collected prior to injection, followed by nine post-injection samples. *significantly different from
vehicle, p<0.05.
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Chapter 4: Behavioral and dopamine transporter binding properties of the modafinil
analog (S, S)-CE-158: reversal of the motivational effects of tetrabenazine and
enhancement of progressive ratio responding.
Submitted; Rotolo et al., Psychopharmacology

4.1 Introduction
Motivational symptoms such as anergia, fatigue, and effort-related dysfunctions are
common and debilitating features of major depressive disorder, schizophrenia, Parkinson’s
disease and other psychiatric and neurological disorders (Tylee et al. 1999; Demyttenaere et al.
2005; Treadway et al. 2012; Barch et al. 2014; Chong et al. 2015). Motivational symptoms are
not well treated by many of the most commonly prescribed antidepressant drugs (Tylee et al.
1999; Demyttenaere et al. 2005; Cooper et al. 2014; Fava et al. 2014; Ghanean et al. 2018).
Patients treated with drugs that block the serotonin transporter (SERT), such as fluoxetine,
sertraline, paroxetine or escitalopram, often suffer from residual symptoms of apathy, fatigue,
and a lack of energy (Katz et al. 2004; Padala et al. 2012; Rothschild et al. 2013; Cooper et al.
2014; Ferguson et al. 2014), which can be detrimental to daily functioning. Clinical reports have
revealed a critical link between symptoms related to fatigue and energy expenditure and the
overall severity of depressive symptoms (Gullion and Rush 1998; Fava et al. 2014; Chung et al.
2015; Ghanean et al. 2018). Moreover, self-reported fatigue is correlated with global functioning
deficits and reduced likelihood of remission (Ferguson et al. 2014). The array and prevalence of
symptoms left unabated by antidepressant medications emphasizes the importance of utilizing
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animal models of fatigue and anergia to aid in the development of new and more effective
treatments.
In order to conduct preclinical studies of motivational dysfunctions using animal models,
tasks have been developed to evaluate effort-based decision making in rodents (Salamone et al.
2006, 2007, 2016a,b, 2018; Mai et al. 2012; Nunes et al. 2013; Sommer et al. 2014; Winstanley
and Floresco 2016; Bailey et al. 2016, 2020; Hart et al. 2017; Stutz et al. 2019). With these tasks,
animals are offered the choice between lever pressing for a highly valued reinforcer vs.
approaching and consuming a freely available but less preferred reinforcer. Tasks such as the
concurrent fixed ratio 5 (FR5)/chow feeding choice task and the concurrent progressive ratio
(PROG)/feeding choice task are useful for measuring effort-related choice behavior (Salamone et
al. 2002, 2007, 2016a; Salamone and Correa, 2012; Randall et al. 2012). Several studies have
shown that selection of the high-effort alternative is reduced when animals are exposed to
manipulations associated with depression and negative motivational symptoms, such as stress
(Shafiei et al. 2012; Bryce and Floresco, 2016; Dieterich et al. 2020), proinflammatory cytokine
administration (Nunes et al. 2014; Yohn et al. 2015; Rotolo et al. 2020, in prep), and dopamine
(DA) depletion or antagonism (Nunes et al. 2013; Randall et al. 2012, 2014; Yohn et al. 2015a;
Hosking et al. 2015; Pardo et al. 2015; Yohn et al. 2016a,b,c; Rotolo et al. 2019; Yang et al.
2020; Bailey et al. 2020). For example, rats treated with the vesicular monoamine transport
(VMAT-2) inhibitor tetrabenazine (TBZ) demonstrate a low-effort bias across several tasks,
shifting choice away from the high-effort alternative (Nunes et al. 2013; Randall et al. 2014;
Yohn et al. 2015a; Pardo et al. 2015). When administered to humans, TBZ induces depressive
symptoms including fatigue (Chitnis and Karunapuzha, 2009; Frank, 2010; Chen et al. 2012).
Importantly, these effort-related dysfunctions in animals are not reversed by co-administration of
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inhibitors of SERT or norepinephrine transport (NET) (Yohn et al. 2016a,b). Unlike drugs that
inhibit SERT or NET, several inhibitors of the DA transporter (DAT), including bupropion,
vanoxerine (GBR12909), lisdexamfetamine, PRX-14040, methylphenidate, and modafinil, can
reverse the low-effort bias induced by TBZ (Nunes et al. 2013, Yohn et al. 2016a,b,c; Salamone
et al. 2016b) and by pro-inflammatory cytokines (Yohn et al. 2016b,d). Moreover, several DAT
inhibitors have demonstrated the ability to increase motivation to exert high levels of effort,
increasing selection of lever pressing in rats tested on the PROG/chow feeding choice task when
administered alone (Sommer et al. 2014; Randall et al., 2015; Yohn et al., 2016b,c,d).
The ability of drugs that block DAT to reverse effort-related impairments and increase
selection of high-effort activities in rodents is consistent with clinical studies showing that DAT
inhibitors, including bupropion, amphetamine, and methylphenidate, can improve motivational
function in people (Stotz et al. 1999; Papakostas et al. 2006; Pae et al. 2007; Blockmans and
Persoons 2016). The wakefulness agent modafinil, which inhibits DAT (Schmitt and Reith
2011), and elevates extracellular DA as measured by microdialysis (Mereu et al. 2017) and
human imaging studies (Volkow et al. 2009), has been shown to improve motivational function
in people with depression (Fava et al. 2007; Lam et al. 2007) and multiple sclerosis (Shangyan et
al. 2018). Moreover, modafinil reduces perception of physical task demands during exercise
(Rattray et al. 2019), and increases motivation and enhances task engagement in humans at doses
that do not produce a powerful euphoria or ‘high’ (Müller et al. 2013). Modafinil has atypical
DAT binding characteristics and behavioral effects (Schmitt and Reith 2011; Mereu et al. 2013,
2017; Cao et al. 2016; Nikiforuk et al. 2017), and is part of an emerging class of drugs (e.g.
benztropine and GBR12909 analogs) that have binding properties and behavioral effects that are
different from cocaine. Recently, various stereoisomers of the novel thiazole-based modafinil
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analog CE-123 were demonstrated to have pro-cognitive effects in both rats and mice (Nikiforuk
et al. 2017; Kristofova et al. 2018; Camats-Perna et al. 2019), as well as the ability to reverse the
effort-related effects of TBZ in rats at doses that increase extracellular DA in nucleus accumbens
core (Rotolo et al. 2019). While CE-123 has shown preclinical effectiveness across a variety of
rodent behavioral tasks without adverse toxic effects (Kalaba et al. 2017), and has a higher
specificity for the DAT than other commercially available drugs (Kalaba et al. 2020), it is
important to provide a detailed characterization of a broad range of modafinil analogs to identify
the most promising candidate for treating motivational dysfunctions and fatigue. The present
study investigated a novel modafinil analog, (S, S)-CE-158, for its ability to bind to DAT, the
specificity of its inhibition of DAT, and its ability to reverse the effort-related effects of TBZ,
enhance high-effort PROG responding, and increase accumbens DA transmission.

4.2 Methods
Animals
Adult male, drug-naïve, Sprague Dawley rats (Envigo, Indianapolis, IN, USA) were
housed in a colony maintained at 23 °C with 12-h light/dark cycles (lights on 07:00). Rats (n=23
for the behavioral pharmacology experiments; n=9 for the microdialysis experiment) weighed
275–299 g at the beginning of the study, and were initially food restricted to 85% of their freefeeding body weight for operant training. Rats were fed supplemental chow to maintain weight
throughout the study, with water available ad libitum. Rats were allowed modest weight gain
throughout the experiment. Animal protocols were approved by the University of Connecticut
Animal Care and Use Committee, and followed NIH guidelines.
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In Vitro Binding Experiment
To determine binding specificity, in vitro binding assays were conducted using
transfected HEK293 cells with stable expression of human DAT with [N-Methyl-3H]WIN35,428 = [3H]CFT = 2ß-carbomethoxy-3ß-(4-fluorophenyl) tropane. Cells were seeded in
poly-D-lysine-coated 24-well plates (3 x 104 HEK293 cells/well) and, 2 days later, binding on
whole cells was performed as described previously (Pifl et al., 2009). Cells were incubated on ice
for 2 h in 0.25ml buffer (mmol/l: 4 Tris–HCl; 6.25 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES); 120 NaCl; 5 KCl; 1.2 CaCl2 ; 1.2 MgSO4; 5 D-glucose; 0.5
ascorbic acid; pH 7.1) containing 6 nM [3H]CFT and various concentrations of (S, S)-CE-158.
Non-specific binding was measured in the presence of 10 µM mazindol. Binding experiments
were performed by the laboratory of Dr. Gert Lubec.

In Vitro Monoamine Transporter Reuptake Inhibition
Monoamine transporter reuptake inhibition was outsourced to Eurofins DiscoverX
Corporation (Fremont, CA) and performed according to the standard company protocol for the
Neurotransmitter Transporter Uptake Assay (Molecular Devices). In short, (S, S)-CE-158 was
tested for monoamine reuptake inhibition using a fluorescence-based assay. Fluorescent
substrates mimicking amine neurotransmitters were taken up into HEK293 cells with stable
expression of DAT, NET, and SERT, and intensity of intracellular fluorescence was quantified.
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Pharmacological Agents and Selection of Doses
(S, S)-CE-158 (5-(((S)-((S)-(3-bromophenyl)(phenyl)methyl)sulfinyl)methyl)thiazole)
(Fig. 4.1) was obtained from the Lubec Laboratory (University of Vienna, Austria) and dissolved
in dimethyl sulfoxide (DMSO), Tween 80, and 0.9% saline. The DMSO/Tween 80/saline
solution was administered as the vehicle control. TBZ (9,10-dimethoxy-3-(2-methylpropyl)1,3,4,6,7, 11b hexahydrobenzo[a]quinolizin-2-one) was obtained from Tocris Bioscience
(Ellisville, MO) and was dissolved in DMSO, 0.9% saline, and titrated with HCl. The
DMSO/saline solution was administered as the vehicle control. The dose of 1.0 mg/kg TBZ was
based on extensive piloting in our laboratory. The doses of (S, S)-CE-158 were selected based on
extensive pilot studies and information about its relative affinity for DAT.

Behavioral Procedures
Concurrent FR5/Chow Feeding Choice Task:
Behavioral sessions were conducted in operant chambers (28 x 23 x 23 cm; Med
Associates, Fairfax, VT). Sessions lasted 30 minutes a day for 5 days/week. First, rats were
trained to lever press on a continuous reinforcement schedule to receive 45 mg highcarbohydrate pellets (Bio-Serv; Frenchtown, NJ, USA) for one week, then were shifted to the
FR5 schedule. After 5 weeks of FR5 training, chow was introduced. During each FR5/chow
feeding choice task session, 15-20 g of lab chow (Laboratory Diet, 5P00 Prolab RMH 3000,
Purina Mills, St. Louis, MO) was concurrently available on the floor of the chamber. Rats were
trained on this FR5/chow feeding choice procedure for 5 weeks, after which drug testing began.
On baseline and drug treatment days, rats consumed all of the operant pellets that were delivered
during each session.
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Concurrent PROG/Chow Feeding Choice Task:
A second behavioral experiment was conducted to determine if (S, S)-CE-158 had an
effect on rats’ behavior on the PROG/chow feeding choice task when administered alone.
Sessions were conducted in operant chambers (28 x 23 x 23 cm; Med Associates, Fairfax, VT)
with 30-minute sessions 5 days/week. Rats were initially trained to lever press on a continuous
reinforcement FR1 schedule (high-carbohydrate 45 mg pellets, Bio-Serv) and then shifted to the
PROG schedule (Randall et al. 2012, 2014, 2015). For PROG sessions, the ratio started at FR1
and was increased by 1 additional response every time 15 reinforcements were obtained
(FR1×15, FR2×15, etc.). A “time-out” feature deactivated the response lever for the rest of the
session whenever 2 minutes elapsed without a completed ratio. After 9 weeks of training on the
PROG schedule, chow was introduced and was concurrently available on the floor of the
chamber during the PROG/chow feeding choice task sessions as previously described. Rats were
trained on the PROG/chow feeding choice procedure for 5 weeks, after which drug testing
began. On baseline and drug treatment days, rats consumed all of the operant pellets that were
delivered during each session.

Surgical Implantation of Dialysis Guide Cannulae
Animals were anesthetized with an intraperitoneal injection of 100.0 mg/kg ketamine
hydrochloride and 10.0 mg/kg xylazine prior to placement in a stereotaxic device (incisor bar 5.0
mm above interaural line). Microdialysis guide cannulae (Bioanalytical Systems) were implanted
2.0 mm dorsal to the accumbens core (AP +2.8 mm, ML +1.8 mm, DV −6.8 mm from bregma).
Cannulae were surgically implanted in nine drug-naïve adult male Sprague Dawley rats, and
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placements were counterbalanced, with four rats implanted on the left and five rats implanted on
the right. After placement, guide cannulae were secured to the skull by stainless steel screws and
cranioplastic cement. A stainless-steel stylet was inserted through each cannula while not in use.
Rats were allowed 7 days to recover from surgery before undergoing dialysis procedures.

DA Microdialysis and High Performance Liquid Chromatography
On sample collection days, dialysis probes (Bioanalytical Systems; 2.0 mm active
surface) were inserted through the microdialysis guide cannulae. Artificial CSF (aCSF; 147.2
mm NaCl, 2.4 mm CaCl2, 4.0 mm KCl) was continuously perfused through the probe at a rate of
2.0 µl/min. Neurochemical samples were collected every 30 min in tubes containing 2.0 μl of
ascorbic acid and sodium metabisulfite to prevent oxidation of DA. Up to 7 baseline samples
were collected before an intraperitoneal injection of 8.0 mg/kg (S, S)-CE-158 to establish a stable
DA level. The last three of those baseline samples were used as the statistical baseline. Samples
were either immediately frozen or analyzed fresh using reverse-phase high-performance liquid
chromatography (HPLC) with electrochemical detection (ESA Coulochem II system). The
electrochemical parameters were as follows: channel 1 = −100 mV, channel 2 = +200 mV, and
guard cell = +350 mV. Each liter of mobile phase contained 27.5 g sodium phosphate
monobasic, 7.0 % methanol, 750 μl of 0.1 m EDTA, and 2200 μl of 0.4 m sodium octyl sulfate
dissolved in deionized ultrapure H2O with a final pH of 4.5. The flow rate was 1.0 ml/min. DA
standards were run each day before the dialysate samples. Probe placements were verified with
histological analyses and only probes with placement in the nucleus accumbens core were used
for analyses.
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Nissl Staining for Identifying Probe Placements
At the completion of behavioral testing in the intracranial injection and microdialysis
experiments, each animal was anesthetized with CO2 and then perfused intracardially with
physiological saline followed by a 3.7 % formaldehyde solution. The brains were removed and
stored in formaldehyde and then sliced with a vibratome in 60 μm sections, which were mounted
on glass microscope slides. After mounting, slides were stained with cresyl violet for
microscopic observation by a blind observer. Any animal with improper cannulae placement or
significant damage around the injection site was excluded from the statistical analyses of
behavioral data.

Experimental Procedures
Effects of systemic administration of TBZ on the concurrent FR5/chow feeding choice procedure
and reversal with (S, S)-CE-158:
Trained rats (n=7) were administered either TBZ (1.0 mg/kg) or vehicle, and (S, S)-CE158 (2.0, 4.0, 8.0 mg/kg) or vehicle, via intraperitoneal (IP) injections on drug testing days. Rats
received TBZ or vehicle 120 minutes before testing and (S, S)-CE-158 or vehicle 30 minutes
before testing. The experiment used a within-groups design, with each rat receiving each drug
treatment in a randomly varied order. The following five treatment combinations were given:
TBZ vehicle + (S, S)-CE-158 vehicle; 1.0 mg/kg TBZ + (S, S)-CE-158 vehicle; 1.0 mg/kg TBZ +
2.0 mg/kg (S, S)-CE-158; 1.0 mg/kg TBZ + 4.0 mg/kg (S, S)-CE-158; 1.0 mg/kg TBZ + 8.0
mg/kg (S, S)-CE-158.
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Effects of systemic administration of (S, S)-CE-158 on the concurrent PROG/chow feeding
choice procedure:
Thirty minutes prior to the testing session, trained rats (n=16) were administered either
vehicle or 2.0, 4.0, or 8.0 mg/kg (S, S)-CE-158. This experiment used a within-groups design,
with each rat receiving each drug treatment in a randomly varied order, once per week over the
course of four weeks.
Effects of (S, S)-CE-158 on extracellular DA in the nucleus accumbens:
Rats were implanted with dialysis probes in nucleus accumbens core as described earlier.
On the test day, after baseline dialysis samples were collected, rats received intraperitoneal
injections of either vehicle (n=4) or 8.0 mg/kg (S, S)-CE-158 (n=5). Seven post-injection
samples were collected.

Statistical Analysis
Repeated measures ANOVA was used to determine the effect of drug treatment on lever
pressing and chow intake in the behavioral pharmacology experiments. Since there were
significant overall F values for the two behavioral measures being used, nonorthogonal planned
comparisons were performed, using the overall error term to assess differences between each
treatment and the control condition. The number of comparisons was restricted to the number of
treatments minus one (Keppel, 1991). Statistical outliers were predefined as any point that is
more than two standard deviations from the mean. No data from this study were excluded as
outliers.
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Changes in extracellular DA levels in the microdialysis experiment were calculated as the
percent change from baseline, with the mean of the three samples immediately preceding the
drug injections serving as the 100% baseline level. A 2 × 7 factorial ANOVA with the treatment
(drug vs. vehicle) factor being between groups, and the sample factor (samples collected after
drug injection) being repeated measures, was used to test for post-injection differences in
extracellular levels of DA. The raw DA levels of the baseline samples were analyzed using t test
to verify that the baseline DA levels were not different between conditions. Nonorthogonal
planned comparisons were performed using the error term from the between-subjects analysis to
assess differences between the two treatments at each particular sample.

4.3 Results
Binding experiments on DAT expressing cells and inhibition of monoamine transporters (DAT,
NET, SERT) by (S, S)-CE-158:
(S, S)-CE-158 concentration-dependently displaced [3H]CFT from human DAT with an
IC50 of 0.052 ± 0.017 µM (Fig. 4.2). As shown in Figure 4.3, (S, S)-CE-158 selectively and
potently blocked DAT (IC50 = 0.2271 µM), while having a weak effect on NET (IC50 = 11.97
µM) and no effect on SERT.
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Ability of (S, S)-CE-158 to reverse the effects of TBZ on the concurrent FR5/chow feeding choice
procedure:
As shown in Figure 4.4, a repeated measures ANOVA revealed that there was an overall
significant effect of drug treatment on lever pressing [F(4,24)=34.940, p<0.001]. Planned
comparisons showed that TBZ significantly decreased lever pressing compared to vehicle
treatment [F(1,24)=63.675, p<0.001], and that co-administration of the dose of 8.0 mg/kg (S, S)CE-158 with TBZ significantly attenuated the effects of TBZ on lever pressing [F(1,24)=39.06,
p<0.001]. A two-tailed t-test revealed no difference in lever pressing between the vehicle plus
vehicle and TBZ plus (S, S)-CE-158 8.0 mg/kg treatments (p=0.17) (Fig. 4.4a). There was also a
significant overall effect of drug treatment on chow intake [F(4,24)=22.086, p<0.001].
Additional planned comparisons revealed that TBZ alone significantly increased chow intake
relative to vehicle treatment [F(1,24)=38.098, p<0.001], and that co-administration of 8.0 mg/kg
(S, S)-CE-158 with TBZ significantly reduced chow intake compared to the TBZ plus vehicle
condition [F(1,24)=21.786, p<0.001]. Furthermore, a two-tailed t-test revealed no difference in
chow intake between the vehicle plus vehicle and TBZ plus 8.0 mg/kg (S, S)-CE-158 treatment
groups (p=0.42) (Fig. 4.4b).

Ability of (S, S)-CE-158 to increase high-effort responding on the concurrent PROG/chow
feeding choice procedure:
Repeated measures ANOVA revealed an overall main effect of drug treatment on lever
pressing [F(3,45)=3.583, p<0.05], and planned comparisons demonstrated that lever presses were
significantly increased at 4.0 mg/kg (S, S)-CE-158 [F(1,45)=9.433, p<0.01] and at 8.0 mg/kg (S,
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S)-CE-158 [F(1,45)=5.54, p<0.05] compared to vehicle treatment (Fig 4.5a). Drug treatment
with (S, S)-CE-158 also had a significant effect on chow intake during the PROG/chow session
[F(3,45)=3.686, p<0.05], with a significant reduction in chow intake at the 4.0 mg/kg dose
[F(1,45)=7.118, p<0.05] and at the 8.0 mg/kg dose [F(1,45)=5.613, p<0.05] compared to vehicle
(Fig. 4.5b).

Systemic administration of (S, S)-CE-158 increased extracellular DA in the nucleus accumbens:
Administration of 8.0 mg/kg (S, S)-CE-158 significantly increased extracellular DA
content in the nucleus accumbens (Fig. 4.6). Factorial ANOVA with repeated measures on the
sample factor demonstrated that there was a significant overall difference across samples
[F(6,42)=3.339, p<0.01] and a significant sample x treatment interaction [F(6,42)=3.011,
p<0.05]. The factorial ANOVA also revealed a significant quadratic trend for the sample x
treatment interaction [F(1,7)=912.422, p<0.01], which statistically characterized the tendency for
DA levels to show a transient increase, followed by a decrease, after injection of (S, S)-CE-158.
In addition, there was a significant overall difference between treatment groups across the seven
samples [F(1,7)=703.162, p<0.001], showing that (S, S)-CE-158 produced a significant overall
difference in DA across samples relative to vehicle injection. Nonorthogonal planned
comparisons assessing the difference between the two treatments at each sample revealed
significant differences at sample 2 (S2) [F(1,7)=14.376, p<0.01] and sample 3 (S3)
[F(1,7)=10.509, p<0.05].
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4.4 Figures

Figure 4.1. Chemical structure of (S, S)-CE-158 (5-(((S)-((S)-(3bromophenyl)(phenyl)methyl)sulfinyl)methyl)thiazole).

Figure 4.2. Effect of (S, S)-CE-158 on binding to DAT expressing cells. HEK293 cells with
stable expression of the human DAT and seeded in 24-well plates were incubated with [3H]CFT
for 2 hrs in the absence (dashed line) or presence of (S, S)-CE-158 at the concentration indicated
(open circles, solid line) or 10 µM mazindol (dotted line) at 4°C, and binding of tritium was
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determined as described under “Experimental procedures”. Symbols represent means of binding
± standard error of four independent experiments, each performed in duplicates.

Figure 4.3. In vitro monoamine transporter reuptake inhibition of (S, S)-CE-158 using HEK293
cells with stable expression of DAT, NET, and SERT. (S, S)-CE-158 selectively and potently
blocked DAT (IC50 = 0.2271 µM), while having a weak effect on NET (IC50 = 11.97 µM) and no
effect on SERT. Symbols represent means of uptake inhibition ± standard error of three
independent experiments, each performed in duplicates.
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Figure 4.4. The effects of the DAT blocker (S, S)-CE-158 on TBZ-induced changes in
performance on the concurrent lever pressing/chow-feeding choice procedure. (a) There was an
overall significant effect of drug treatment on lever pressing (p<0.001). TBZ significantly
decreased lever pressing compared to vehicle treatment (#p<0.001). (b) There was a significant
overall effect of drug treatment on chow intake (p<0.001), and TBZ alone significantly increased
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chow intake relative to vehicle treatment (#p<0.001). Co-administration of the dose of 8.0 mg/kg
(S, S)-CE-158 with TBZ significantly attenuated the effects of TBZ on lever pressing (*p<0.001)
and chow intake (*p<0.001).
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Figure 4.5. The effects of the DAT blocker (S, S)-CE-158 on performance on the concurrent
lever pressing/chow-feeding choice procedure. (a) There was an overall main effect of drug
treatment on lever presses (p<0.05). Lever presses were significantly increased at 4.0 mg/kg (S,
S)-CE-158 (**p<0.01) and at 8.0 mg/kg (S, S)-CE-158 (*p<0.05) compared to vehicle treatment.
(b) Drug treatment with (S, S)-CE-158 had a significant effect on chow intake during the
PROG/chow session (p<0.05), with a significant reduction in chow intake at the 4.0 mg/kg dose
(*p<0.05) and at the 8.0 mg/kg dose (*p<0.05) compared to vehicle.

Figure 4.6. Effect of (S, S)-CE-158 on extracellular DA in the nucleus accumbens. Left:
Photomicrograph and schematic showing a representative probe placement in nucleus
accumbens. Abbreviations: acb: nucleus accumbens; cpu: caudate nucleus-putamen
(neostriatum) (Pellegrino et al. 1979). Right: Mean (± SEM) extracellular DA (expressed as
percent baseline) in 30-min samples. Three baseline (BL) samples were collected prior to
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injection of vehicle or 8 mg/kg (S, S)-CE-158, followed by seven post-drug samples (S1-7).
**p<0.001, (S, S)-CE-158 significantly differs from vehicle at S2. *p<0.05, (S, S)-CE-158
significantly differs from vehicle at S3. #p<0.05 significant overall difference between vehicle
and (S, S)-CE-158 across the seven post-drug samples.
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Chapter 5: The Novel Atypical Dopamine Transport Inhibitor CT-005404 Reverses the
Effort-Related Motivational Effects of Tetrabenazine and Interleukin-1β and Increases
Progressive Ratio Responding
Submitted; Rotolo et al., Neuropharmacology

5.1 Introduction
Patients with major depressive disorder (MDD), Parkinsonism, schizophrenia, multiple
sclerosis (MS) and other psychiatric or neurological disorders commonly experience
motivational symptoms such as fatigue and loss of energy (Feinstein, 2007; Fava et al., 2014).
According to the DSM-V, one of the nine core symptoms of MDD is “fatigue or loss of energy
nearly every day”, and this is the second most frequently reported symptom (Zimmerman et al.
2015; Tolentino and Schmidt, 2018). Fatigue and anergia are demonstrated by an individual’s
lack of energy or willingness to work for something that is significant (Treadway et al. 2012;
Yang et al. 2014; Zimmerman et al. 2015; Corfield et al. 2016), which has been demonstrated by
the tendency of individuals with depression, Parkinsonism, and schizophrenia to show a loweffort bias when tested on effort-related choice procedures (Treadway et al. 2012; Yang et al.
2014; Chong et al. 2016; Barch et al. 2017). The risk of depression in individuals who report
fatigue is two-fold greater compared to non-fatigued individuals (Corfield et al. 2016).
Historically, serotonin transport (SERT) inhibitors have been the most commonly prescribed
drugs for treating MDD patients, but SERT blockers are relatively ineffective at improving
anergia or fatigue-related aspects of motivation (Cooper et al., 2014; Fava et al. 2014; Rothschild
et al. 2014). In contrast, evidence indicates that the catecholamine uptake inhibitor bupropion
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(Pae et al., 2007; Papakostas et al., 2006; Cooper et al., 2014), and drugs that inhibit the
dopamine (DA) transporter (DAT) such as d-amphetamine and methylphenidate (Stotz et al.,
1999; Hanna et al. 2006), can partially alleviate these symptoms in depressed patients.
Bupropion also was reported to reduce fatigue associated with MS (Duffy and Campbell 1994).
Given the clinical importance of motivational dysfunctions in psychopathology, it is vital
to employ animal models that are useful for drug development. Thus, several recent studies have
focused on rodent tasks involving effort-related choice behavior. For assessment of effort-based
choice, animals are offered the option of a high-effort instrumental action leading to highly
valued reinforcer (preferred, or higher magnitude) vs. a low effort/low reward choice. A loweffort bias in rodents can be induced by several conditions associated with motivational
dysfunction in depression and other disorders, including stress (Shafiei et al. 2012; Bryce and
Floresco 2016) and inflammatory challenge (Nunes et al. 2014; Yohn et al. 2016b,d). DA
antagonists or depletions reliably produce a low-effort bias in rodents (Salamone et al. 1991,
2002; Mai et al. 2012; Pardo et al. 2012; Nunes et al. 2013; Randall et al. 2014; Yohn et al.
2015a,b; Yang et al. 2020). Tetrabenazine (TBZ) is an inhibitor of the vesicular monoamine
transporter type-2 (VMAT-2), which blocks vesicular storage and depletes monoamines, though
its greatest effects at low doses are on striatal and accumbens DA (Pettibone et al. 1984; Tanra et
al. 1995; Nunes et al. 2013). TBZ has been shown to produce depressive symptoms including
anergia and fatigue in humans (Frank 2009, 2010; Guay 2010; Chen et al. 2012), and thus it has
been used in numerous preclinical experiments involving effort-based choice to induce a loweffort bias (Nunes et al. 2013; Randall et al. 2014; Yohn et al. 2015, 2016a,b,c; Salamone et al.
2016b; Carratala-Ros et al. 2020). TBZ-induced shifts in effort-based choice are not due to
changes in food intake or preference, sucrose preference or hedonic reactivity, or changes in
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reference memory, and the effects of TBZ do not resemble those produced by appetite
suppressant drugs or reinforcer devaluation (Nunes et al. 2013; Randall et al. 2014; Pardo et al.
2015; Yohn et al. 2015, 2016a,b,c; Salamone et al. 2016b; Yang et al. 2020; Carratala-Ros et al.
2020). The low-effort bias induced by TBZ in rats was not reversed by the commonly prescribed
SERT inhibitors fluoxetine or citalopram (Yohn et al. 2016a,b), but it was attenuated by several
drugs that block DAT, including bupropion, GBR12909, PRX-14040, lisdexamfetamine, (S)-CE123, methylphenidate, and modafinil (Nunes et al. 2013; Randall et al. 2014; Yohn et al. 2015,
2016a,b,c; Salamone et al. 2016a,b; Rotolo et al. 2019).
Although there are classical DAT inhibitors such as cocaine, and drugs that block DAT
and release DA such as amphetamines and methylphenidate, there is an emerging interest in the
neurochemical and behavioral characteristics of novel atypical DAT blockers, such as Nsubstituted benztropine analogs and modafinil analogs (Schmitt and Reith, 2011; Zhang et al.
2017; Rotolo et al. 2019). In contrast to cocaine and amphetamines, which rapidly increase
extracellular DA in nucleus accumbens (Tanda et al. 1997; Desai et al. 2010), GBR 12909 and
some benztropine analogs induce a relatively slow increase in extracellular DA over a broad time
course (Raje et al. 2003; Desai et al. 2005a,b, 2010; Tanda et al, 2005, 2009, 2013; Kohut et al.
2014), which may offer advantages in terms of clinical utility. In view of the potential
importance of DAT inhibition as a target for developing drugs to treat motivational dysfunction,
the present paper provides an initial characterization of the neurochemical and effort-related
behavioral effects of a novel atypical DAT inhibitor, CT-005404. As well as providing data on
DAT binding and alterations in extracellular DA as measured by microdialysis, the present
studies evaluated the ability of CT-005404 to reverse the effort-related impairment induced by
TBZ and the suppression of lever pressing induced by the pro-inflammatory cytokine IL-1β in
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rats tested on the concurrent fixed ratio 5 (FR5)/chow feeding choice task. Furthermore, CT005404 was assessed for its ability to increase selection of high-effort lever pressing in rats
tested on the progressive ratio (PROG)/chow feeding choice task.

5.2 Materials and Methods
Animals
Sprague Dawley rats were obtained from Charles River Laboratories (Germany) and
divided into 6 groups (n=4/group; 220-250 g) for the in vivo receptor occupancy experiment.
Fifteen adult males (328-485 g) were used for the microdialysis experiments. Experiments were
conducted in accordance with the Guide for the Care and Use of Laboratory Animals (National
Research Council 2011), European Union directive 2010/63, and Dutch law. Experiments were
licensed by the national committee for animal experiments (AVD247002015341; Centrale
Commissie Dierproeven) and approved by the Animal Care and Use Committee of Charles River
Discovery Groningen. Animals were housed in groups of 5 in polypropylene cages (40 X 50 X
20 cm) with wire mesh tops in a temperature (22 ± 2 °C) and humidity (55 ± 15%) controlled
environment (12-h light/dark cycle, lights on 07:00). Standard diet (SDS Diets, RM1 PL) and
water were available ad libitum.
For the behavioral pharmacology experiments, adult male Sprague Dawley rats (Envigo,
Indianapolis, IN, USA; 279-299 g) were pair-housed in a colony maintained at 23°C (12-h
light/dark cycle, lights on at 07:00). Rats were initially food restricted to 85% of their freefeeding body weight for operant training and then allowed modest growth, with water available
ad libitum in the home cages for the duration of the experiment. Protocols were approved by the
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University of Connecticut Institutional Animal Care and Use Committee, and studies were
conducted according to NIH guidelines.

CT-005404 In Vivo Receptor Occupancy
Rats were treated with either vehicle (0.5% (w/v) (hydroxypropyl)methyl cellulose
(HPMC) in 0.9% saline) or CT-005404 (1.0, 3.0, 10.0, 30.0, or 100.0 mg/kg), and 100 minutes
later were given [18F]FECNT (8-(2-[18F]fluroethyl)-2betacarbomethoxy-3beta-(4chlorophenyl)nortropane) (i.v. 3.0 µg/kg, 0.5 ml/kg). After the tracer survival interval, rats were
euthanized by cervical dislocation. Trunk blood was collected in K2-EDTA coated tubes and
stored on ice. Whole brains were removed and rinsed with sterile water. Target tissues (striatum
and cerebellum), were dissected, weighed, and stored in 1.5 ml tubes on dry ice at -80°C until
tissue extraction. Blood samples were centrifuged at 1650 x g for 16 minutes, and serum was
pipetted into tubes and stored at -80°C. Receptor occupancy experiments were performed by
Chronos Therapeutics laboratories.

In Vivo Microdialysis
Surgical Implantation of Dialysis Guide Cannulae:
Rats were anesthetized using isoflurane (2% and 500 mL/min O2). Before surgery,
Finadyne analgesia (1.0 mg/kg, s.c.) was administered. A bupivacaine/epinephrine mixture was
used for local analgesia of the incision site. Animals were placed in a stereotaxic apparatus (Kopf
instruments, USA) with the incisor bar at -3.0 mm, and guides for I-shaped microdialysis probes
with 2.0 mm exposed surface (polyacrylonitrile membrane; CRL, the Netherlands) were
implanted into nucleus accumbens (coordinates: AP = +1.6 mm (from bregma), lateral +/-1.8
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mm (from midline), ventral -7.7 mm (from dura), based on Paxinos and Watson (2008)).
Cannulae were attached to the skull with stainless steel screws and dental cement.

DA Microdialysis:
Experiments were initiated one day after cannulae implantation. Microdialysis probes
were connected with PEEK tubing (Western Analytical Products Inc. USA; PK005-020) to a
microperfusion pump (Harvard Apparatus) and perfused with artificial CSF (aCSF: 147 mM
NaCl, 3.0 mM KCl, 1.2 mM CaCl2 and 1.2 mM MgCl2) at 1.5 µl/min flow rate. After two hours
of stabilization, microdialysis samples were collected in 20-minute intervals. After the third basal
sample (t=0 minutes) vehicle or 10.0 or 30.0 mg/kg CT-005404 (0.5% (w/v)
(hydroxypropyl)methyl cellulose (HPMC) in 0.9% saline) were orally administered.
Microdialysates were collected for 360 minutes after compound administration. Samples were
collected into polystyrene microvials (Microbiotech/se AB, Sweden; 4001029) using an
automated collector (UV 8301501, TSE, Univentor, Malta). The vials contained 10 μL
stabilization fluid (0.02 M formic acid + 0.04% ascorbic acid in ultrapurified water). Samples
were stored at -80 °C. After the experiment animals were sacrificed, and brain tissue was
collected for verification of probe placements. Microdialysis experiments were performed by
Chronos Therapeutics laboratories.

Analytical Procedure:
The volume for the microdialysis samples was 40 μL. Concentrations of DA were
determined by HPLC with tandem mass spectrometry (MS/MS) detection using the following
internal standards (IS): D4-DA for DA. An aliquot of IS solution was mixed with an aliquot of
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each sample. The resulting mixture was derivatized with SymDAQ™ automatically in the
autosampler and then injected onto the HPLC by an automated sample injector (Shimadzu,
Japan). Chromatographic separation was performed with a Phenomenex, Synergi MAX-RP
column (100 x 3 mm, 2.5 µm; 35 °C). The mobile phases consisted of A: ultrapurified
water+0.2% acetonitrile+0.1% formic acid and B: 70% acetonitrile in ultrapurified water+0.1%
formic acid. Elution of compounds proceeded using a linear gradient (flow rate- 0.3 mL/min).
The MS analyses were performed using an API 4000 MS/MS system (API 4000 MS/MS
detector, Turbo Ion Spray interface, Applied Biosystems, The Netherlands). The acquisitions
were performed in positive ionization mode with the instrument operated in multiple-reactionmonitoring mode.

Behavioral Pharmacology Procedures
FR5/Chow Feeding Choice Task:
Behavioral sessions (30 minutes/day, 5 days/week) were conducted in operant chambers
(28 x 23 x 23 cm; Med Associates, Fairfax, VT). First, rats were trained to lever press on a FR1
schedule reinforced by 45 mg high-carbohydrate pellets (Bio-Serv; Frenchtown, NJ, USA) for
one week, then were shifted to the FR5 schedule. After 5 weeks of FR5 training, chow was
introduced. During FR5/chow feeding choice sessions, 15-20 g of lab chow (Laboratory Diet,
5P00 Prolab RMH 3000, Purina Mills, St. Louis, MO) was concurrently available on the floor of
the chamber. At the end of each session, rats were removed from operant chambers, the number
of lever presses was recorded, and the remainder of chow and spillage in the chamber floor was
weighed and recorded. Rats received FR5/chow feeding choice training for 5 weeks, after which
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drug testing began. On baseline and drug treatment days, rats consumed all the operant pellets
that were delivered during each session.

PROG/Chow Feeding Choice Task:
Behavioral sessions (30 minutes/day, 5 days/week) were conducted in operant chambers.
Rats were initially trained to lever press on a FR1 schedule on Bio-Serv pellets as described
above, then were shifted to the PROG schedule. For PROG sessions, the ratio started at FR1 and
was increased by one additional response every time 15 reinforcers were obtained. A “timeout”
feature deactivated the response lever and turned off the house light for the rest of the session
whenever 2 min elapsed without a completed ratio. After 9 weeks of PROG training, chow was
introduced. During each session, 15-20 g of lab chow (Laboratory Diet, 5P00 Prolab RMH 3000,
Purina Mills, St. Louis, MO) was concurrently available on the floor of the chamber. At the end
of each session, rats were removed from operant chambers, the number of lever presses was
recorded, and the chow intake was determined. Rats were trained on this PROG/chow feeding
choice procedure for 5 weeks, after which drug testing began. On baseline and drug treatment
days, rats consumed all of the operant pellets that were delivered during each session.

Behavioral Pharmacology Experiments
Drug Treatments and Dose Selection:
CT-005404 was obtained from Chronos Therapeutics (Oxford, UK), and was dissolved in
dimethylsulfoxide (DMSO) (1%) and hydroxypropyl methylcellulose (HPMC) (99%). The
DMSO/HPMC solution was administered as the vehicle control. For Exp. 1, TBZ (9,10dimethoxy- 3-(2-methylpropyl)-1,3,4,6,7, 11b hexahydrobenzo[a]quinolizin- 2-one) was
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obtained from Tocris Bioscience (Ellisville, MO), and was dissolved in DMSO (20%) and 0.9%
sterile saline (20%). Once partially dissolved, the TBZ solution was titrated with microliter
quantities of 1.0 N HCl to fully dissolve the drug at a pH of 4.0-4.5. The dose of 1.0 mg/kg TBZ
was based on previous studies (Rotolo et al. 2019). For Exp. 2, IL-1β was obtained from R&D
Systems (Minneapolis, MN, USA), and was dissolved in 0.9% saline, which also served as the
vehicle control. The dose of IL-1β was based on previously published data (Merali et al., 2003;
Nunes et al. 2014) and pilot studies. The doses of CT-005404 were selected based on target
engagement pilot studies (e.g. time course of receptor occupancy and receptor occupancy by
dose) conducted by Chronos Therapeutics (see Figure 1).

Behavioral Pharmacology Experiments:
Rats (n=15) trained on the FR5/chow choice feeding procedure were administered either
TBZ (1.0 mg/kg i.p.) or vehicle and CT-005404 (7.5, 15.0, and 30.0 mg/kg p.o.) or vehicle on
drug testing days. CT-005404 or vehicle was administered 240 min (n=7) or 180 min (n=8)
before testing, and TBZ or vehicle was administered 120 min before testing. A within-subjects
design was used, with each animal receiving each drug treatment in a randomly varied order.
Treatment combinations were as follows: TBZ vehicle + CT-005404 vehicle (control); 1.0 mg/kg
TBZ + CT-005404 vehicle; 1.0 mg/kg TBZ + 7.5 mg/kg CT-005404; 1.0 mg/kg TBZ + 15.0
mg/kg CT-005404; 1.0 mg/kg TBZ + 30.0 mg/kg CT-005404. Drug treatments were given once
per week, with none of the treatment sequences repeated across different animals.
For the CT-005404/IL-1β reversal study, a second group of trained rats (n=11) were
administered either IL-1β (4.0 µg/kg i.p.) or vehicle and CT-005404 (7.5, 15.0, and 30.0 mg/kg
p.o.) or vehicle on drug testing days. CT-005404 or vehicle was administered 240 min before
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testing, and IL-1β or vehicle was administered 90 min before testing. A within-subjects design
was used, with each animal receiving each drug treatment in a randomly varied order. Treatment
combinations were: IL-1β vehicle + CT-005404 vehicle (control); 4.0 μg/kg IL-1β + CT-005404
vehicle; 4.0 μg/kg IL-1β + 7.5 mg/kg CT-005404; 4.0 μg/kg IL-1β + 15.0 mg/kg CT-005404; 4.0
μg/kg IL-1β + 30.0 mg/kg CT-005404. Drug treatments were given once per week, with none of
the treatment sequences repeated across different animals.
For the CT-005404 PROG/chow feeding choice study, a group of rats (n=16) trained on
the PROG/chow feeding choice procedure received 7.5, 15.0, or 30.0 mg/kg CT-005404 or
vehicle 240 min before testing. Treatments were given once per week, in a randomly varied
order, over the course of 4 weeks.

Statistical Analysis
For evaluation of the in vivo receptor occupancy data, a [agonist] vs. response variable
slope model was used. The dose required to produce 50% occupancy (Occ50) and SEM was
calculated using GraphPad Prism 8.4.1.
Changes in extracellular DA levels in the microdialysis experiment were calculated as the
percent change from baseline, with the mean of the three samples immediately preceding the
drug injections serving as the 100% baseline level. Data from one rat was excluded due to
interrupted sample collection. Data from a total of 14 rats were included in the analysis (vehicle
n=4, 10.0 mg/kg n=5, 30.0 mg/kg n=5). All post-administration samples were expressed as a
percentage of basal level within the same subject. A 3 × 17 factorial ANOVA with the treatment
(two doses of CT-005404 vs. vehicle) factor being between groups, and the sample factor
(samples collected after drug injection) being repeated measures, was used to test for post-
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injection differences in extracellular levels of DA. The raw DA levels of the baseline samples
were analyzed using t tests to verify that the baseline DA levels were not different between
conditions. Dunnett’s tests using the error term from the between-subjects analysis were used to
assess differences between each drug treatment and vehicle at each particular sample.
For the behavioral pharmacology experiments, total number of lever presses and gram
quantity of chow intake were analyzed using repeated measures ANOVA. Nonorthogonal
planned comparisons restricted to the number of treatments minus 1 (Keppel, 1991) using the
overall error term were performed when the repeated measures ANOVA yielded a significant F
value, to assess differences between each treatment and the control condition. The level of
statistical significance was defined a priori at p<0.05. SPSS Statistics (Version 25), was used to
perform all statistical analyses.

5.3 Results
CT-005404 In Vivo Receptor Occupancy:
In vivo receptor occupancy studies were performed. Occupancy of the DAT as it relates
to dose was calculated for CT-005404. It was determined that the Occ50 of CT-005404 was
8.224 mg/kg (± SEM 1.646) (Fig. 5.1A). Receptor occupancy was measured after CT-005404
administration at 0.5, 1, 2, 4, 8, 12, and 24 hours. The peak receptor occupancy percentage was
observed 4 hours post-treatment with a 78% occupancy (± 2.2 SEM) (Fig. 5.1B). Table 5.1
shows the in vitro binding affinities for CT-005404 at DAT, NET, and SERT binding sites. CT005404 showed an 80-fold selectivity for binding to the DAT relative to the NET, and a 1600fold selectivity for DAT vs. SERT.
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In Vivo Microdialysis:
Administration of CT-005404 significantly increased extracellular DA content in the
nucleus accumbens (Fig. 5.1C). Factorial ANOVA with repeated measures on the sample factor
demonstrated that there was a significant overall difference across samples [F(16,176)=13.58,
p<0.001] and a significant sample x treatment interaction [F(32,176)=2.90, p<0.001]. In
addition, administration of CT-005404 yielded a significant overall main effect of treatment
group on extracellular DA across the seventeen post-injection samples [F(2,11)=7.03, p<0.05].
Simple effects of treatment group were assessed by computing between groups ANOVAs at each
time point. For each significant between groups overall ANOVA, post-hoc two-tailed Dunnett’s
tests were performed, which revealed significant differences in extracellular DA for both the
10.0 mg/kg and 30.0 mg/kg treatment groups compared to vehicle from 80-280 min postinjection (with the exception of the 180-minute time point due to increased error).

Behavioral Pharmacology Experiments
FR5/Chow Feeding Choice Task:
Figure 5.2 shows the effects of CT-005404 on TBZ-induced changes in rats tested on the
FR5/chow feeding choice procedure. CT-005404 was administered either 3 hours or 4 hours
prior to testing in two different groups of rats. In both groups, TBZ shifted effort-based choice,
decreasing lever pressing and increasing chow intake. A treatment x lead time repeated measures
factorial ANOVA revealed a significant overall main effect of treatment on lever pressing
[F(4,52)=32.28, p<0.001], but no effect of lead time on lever pressing [F(1,13)=0.39, p=n.s.],
and no significant treatment x lead time interaction [F(4,52)=0.824, p=n.s.] (Fig. 5.2A). Due to a
non-significant interaction, non-orthogonal planned comparisons were computed collapsed
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across the 3- and 4-hour lead times. TBZ+vehicle significantly reduced lever presses relative to
the vehicle+vehicle treatment [F(1,52)=102.682, p<0.001]. Planned comparisons revealed a
significant increase in lever presses for both the TBZ+15.0 mg/kg CT-005404 [F(1,52)=9.844,
p<0.01] and TBZ+30.0 mg/kg CT-005404 [F(1,56)=9.068, p<0.01] relative to the TBZ+vehicle
treatment (Fig. 5.2A). Factorial ANOVA assessing chow intake revealed a significant treatment
effect [F(4,52)=15.399, p<0.001], but no effect of lead time on chow intake [F(1,13)=2.268,
p=n.s.], and no significant treatment x lead time interaction [F(4,52)=0.800, p=n.s.] (Fig. 5.2B).
TBZ+vehicle significantly increased chow intake relative to vehicle+vehicle treatment
[F(1,52)=47.645, p<0.001]. Planned comparisons revealed a significant decrease in chow intake
for both the TBZ+15.0 mg/kg CT-005404 [F(1,52)=4.829, p<0.05] and TBZ+30.0 mg/kg CT005404 [F(1,52)=18.495, p<0.001] relative to the TBZ+vehicle treatment (Fig. 5.2B).
For the CT-005404/IL-1β reversal study, repeated measures ANOVA demonstrated a
significant overall treatment effect on lever presses [F(4,40)=12.504, p<0.001] (Fig. 5.3A). IL1β+vehicle significantly reduced lever presses compared to vehicle+vehicle [F(1,40)=40.759,
p<0.001]. Planned comparisons revealed that treatment with both 15.0 mg/kg CT-005404 and
30.0 mg/kg CT-005404 were able to significantly increase lever presses from IL-1β plus vehicle
treatment [F(1,40)=4.180, p<0.05; F(1,40)=8.992, p<0.01, respectively] (Fig. 5.3A). There was
no overall treatment effect for chow intake [F(4,40)=1.558, p=n.s.] (Fig. 5.3B).

PROG/Chow Feeding Choice Task
Repeated measures ANOVA revealed for the effect of CT-005404 on lever pressing
closely approached statistical significance [F(3,45)=2.628, 0.1 < p > 0.05] (Fig. 5.4A), and a
statistically significant effect of CT-005404 on chow intake was found [F(3,45)=8.835, p<0.01]
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(Fig. 5.4B). However, orthogonal analysis of trend showed that there were significant linear
dose-related effects for lever presses [F(1,15)=6.632, p<0.05] and chow intake [F(1,15)=12.035,
p<0.01]. Because the linear dose-related trend was significant, planned comparisons were
computed for number of lever presses. Rats treated with 30.0 mg/kg CT-005404 lever pressed
significantly more [F(1,45)=6.617, p<0.05] and consumed less chow [F(1,45)=11.240, p<0.01]
than rats treated with vehicle. Rats treated with 15.0 mg/kg CT-005404 also consumed
significantly less chow during the session compared to vehicle [F(1,45)=7.911, p<0.01].
Moreover, a significant negative correlation was found when the percent change in lever presses
was compared to the percent change in chow intake from vehicle at the 15.0 mg/kg treatment
dose (Pearson’s r = -0.538, p<0.05).

5.4 Figures

Table 5.1. Binding affinity of CT-005404 to the DA transporter (DAT), the norepinephrine
transporter (NET), and the 5-HT transporter (SERT). Values represent IC50s calculated from
means of technical replicates in a 10 point dose response curve.
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Figure 5.1. DAT occupancy and extracellular levels of DA in nucleus accumbens after oral
administration of CT-005404. (A) DAT occupancy as it relates to dose (mg/kg). The dose of CT005404 required to produce 50% occupancy (Occ50) of the DAT was 8.224 mg/kg (± 1.6 SEM).
(B) DAT occupancy over time (hours). DAT occupancy was measured after CT-005404
administration at 0.5, 1, 2, 4, 8, 12, and 24 hours. The peak % DAT occupancy was observed 4
hours post-treatment with a 78% occupancy (± 2.2 SEM). (C) Microdialysis data showing
extracellular DA in nucleus accumbens after p.o. administration of CT-005404. Mean (± SEM)
extracellular DA (expressed as percent baseline) in 20-min samples. Three baseline samples
were collected prior to injection of vehicle or 10.0 or 30.0 mg/kg CT-005404, followed by 17
post-injection samples. There was a significant overall effect of treatment group across the 17
post-drug samples, and a significant group x sample interaction. †p<0.05, 30.0 mg/kg CT005404 significantly different from vehicle. *p<0.05, 10.0 mg/kg significantly different from
vehicle.
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Figure 5.2. The effects of the DAT inhibitor CT-005404 on TBZ-induced changes in
performance on the FR5 concurrent lever pressing/chow feeding choice procedure. (A) Lever
presses during the 30-minute session. #p<0.001, TBZ plus vehicle significantly differed from
vehicle plus vehicle; **p<0.01, TBZ plus 15.0 mg/kg CT-005404 (3 hours) significantly differed
from TBZ plus vehicle; *p<0.05, TBZ plus 30.0 mg/kg CT-005404 significantly differed from
TBZ plus vehicle. (B) Gram quantity of chow intake. #p<0.001, TBZ plus vehicle significantly
differed from vehicle plus vehicle; **p<0.01, TBZ plus 30.0 mg/kg CT-005404 significantly
differed from TBZ plus vehicle.
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Figure 5.3. The effects of the DAT inhibitor CT-005404 on IL-1β-induced changes in
performance on the FR5 concurrent lever pressing/chow-feeding choice procedure. (A) Lever
presses during the 30-minute session. #p<0.001, IL-1β plus vehicle significantly differed from
vehicle plus vehicle; † 0.10>p>0.05, IL-1β plus 15.0 mg/kg CT-005404 trended towards a
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significant difference from IL-1β plus vehicle; **p< 0.01, IL-1β plus 30.0 mg/kg CT-005404
significantly differed from IL-1β plus vehicle. (B) Gram quantity of chow intake. IL-1β plus
vehicle did not significantly differ from vehicle plus vehicle.
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Figure 5.4. The effects of the DAT inhibitor CT-005404 on performance on the Progressive
Ratio/chow-feeding choice procedure. (A) Lever presses during the 30 minute session. Rats
treated with 30.0 mg/kg CT-005404 lever pressed significantly more than vehicle-treated rats
(*p<0.05). (B) Gram quantity of chow intake. Rats treated with 15.0 mg/kg and 30.0 mg/kg CT005404 consumed significantly less chow than rats treated with vehicle (**p<0.01).
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Chapter 6: Effort-related effects of altering lever pressing ratio requirements, and of
tetrabenazine administration, on progressive ratio work output.

6.1 Introduction
Motivation has been defined as the set of processes through which organisms regulate the
probability, proximity, and availability of significant stimuli (Salamone 1992; Salamone and
Correa 2002; Salamone 2010; Salamone et al. 2016a). Motivated behaviors are characterized by
a high degree of behavioral activation, which is manifested as the vigor and persistence of work
output (Salamone 1988, 1992; Salamone and Correa 2002, 2012; Croxson et al. 2009; McGinty
et al. 2013; Salamone et al. 2016a). These features facilitate the exertion of effort during the
instigation and maintenance of instrumental responding, allowing organisms to overcome effortrelated response costs in order to obtain something valued by the organism (e.g. food).
Considerable research has shown that mesolimbic dopamine (DA) plays an important role in
regulating motivated behaviors (Salamone et al. 1997, 2007, 2012; Salamone and Correa, 2002,
2012; Robbins and Everitt, 2007). More specifically, interference with nucleus accumbens DA
can affect the willingness of animals to exert high levels of effort to obtain food reinforcers,
while leaving primary aspects of motivation such as appetite and the direction and acquisition of
food intact (Salamone and Correa 2002, 2012).
A growing body of clinical neuroscience research emphasizes the importance of effortrelated symptoms, such as fatigue, anergia, and psychomotor retardation in major depression,
multiple sclerosis, chronic fatigue syndromes, schizophrenia, Parkinson’s disease, and other
neurological and psychiatric disorders (Stahl 2002; Demyttenaere et al. 2005; Salamone et al.
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2006; Treadway and Zald 2011; Fava et al. 2014; Chong et al. 2015). Human tests of effortrelated decision making are increasingly being employed for characterizing the motivational
impairments seen in people with Parkinsonism, schizophrenia, and depression (Treadway et al.
2012a; Gold et al. 2013, 2015; Chong et al. 2015; Green et al. 2015; Green and Horan 2015;
Reddy et al. 2015). Patients with major depression have a reduced likelihood of selecting high
effort alternatives when assessed in tests of effort-related decision making (Treadway et al.
2012a; Yang et al. 2014). Furthermore, Guillion and Rush (1998) conducted a factor analytic
study of patients with major depression and identified a “lack of energy” factor (i.e., problems
with energy/fatigability, psychomotor retardation, inability to work), which was the factor that
loaded most strongly onto a second order general depression factor. These symptoms can
strongly interfere with daily living, and can be difficult to treat (Tylee et al. 1999; Stahl 2002;
Fava et al. 2014). Moreover, it has been suggested that fatigue could be used as a predictor of
clinical depression, and can contribute to deficits in global functioning (Corfield et al. 2016),
highlighting its importance as a critical feature in animal research. Thus, it is important to study
the neural and behavioral processes related to the exertion of effort to better understand the
physiological underpinnings of these symptoms.
In view of the clinical relevance of motivational dysfunctions related to deficits in
behavioral activation and exertion of effort, it is critical to develop animal models that focus
specifically on effort-related motivational symptoms. Animal studies of effort-based choice have
been developed as formal models to study motivational dysfunctions. In these tasks, animals are
offered a choice between high-effort instrumental actions leading to highly valued reinforcers,
versus low-effort options leading to less valued reinforcers. Fixed ratio (FR) reinforcement
schedules offer trained animals the option to exert high levels of responding for a preferred food
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reinforcer (high-carbohydrate pellets), or to choose a concurrently available but less preferred
option (standard laboratory chow). DA D1 and D2 family antagonists decrease food-reinforced
FR5 lever pressing but substantially increase chow intake (Salamone et al., 1991, 2002; Sink et
al. 2008). The shift from lever pressing to chow intake is not produced by neostriatal DA
depletions or antagonism (Cousins et al. 1993; Farrar et al. 2010), but instead results from
accumbens DA depletions, and intra-accumbens injections of D1 or D2 antagonists (Cousins et al.
1993; Nowend et al. 2001; Farrar et al. 2010). Drug treatments that produce the shift in choice
behavior did not alter food intake or preference in free-feeding choice tests (Salamone et al.
1991; Koch et al. 2000; Farrar et al. 2008), and did not resemble the effects of appetite
suppressant drugs (Salamone et al. 2002; Sink et al. 2008; Randall et al. 2012, 2013).
The Salamone lab also has employed a progressive ratio (PROG)/chow feeding
concurrent choice task (Salamone 2006; Randall et al. 2012, 2014, 2015; Yohn et al. 2016b,c,d,
2018), which offers the choice of lever pressing on a PROG schedule reinforced by the preferred
high carbohydrate pellets vs. approaching and consuming the less preferred chow. The PROG
schedule requires that the rat repeatedly make within-session choices between lever pressing and
chow intake under conditions in which the ratio requirement is gradually incrementing. DA D 1
and D2 family antagonists decreased PROG lever pressing (e.g., number of lever presses, highest
ratio achieved, and time spent responding), but rats maintained normal levels of chow intake,
indicating that their appetite for food was still intact (Randall et al. 2012, 2014). Importantly, the
effects of DA antagonism or depletion differed markedly from those of reinforcement or
appetite-related manipulations (reinforcer devaluation by pre-feeding, the cannabinoid CB1
antagonist/inverse agonists AM251 and AM4113), which decrease both lever pressing and chow
intake (Randall et al. 2012, 2014). In summary, low-to moderate doses of DA antagonists, or
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local antagonism or depletion of DA in nucleus accumbens, do not affect primary food
motivation or appetite when access to food is unconstrained, but instead make it less likely that
animals will work for food. These findings demonstrate that interference with DA transmission
causes animals to reallocate their instrumental actions based on the response requirements of the
task, and select lower cost alternatives to obtain food (Salamone et al. 2007, 2009b, 2012,
2016a,b,c; Salamone and Correa 2002, 2012).
Due to the prevalence of effort-related dysfunctions observed in human
psychopathologies, it is critical to characterize the impact of varying response costs on an
organism’s willingness to exert high levels of effort. Human clinical research has shown that
willingness to work for monetary reward on a PROG task was impaired in people with
depression (Hershenberg et al. 2016), and in schizophrenics with high levels of negative
symptoms (Wolf et al. 2014). PROG schedules can also be used to measure exertion of higheffort behavior in rats (Salamone 2006; Randall et al. 2012, 2014, 2015; Yohn et al. 2016b,c,d,
2018). Typically, animals tested on PROG schedules will lever press until the work requirement,
or the ‘cost’, becomes too high, while others will continue responding throughout the entire
session. The point at which an animal ceases high-effort responding is referred to as the
breakpoint, and can be used as a measure of maximal effort exertion. In the concurrent
PROG/chow feeding choice procedure described above, the freely available lab chow acts as a
‘magnet’, effectively pulling the animal away from high-effort lever pressing towards a loweffort alternative, as soon as the animal perceives the work requirement as too difficult to
overcome. In the present experiment, rats were trained on a PROG reinforcement schedule
without the option of freely available lab chow, so the only way to receive food was to lever
press. In addition, the PROG schedule was manipulated to produce a steeper ratio increment
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increase in order to shift animals’ breakpoint earlier in order to be observed within a 30-minute
session.
The present studies were conducted to evaluate the effects of altering ratio requirements
on a PROG schedule of reinforcement, and to establish a PROG schedule that is difficult enough
to cause animals to exhibit a breakpoint during a 30-minute session. It was predicted that altering
the number of reinforcers delivered at each ratio (N), and the increment at which the ratio
requirement increases after N reinforcers are delivered (I), would produce a drastic change to the
total number of lever presses and breakpoint exhibited during a session. It also was hypothesized
that the VMAT-2 inhibitor TBZ, which pharmacologically depletes DA, would decrease the
number of lever presses, the time of last response, and the breakpoint during the modified PROG
session. Ultimately, the PROG schedule determined by these experiments will be used in future
electrophysiological recording experiments to assess frontal cortex electroencephalography
(EEG) changes under baseline and pharmacological conditions in which animals shift their
behavior away from high-effort instrumental responding towards the low effort-alternative (see
Chapter 7 for initial development of recording techniques and effects of TBZ in untrained
animals).

6.2 Materials and Methods
Animals
Sixteen adult male Sprague Dawley rats were obtained from Envigo (Indianapolis, IN,
USA), and were housed in a colony maintained at 23 °C with 12-h light/dark cycles (lights on
07:00). Rats weighed 275–299 g at the beginning of the study, and were initially food restricted
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to 85% of their free-feeding body weight for operant training. Rats were fed supplemental chow
to maintain weight throughout the study, with water available ad libitum. Rats were allowed
modest weight gain throughout the experiment. Animal protocols were approved by the
University of Connecticut Animal Care and Use Committee, and followed NIH guidelines.

PROG Lever Pressing Task and Schedule Modifications
Rats were initially trained to lever press for 45 mg high-carbohydrate pellets (Bio-Serv)
on an FR1 (continuous reinforcement) schedule for one week or until a stable baseline was
reached. Then, rats were switched to a PROG schedule (Randall et al. 2012, 2014, 2015), in
which the number (N) of pellets delivered at each ratio was equal to 15, and the increment (I) at
which the ratio increased after the delivery of each reinforcer was equal to 1 (e.g. FR1 x 15
reinforcers, FR2 x 15 reinforcers, FR3 x 15 reinforcers, and so on) for nine weeks (30 min
sessions, 5 times/week). The PROG schedule was then modified so that N = 1 and I = 1 (e.g.
FR1 x 1 reinforcer, FR2 x 1 reinforcer, FR3 x 1 reinforcer, and so on), and rats were trained on
this schedule for six and a half weeks. After a stable baseline was reached, the PROG schedule
was further modified to change the ratio increase increment after each reinforcer delivery, so that
N = 1 and I = 2 (e.g. FR1 x 1 reinforcer, FR3 x 1 reinforcer, FR5 x 1 reinforcer, and so on). After
three days of training on the modified PROG schedule, a stable baseline was reached. Then, the
schedule underwent a final modification, increasing the ratio increment to I = 4 (e.g. FR1 x 1
reinforcer, FR5 x 1 reinforcer, FR9 x 1 reinforcer, and so on). Rats remained on this training
schedule for three weeks before drug testing began. At the end of each 30 minute session, rats
were immediately removed from the chambers and number of lever presses, time of last
response, and breakpoint ratio (i.e. last successfully completed ratio during the session) was
82

recorded for each rat. On baseline training and drug treatment days, rats consumed all of the
operant pellets that were delivered during each session.

Drug Treatments and Dose Selection
Tetrabenazine (TBZ) (9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7, 11b
hexahydrobenzo[a]quinolizin-2-one) was obtained from Tocris Bioscience (Ellisville, MO) and
was dissolved in DMSO (20%), 0.9% saline (80%), and was titrated with microliter quantities of
1.0 N HCl until the solid drug was in solution at a pH of 4.0-4.5. The DMSO/saline solution was
administered as the vehicle control. The dose of 1.0 mg/kg TBZ was selected based on extensive
piloting in our laboratory.

Behavioral Pharmacology Experiment
Fifteen out of sixteen trained rats were used for the behavioral pharmacology experiment.
One rat was excluded from the experiment due to an unstable baseline. On drug testing days,
trained rats were administered either TBZ (1.0 mg/kg) or vehicle via intraperitoneal (IP)
injections 120 minutes before testing. The experiment used a within-groups design, with half of
the rats receiving a vehicle treatment on the first day of drug testing, while the other half
received TBZ, and vice versa on the second drug testing day. The only PROG schedule used for
the behavioral pharmacology experiment was the schedule where N = 1 and I = 4, which was the
final stage of training.
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Statistical Analysis
For the PROG training progression, differences in lever presses across time within each
phase of training was analyzed using repeated measures ANOVA. For the behavioral
pharmacology experiment, number of lever presses, time of last response, and breakpoint ratio
were all analyzed using paired-samples t tests. Factorial ANOVA was used to determine an
overall main effect of treatment on the three behavioral measures during the PROG session as a
percentage of their baseline performance. A statistical program (SPSS, Version 25) was used to
perform all analyses.

6.3 Results
Rats underwent a training progression on various schedules of PROG reinforcement over
a time period of 20 weeks. Shown in Figure 6.1, a repeated measures ANOVA demonstrated a
statistically significant main effect of week on average lever presses during the ‘N=15; I=1’
phase [F(8,120)=69.626, p<0.001] and a significant linear trend [F(1,15)=147.635, p<0.001].
There was no significant effect of week on lever presses in the second phase, ‘N=1; I=1’
(p=n.s.), or final phase, ‘N=1; I=4’ (p=n.s.) (Fig. 6.1).
TBZ was administered to rats trained on the modified PROG reinforcement schedule
(N=1; I=4). The mean number of lever presses under vehicle conditions was 1853.2 ± 259.5.
TBZ administration yielded an average of 982.3 ± 194.8 lever presses, equating to a 47%
reduction compared to the vehicle-treated group. Paired-sample t test indicated a statistically
significant difference in lever presses between the vehicle and TBZ treatment groups
[t(14)=5.231, p<0.001] (Fig. 6.2A). Time of last response and end of session breakpoint ratios
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were also compared. Paired-sample t test indicated that TBZ significantly reduced the time of
last response during the session [t(14)=4.588, p<0.001] (Fig. 6.2B). There was also a significant
reduction of breakpoint ratio as a result of TBZ administration, as demonstrated by a pairedsample t test [t(14)=4.885, p<0.001] (Fig. 6.2C). TBZ administration resulted in a 29-30%
reduction of both time of last response and breakpoint ratio measures.
Figure 6.3 shows the effects of TBZ on PROG lever presses, time of last response, and
breakpoint ratio during a 30-minute session in rats as a percentage of baseline performance.
Factorial ANOVA indicated an overall significant main effect of treatment [F(1,42)=39.283,
p<0.001] and a non-significant interaction between treatment and any of the dependent variables
(p=n.s.). After reaching a stable baseline in the final phase, average baseline values were
calculated for lever presses, time of last response, and breakpoint ratio. Prior to the first day of
drug testing, the average number of lever presses was 1752.1 ± 310.5, average time of last
response was 1371.0 ± 93.0 seconds, and average breakpoint ratio was 111.3 ± 10.6. Prior to the
second day of drug testing, the average number of lever presses was 1803.9 ± 255.7, average
time of last response was 1324.8 ± 86.4 seconds, and average breakpoint ratio was 114.3 ± 8.4
(data not shown). Paired sample t tests indicated no statistically significant differences between
any of the baseline measures from the first to second drug testing day. These averages were used
to calculate % baseline values (Fig. 6.3).
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6.4 Figures

Figure 6.1. Progressive ratio (PROG) training procedure. Rats (n=16) were trained on various
PROG schedules over the course of 20 weeks. Each point ( •) represents weekly average lever
presses ± SEM. Dashed lines represent training phase transitions, each phase labeled accordingly
as ‘PROG (N=X; I=X)’. Overall effect of week on lever presses during the first training phase
(N=15; I=1) (*p<0.001).
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Figure 6.2. Effects of tetrabenazine (TBZ) on PROG lever presses, time of last response, and
breakpoint ratio during a 30-minute session in rats (n=15). (A) Mean ± SEM number of lever
presses after treatment with vehicle or 1 mg/kg TBZ. *p<0.001, difference between vehicle and
TBZ. (B) Mean ± SEM time of last response (sec) in a 30-minute session after treatment with
vehicle or 1 mg/kg TBZ. *p<0.001, difference between vehicle and TBZ. (C) Mean ± SEM
breakpoint ratio in a 30-minute session after treatment with vehicle or 1 mg/kg TBZ. *p<0.001,
difference between vehicle and TBZ.
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Figure 6.3. Effects of tetrabenazine (TBZ) on PROG lever presses, time of last response, and
breakpoint ratio during a 30-minute session in rats (n=15) as a percentage of baseline
performance. Factorial ANOVA indicated an overall significant main effect of treatment
(p<0.001) and a non-significant interaction between treatment and any of the dependent variables
(p=n.s.).
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Chapter 7: Exploration of frontal cortex electrophysiology in freely moving untrained rats:
effects of TBZ.

7.1 Introduction
Motivational symptoms such as psychomotor slowing, fatigue, lassitude, loss of energy
and reduced exertion of effort are critical and debilitating features of psychopathology (Stahl
2002; Demyttenaere et al. 2005; Salamone et al. 2006; Treadway and Zald 2011; Treadway et al.
2012a; Fava et al. 2014). Effort-related motivational symptoms are present in major depressive
disorder, bipolar disorder, schizophrenia, Parkinsonism, chronic fatigue syndrome and multiple
sclerosis (Salamone et al. 2006, 2010, 2016b; Friedman et al. 2007; Tellez et al. 2008; Green et
al. 2015). The neural basis of the effort-related dysfunctions in psychopathology are still being
characterized, nevertheless, considerable evidence shows that the selection of high-effort
activities is dependent upon forebrain mesolimbic DA circuitry as well as integrity of the
circuitry connecting ventral striatum, ventral pallidum, and prefrontal cortex (Salamone et al.
1991, 1994; 2007, 2016a,b, 2018; Walton et al. 2003; Floresco and Ghods-Sharifi 2007; Mingote
et al. 2008; Farrar et al. 2008, 2010; Winstanley and Floresco 2016).
Our laboratory has demonstrated that tests of effort-based choice can be used as animal
models of effort-related motivational symptoms in psychopathology (Salamone and Correa 2002;
Salamone et al. 2007, 2016a,b,c, 2018). Pharmacological conditions that induce a low-effort bias
in humans can alter effort-related choice in rats, and bias animals towards low-effort options
(Salamone et al. 2016a,b,c; Yohn et al. 2016a,b,c). For example, rats treated with vesicular
monoamine transport type-2 inhibitor tetrabenazine (TBZ), which induces or exacerbates anergia
and fatigue symptoms in humans, can alter effort-related choice, reducing selection of the high
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effort alternative. These effects can be reversed by co-administration of the established
antidepressant bupropion (Wellbutrin), which inhibits catecholamine uptake, and the DA
transport (DAT) blockers GBR12909, PRX-14040, lisdexamfetamine, methylphenidate, and
modafinil. This pattern of effects is consistent with data from human clinical neuroscience on
effort-related motivational dysfunctions in psychopathology, and the effects of drugs that act on
DA. Though the neurochemical changes underlying these effects have been characterized
through the use of animal studies, electrophysiological markers of the selection of high or low
effort activity have not been defined. Moreover, it is unclear if such markers developed from
animal studies can be readily translatable to human psychopathologies.
Recent evidence has indicated that there are electroencephalographic (EEG) markers of
frontal cortex activity that are characteristic of engagement in motivated behavior and
anticipation of reinforcement, and that these markers are reduced in depressed people (Nelson et
al. 2018; Gheza et al. 2019). These findings are consistent with well characterized role of frontal
cortex, including prefrontal areas, in regulating decision making processes (Winstanley and
Floresco 2016). Preclinical tests using rodent effort-based choice tasks can serve as valuable
models of motivational dysfunction in humans, since human tests of effort-related decision
making derived from animal studies are increasingly being employed for characterizing the
motivational impairments seen in people with Parkinsonism, schizophrenia, and depression
(Treadway et al. 2012a; Gold et al. 2013, 2015; Chong et al. 2015; Green et al. 2015; Green and
Horan 2015; Reddy et al. 2015). Patients with major depression have a reduced likelihood of
selecting high effort alternatives when assessed in tests of effort-related decision making
(Treadway et al. 2012a; Yang et al. 2014). Such translational results clearly validate the use of
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tests of effort-based decision making as animal models of the effort-related symptoms in
psychopathology.
A number of imaging papers have aimed to identify the neural correlates of psychomotor
retardation, anergia, and lassitude in depression and other disorders (Hickie et al. 1999; Capuron
et al. 2007), and several recent studies have reported on the brain areas involved in effort-related
decision making (Wardle et al. 2011; Schouppe et al. 2014; Huang et al. 2016; Hogan et al.
2018; Aridan et al. 2019). Generally speaking, these studies have implicated striatal and frontal
cortical processes in approach motivation and effort-based decision making, which is consistent
with the animal studies reviewed above. Additional lines of inquiry have employed EEG
methods to characterize alterations in approach motivation. One psychophysiological marker of
instrumental approach motivation in humans is an asymmetry in EEG activity between left and
right frontal brain regions (Allen, Coan, & Nazarian, 2004; Coan & Allen, 2004). Pizzagalli et al.
(2005) observed that higher task-independent alpha EEG activity in left dorsolateral prefrontal
and medial orbitofrontal cortices was associated with a stronger tendency to respond to rewardrelated cues, supporting the idea that frontal EEG asymmetry modulates the propensity to engage
in appetitively motivated behavior. Moreover, several papers have reported that people with
major depressive disorder, as well as individuals with high levels of depressive symptoms,
exhibit decreased relative left frontal cortical activity at rest (Bruder et al., 1997; Henriques &
Davidson, 1991; Diego, Field, & Hernandez-Reif, 2001; Feng et al., 2012; see Thibodeau,
Jorgensen, & Kim, 2006 for a meta-analysis). A recent study by Nelson et al. (2018) investigated
the association between multiple depression symptom dimensions and asymmetrical frontal
cortical activity in people with major depression as well as two different control groups. EEG
activity in frontal cortex was measured while people were performing a computerized slot
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machine task, during which participants anticipated possible monetary reward in some
conditions, or no reward in others. In undergraduates with low depression symptoms and control
participants that had no history of depression, reward trials induced greater relative left frontal
cortical activity relative to no incentive trials. Furthermore, in both samples across all
participants, increased presentation of lassitude symptoms was associated with decreased relative
left frontal cortical activity while anticipating reward. The authors concluded that “depression
symptoms consistent with motivational disengagement are associated with decreased relative left
frontal cortical activity” (Nelson et al. 2018). These results are consistent with a recent report by
Gheza et al. (2019), who recorded frontal EEG activity from a large cohort of depressed patients
that were performing a reinforcement learning task. Although depressed participants showed
intact reinforcement learning compared to control participants, they had greater alpha EEG
power asymmetry, consistent with the results of Nelson et al. (2018) and potentially reflecting
lower approach motivation.
Although the precise relationship between frontal EEG in rats and humans is uncertain,
the goal of this experiment was to characterize frontal and parietal cortex EEG activity from both
left and right hemispheres in awake rats under baseline conditions, and then under
pharmacologically-induced DA depletion conditions by administration of tetrabenazine (TBZ).
This experiment was intended to be the first step in a larger project focusing on the development
of physiological markers associated with altered DA transmission and effort-related dysfunction
in preclinical animal models that can be readily translated to human studies. It was hypothesized
that frontal cortex activity will provide a correlate of the pharmacological manipulations that
affect the functions of ventral striatum and striatopallidal circuits that are known to be involved
in effort-based decision making. Beyond the scope of the present studies, it is hypothesized that
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frontal EEG markers can be developed that also are sensitive to the selection of high and low
effort instrumental activities. Frontal cortex was selected as a region of interest because of the
extensive animal and human literatures linking prefrontal cortex to executive function, decision
making, and effort-based choice. Parietal cortex recordings were conducted to provide a
comparison with the frontal recordings, and also to determine if other cortical areas are
responsive to TBZ.

7.2 Materials and Methods
Surgeries
One cohort of untrained male (n=8) rats were used for the initial EEG recordings. Rats
were anesthetized with an intraperitoneal injection of 100.0 mg/kg ketamine hydrochloride and
10.0 mg/kg xylazine prior to placement in a stereotaxic device. Up to six stainless-steel skull
screw EEG electrodes were implanted adjacent to the frontal and parietal cortices, and as ground
and reference electrodes. Rats were given seven days to recovery from surgery before recording
took place.

Electrophysiological Recording Experiment
A Digital Lynx SX Electrophysiology System (Neuralynx) was used to acquire EEG
activity from awake rats. Rats were connected to the electrophysiology system using a tethered
cable. Wide-band activity (1-2000 Hz, 4006 samples/sec) will be recorded using the Neuralynx
system and analyzed offline using MATLAB software (MathWorks Inc, Natick, MA). After a
brief acclimation period, ~1 minute of baseline EEG activity was recorded from each rat. Then,
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rats were injected with vehicle or TBZ (1.0 mg/kg). EEG activity was recorded immediately after
injection for up to five minutes. A lead time of 120 minutes elapsed before resuming recordings.
Each rat was exposed to vehicle and TBZ treatments, counterbalanced, over the course of two
separate testing days (one treatment per week).

Data Preprocessing
All signal processing and related procedures were performed using the FieldTrip software
package (Oostenveld et al. 2011; http://www.fieldtriptoolbox.org/) and custom scripts in
MATLAB (The MathWorks, Natick, MA). EEG data were preprocessed as follows: 1) data were
down-sampled from 32 kHz to 1 kHz; 2) data were mean subtracted; 3) data were split into 1-s
epochs to remove the epochs with artifacts; and 4) the first epoch and the last epoch were
removed, and the epochs that were visually inspected to contain high-amplitude artifacts were
removed.

Neurophysiological Analysis
To assess how the power spectral density (PSD) of each frequency varied across time, a
time frequency analysis was conducted using short-time Fourier transform. We segmented the
preprocessed EEG data into 10-s epochs with 5-s overlap. Each epoch is windowed with a
Hamming window. We estimated the PSDs over frequencies from 1 Hz to 50 Hz (0.5 Hz
resolution).
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For power spectral analysis, the preprocessed EEG data were segmented into 1-s epochs
with 0.5-s overlap. We estimated the PSDs using Welch’s overlapped averaged periodogram
method (Welch, 1967) with a Hamming window on each epoch. We estimated the PSDs over
frequencies from 1 Hz to 50 Hz (0.5 Hz resolution).
In addition to power in specific sub-bands, EEG signals throughout frontal cortex were
also analyzed to assess coherence and phase relationships. Coherence values (see Bullock et al,
1990) for each channel pair will be computed using the Welch periodogram estimation procedure
with a spectral resolution of ~ 2 Hz. Coherence is a measure of the linear association between
two signals as a function of frequency. In this experiment, the consistency of the relative
amplitude and phase between interhemispheric channels at each frequency was quantified. To
ensure that the measured coherence values were not due to chance alone, a significance
estimation procedure was used where the coherence estimate is compared to that of signals with
identical magnitude spectrum but with zero phase coherence. For each channel pair, the
cumulative distribution of the frequency-specific coherence values is created by circularly phaseshifting one signal in the pair randomly, calculating the coherence and bootstrapping the
procedure 250 times (Efron and Tibshirani, 1993). This procedure guarantees that the signal
spectrums are identical but have no linear association (because the phase information is
removed). Coherence values for each pair were then analyzed using univariate analysis of
variance (ANOVA) followed by Tukey tests.
The preprocessed EEG data were segmented into 1-s epochs with 0.5-s overlap. We
estimated the coherence using Welch’s overlapped averaged periodogram method (Welch, 1967)
with a Hamming window on each epoch. The interhemispheric coherence was calculated using
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the following formula, where P_xx and P_yy are the estimated power spectral densities of the
two signals, and P_xy is the cross power spectral density of the two signals.

𝐶𝑥𝑦 =

[𝑃𝑥𝑦 ]2
𝑃𝑥𝑥 ∙ 𝑃𝑦𝑦

We estimated the coherences over frequencies from 1 Hz to 50 Hz (0.5 Hz resolution).

7.3 Results
For the recording experiments, a power spectral analysis was performed to quantify the
effects of TBZ (1.0 mg/kg IP) or vehicle treatment on EEG activity recorded from awake rats
(n=6) (Fig. 7.1). At baseline, EEG spectral analysis showed the highest peak PSD at 7.5 Hz. This
effect was detectable in frontal and parietal channels, but was more robust in the parietal
channels. In general, TBZ caused a reduction in EEG power in a frequency range of 7-8 Hz in all
four channels relative to baseline (Fig. 7.1B). Also, PSD was slightly reduced at higher
frequencies (e.g. >25 Hz in frontal channels; >35 Hz in parietal channels) in the TBZ condition
compared to vehicle.
Analyses of inter-hemispheric EEG signal coherence revealed much stronger coherence
measurements from electrodes that were placed in the same position on either side of the midline
(e.g. left and right frontal electrodes) compared to electrodes that were placed in different
positions on either side of the midline (e.g. left frontal and right parietal electrodes). Specifically,
on a scale of 0-1, coherence was greater than 0.5 for congruous electrode placements at baseline
under both vehicle (Fig. 7.2A) and TBZ (Fig. 7.2B) conditions, while coherence for incongruous
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electrode placements remained below 0.5 in both treatment conditions across frequencies. Data
from one rat was removed from the coherence analyses due to missing signal from one electrode.

7.4 Figures

A

B
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Figure 7.1. Effects of TBZ on power spectral density (PSD) (dB/Hz) of frequency (Hz)
measured by EEG in left and right frontal and parietal electrodes. (A) PSD of EEG signal under
baseline and vehicle conditions. (B) PSD of EEG signal under baseline and TBZ conditions.
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A

B

Figure 7.2. Effects of TBZ on inter-hemispheric coherence by frequency (Hz) measured by EEG
in left and right frontal and parietal electrodes. (A) Coherence analysis of EEG signal under
baseline and vehicle conditions. (B) Coherence analysis of EEG signal under baseline and TBZ
conditions.
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Chapter 8: Discussion

8.1 Summary of Results
The major objectives of the present research outlined in this dissertation were to investigate the
role of DA in a model of effort-related motivational dysfunction in rats, to explore novel
treatment options for motivational symptoms of depression and other disorders through the use
of effort-based choice paradigms, and to identify physiological biomarkers related to
motivational dysfunctions.
The first set of experiments, outlined in Chapter 2, assessed the effects of chronic
subcutaneous administration of the DA D2 antagonist haloperidol on effort-based choice. This
specific procedure was used to mimic the development of secondary negative symptoms which
can be induced by long-term drug treatment. The results showed that chronic haloperidol
administration significantly and dose-dependently reduced lever presses and increased chow
intake during the FR5/chow feeding choice task and that continuous infusion of haloperidol via
subdermal pumps provided a translatable model of chronic slow-release DA D2 antagonist
administration.
The experiments described in Chapters 3 and 4 provided an initial characterization of
the effort-related behavioral effects of the novel atypical DAT inhibitors that are analogs of
modafinil, (S)-CE-123 and (S, S)-CE-158. Co-administration of 24.0 mg/kg (S)-CE-123
(Chapter 3) with TBZ produced a significant but partial reversal of the effects of TBZ and
significantly increased PROG lever pressing, accompanied by a decrease chow intake.
Furthermore, the effective dose of (S)-CE-123 in both the TBZ reversal and PROG/chow feeding
choice studies significantly increased extracellular DA in nucleus accumbens core as measured
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by microdialysis. The experiments in Chapter 4 demonstrated the ability of the modafinil analog
(S, S)-CE-158 to reverse the effort-related effects of TBZ, increase PROG/chow lever pressing,
and decrease chow intake during PROG/chow sessions. In addition, systemic administration of
(S, S)-CE-158 increased extracellular DA in the nucleus accumbens during the behaviorally
active time course. Ultimately, this research will guide future studies to advance target
identification for treatments of motivational dysfunction.
The experiments discussed in Chapter 5 provided a characterization of the effort-related
effects of another recently synthesized DAT inhibitor known as CT-005404. This compound was
assessed for its ability to reverse the effort-related effects of TBZ, and the suppression of lever
pressing induced by the pro-inflammatory cytokine IL-1β. CT-005404 also produced a
significant increase in lever pressing and decrease in chow intake when administered to rats on
the PROG/chow procedure, and significantly increased extracellular accumbens DA over the
course of >340 minutes. Collectively, results from Chapters 3-5 suggest that novel atypical
DAT inhibitors such as (S)-CE-123, (S, S)-CE-158, and CT-005404 may ultimately be useful as
compounds that are suitable for treating motivational dysfunction.
A critical goal of the final experiments in this dissertation (Chapters 6-7) was to employ
a novel operant lever pressing task and EEG methods to aid in the development of physiological
markers associated with altered DA transmission and effort-related dysfunction in preclinical
animal models that can be readily translated to human studies. In Chapter 6 experiments, the
PROG operant reinforcement schedule was modified to increase the overall work requirement.
After achieving a steady baseline level of responses on the modified PROG schedule, TBZ was
administered, which significantly reduced number of lever presses, time of last response in the
session, and breakpoint ratio. This information was used to guide the experimental design
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outlined in Chapter 7. The final experiments (Chapter 7) employed frontal cortex skull screw
EEG activity recordings in behaving rats under baseline and pharmacological DA manipulations.
Results from this experiment suggested several notable differences in relative frequency band
power and inter-hemispheric coherence as a result of TBZ administration, which can be used as
an initial step towards identifying a physiological biomarker of a low-effort bias and
motivational dysfunctions as seen in clinical depression.

8.2 Chapter 2 Discussion:
The experiments described in Chapter 2 were conducted to evaluate the effects of
chronic DA D2 antagonism in an animal model of effort-related choice behavior in rats. A
chronic subcutaneous infusion of either vehicle, a high dose (HAL 2.0 mg/ml, 3.0 µl/hour), or a
low dose (HAL 1.0 mg/ml, 3.0 µl/hour) of haloperidol was delivered via minipump for a period
of four weeks, followed by a four-week washout. Consistent with previous work involving acute
haloperidol administration (Salamone et al. 1991, 2009; Yohn et al. 2017), our results
demonstrated that continuous chronic infusions of haloperidol to rats produced significant
reductions of high-effort lever pressing on the FR5 procedure (Fig. 2.1), and a shift from lever
pressing to chow intake on the concurrent FR5/chow feeding choice task (Fig. 2.2).
The effects of haloperidol in rats performing on the FR5 lever pressing schedule are
depicted in Figure 2.1. In the drug exposure phase, significant overall effects of week and
treatment group were found. Across weeks, drug treatment produced a significant overall effect
on FR5 lever pressing, which was evident when the high dose was compared to vehicle, but not
when the low dose was compared to vehicle, demonstrating that only the high dose rats lever
pressed significantly less than the vehicle group throughout the drug exposure phase. There was
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very little carry over of the drug effect into the washout phase, as demonstrated by a significant
reduction in lever presses in the high dose group relative to vehicle at only at week 1. This effect
was completely washed out by the second week. During the washout phase of Exp 2.1, a
significant effect of week and week x treatment interaction were found, with no overall
significant effect of treatment group, as the average number of lever presses returned to baseline.
Haloperidol produced a different pattern of dose-related effects on lever pressing in Exp
2.2. As shown in Figures 2.1 and 2.2A, rats in the high dose groups in both studies showed
substantial and significant reductions in lever pressing, which were marked by very large effect
sizes. However, the effects of the low dose were very different in the two studies. While the low
dose did not significantly suppress lever pressing when the FR5 schedule was the only path to
obtain food, and the effect size was relatively low (0.372), there was a significant suppression of
lever pressing in the low dose group that was seen when animals were tested on the FR5/chow
feeding choice task, and the effect size was much larger (0.744). This difference can be attributed
to having the option of freely available lab chow offered in the FR5/chow feeding choice task.
When a substitute food source was available (FR5/chow, Exp 2.2), rats treated with the low as
well as the high dose of haloperidol shifted away from FR5 lever pressing and towards
consumption of the freely available lab chow. However, when the only way to obtain the food
reinforcer was to press the lever (FR5 alone, Exp 2.1), the low dose of haloperidol did not
significantly reduce the tendency of rats to engage in FR5 lever pressing. These findings are
consistent with the results of Cousins and Salamone (1994), who compared the effects of nucleus
accumbens DA depletions induced by 6-hydroxydopamine on FR5 lever pressing vs.
performance on the FR5/chow feeding choice task. They reported that while moderate depletions
of accumbens DA shifted choice behavior in rats performing on the FR5/chow feeding choice
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task, decreasing lever pressing and increasing chow intake, the same animals showed no
significant suppression of FR5 responding when no concurrent chow was available. Similar
findings were described by Yohn et al. (2015a), in which the DA depleting agent TBZ was
assessed for its effort-related effects on a T-maze barrier choice task in rats. TBZ reduced
selection of the high-effort behavior when there was a low-effort option, but did not affect high
density vs. low density arm selection when there was no barrier, or when there were only pellets
in one arm. Such an effect on T-maze performance was also seen after administration of
haloperidol and nucleus accumbens DA depletions induced by 6-hydroxydopamine (Salamone et
al. 1994). In mice tested on the T-maze barrier choice task, haloperidol reduced selection of the
arm with the high density of food reinforcement when that arm was blocked by a barrier, but
when both arms had a barrier, haloperidol did not affect choice (Pardo et al. 2012). Taken
together, these results indicate that the effects of haloperidol and accumbens DA depletions are
not simply due to an effect on primary food reinforcement, appetite, or discrimination of
reinforcement magnitude. In this regard, it is worth emphasizing the effects of DA antagonism
via chronic infusion of haloperidol in this experiment produced effects that do not resemble the
effects of reinforcement or appetite-related manipulations (reinforcer devaluation by pre-feeding,
administration of cannabinoid CB1 antagonist/inverse agonists) in rats (Randall et al. 2012,
2014), or in mice (Pardo et al. 2012; Yang et al. 2020), which decreased both lever pressing and
chow intake. Nevertheless, instrumental responding is consistently impaired by manipulations
that interfere with DA transmission when either there is a very high effort-related challenge (e.g.
Aberman and Salamone 1999; Salamone et al. 2001) or when animals have a low-cost alternative
as a substitute (i.e., the effort-based choice tasks).
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After prolonged exposure to a drug, changes in the effects of the drug, termed ‘tolerance’
or ‘sensitization,’ can occur due to physiological or psychological factors. These phenomena are
often difficult to measure in humans due to extreme variability in an individual’s previous drug
exposure and medication compliance, genetic factors, comorbidities, concomitant treatment
regimens, etc., and are often overlooked by clinicians (Li 2016). Animal research has suggested
that the frequency of repeated antipsychotic dosing (e.g. intermittent vs. continuous) can
influence a drug’s behavioral effects, including potential tolerance and sensitization (Kurachi et
al. 1995; Trevitt et al. 1998; Gao and Li 2014; Sebel et al. 2017). The present experiments were
designed to assess the effects of continuous exposure to haloperidol at two different doses over
the course of four weeks, and to observe for signs of tolerance or sensitization, demonstrated by
either an increase or decrease in the effects of the drug across weeks. In these experiments, there
was clearly an overall significant effect of haloperidol treatment, but the lack of a week x
treatment interaction indicates that rats did not develop tolerance or sensitization to haloperidol
at either dose. Nevertheless, the response to acute haloperidol after washout from a period of
chronic administration demands further exploration in order to elucidate the possible roles of
drug exposure duration and concentration on the development of tolerance.
In addition to effects such as drug tolerance or sensitization, prolonged drug exposure can
produce other undesirable effects. Previous work has demonstrated that repeated daily dosing of
haloperidol over the course of 14 days significantly reduced lever pressing and increased chow
intake, without producing a sedative (i.e., drowsiness) effect in the dose range tested (0.05-0.15
mg/kg) (Salamone et al. 1996). In contrast, the atypical antipsychotic drug clozapine clearly
produced sedation (i.e. drowsiness and sleepiness as observed with a reliable rating scale), and
this effect was clearly related to the suppression of lever pressing induced by clozapine. Thus,
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while some antipsychotic drugs show a dissociation between sedative effects and the suppression
of lever pressing, with other drugs these actions appear to be related to each other. The present
studies did not assess sedation or reinforcer preference in the absence of a work component, but
our results suggest that possible sedative effects were unlikely, due to the very substantial intake
of chow consumption observed during the concurrent FR5/chow feeding choice task in Exp 2.2.
This effect was steady over the course of four week drug exposure phase (see Fig. 2.2), and no
overt behavioral differences or drowsiness were observed. Moreover, animals in this study were
able to maintain their target weights throughout the experiment (supplemental chow was given as
needed), whereas rats in a previous pilot experiment given a higher concentration of haloperidol
(3.0 mg/ml) were unable to maintain target weights. Therefore, a ‘high dose’ of 2.0 mg/ml was
determined to be effective at suppressing lever pressing and increasing chow consumption by
altering effort-related choice behavior without any apparent sedation. Moreover, the low dose
was even more selective, in that it clearly suppressed lever pressing and shifted animals to chow
intake when there was a choice, but failed to significantly suppress lever pressing when the only
way to obtain food was to press the lever (i.e., FR5 alone).
This work has important implications for advances in clinical drug therapies for
schizophrenia and related disorders. At baseline, individuals with schizophrenia exhibit effortrelated impairments and other negative symptoms (Gold et al. 2013; Strauss et al. 2014;
Treadway et al. 2015). As described earlier, some of the most common antipsychotics do not
treat these symptoms, and may even induce or exacerbate them. The present findings highlight
the effort-related motivational impairments that can be produced by antipsychotic medications
such as haloperidol. Several types of drugs such as adenosine A2A receptor antagonists, glycine
uptake inhibitors, and atypical DAT inhibitors have demonstrated the ability to attenuate the
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motivational effects of DA D2 antagonists and DA depleting agents in animals with limited signs
of potential side effects (Salamone et al. 2009; Yohn et al. 2017; Rotolo et al. 2019), however,
these potential treatments have not yet been assessed in chronic administration models. Future
studies should assess whether chronic co-administration of drugs in these classes reduces the
effects of reduced DA transmission, which may ultimately improve clinical therapeutic strategies
for the negative symptoms of schizophrenia and other affective disorders.

8.3 Chapter 3 Discussion:
The synthesis of (S)-CE-123 afforded highly pure desired enantiomer, and NMRs and
mass spectroscopy methods yielded spectra unambiguously identifying the compound (see
supplementary materials of Rotolo et al. 2019). In previous studies, the absolute configuration
was characterized as the (S)-enantiomer which was shown to be stronger at inhibiting DAT than
the (R)-enantiomer (Nikiforuk et al. 2017). In uptake inhibition assays conducted in HEK293
cells stably expressing human isoforms of DAT, NET and SERT, the EC 50 for inhibition of DAT
by (S)-CE-123 was reported to be 2.76 x 10-6M, which was 30-fold selective relative to
inhibition of NET and more than 400-fold selective compared to SERT inhibition (Nikiforuk et
al. 2017, supplementary figure 17A). Thus, we present the first enantioselective synthesis of (S)CE-123.
The behavioral studies sought to provide an initial characterization of the behavioral
effects of the novel atypical DAT inhibitor, (S)-CE-123, in terms of its ability to alter effortrelated choice behavior in rats. Specifically, one of the experiments employed a task designed to
measure effort-related choice, which was used to assess the ability of (S)-CE-123 to reverse the
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effort-related effects of TBZ. In this experiment, rats trained on the FR5/chow feeding choice
task shifted from the high effort option (FR5 lever pressing) to the low-effort option (chow
intake) when treated with TBZ, consistent with previous findings (Nunes et al. 2013; Randall et
al. 2014; Yohn et al. 2015a,b,c). Several previous studies with TBZ have shown that these shifts
in effort-based choice are not due to changes in food intake, food preference, sucrose preference,
motor incapacity, or reference memory, and do not resemble the effects of appetite suppressant
drugs or reward devaluation by pre-feeding (Nunes et al. 2013; Randall et al. 2014; Yohn et al.
2015a; Pardo et al. 2015). Co-administration of 24.0 mg/kg (S)-CE-123 with TBZ produced a
significant but partial reversal of the effects of TBZ, as indicated by an increased selection of
FR5 lever pressing (Fig. 3.2A) and a decrease in chow intake (Fig. 3.2B) compared to TBZ plus
vehicle. In a parallel control experiment in rats tested on the same task, 24.0 mg/kg (S)-CE-123
administered in the absence of TBZ did not did not have any effect on lever pressing (Fig. 3.3A)
or chow intake (Fig. 3.3B).
In order to develop a more comprehensive characterization of the effort-related actions of
monoamine uptake inhibitors, it also is important to administer them alone, in the absence of a
drug like TBZ, because that would allow for the assessment of both increases and decreases in
performance, in the absence of a drug condition like TBZ, which induces an impairment. In
previous studies, the PROG/chow feeding choice task has been used to assess the ability of drugs
to enhance selection of high effort PROG lever pressing (e.g. Randall et al. 2012, 2015). This
task is especially well suited for such an assessment because unlike the FR5/chow feeding choice
task, baseline lever pressing rates are relatively low on the PROG component due to the
increasing response requirement of the PROG schedule. Thus, as the ratio work requirement gets
gradually higher, animals eventually shift over to chow consumption (Randall et al. 2012, 2014,
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2015). Previous research has demonstrated that the NET inhibitors desipramine and atomoxetine,
as well as the SERT inhibitor fluoxetine, all fail to increase PROG lever pressing in rats tested on
the PROG/chow feeding choice procedure (Yohn et al. 2016d). In contrast, drugs that inhibit
DAT, including bupropion, lisdexamfetamine, PRX-14040, MRZ-9547, and GBR 12909 all have
been shown to increase selection of PROG responding on this task (Sommer et al. 2014; Randall
et al. 2015; Yohn et al. 2016b,c,d). In the present studies, (S)-CE-123 was shown to significantly
increase PROG lever pressing and decrease chow intake in rats tested on the PROG/choice
procedure (Fig. 3.4). Furthermore, the effective dose of (S)-CE-123 in both the TBZ reversal and
PROG/chow feeding choice studies, 24.0 mg/kg, significantly increased extracellular DA in
nucleus accumbens core as measured by microdialysis (Fig. 3.5). The magnitude of the
increases in PROG lever pressing and accumbens core DA shown in the present studies with (S)CE-123 are comparable to those reported previously for 20.0 mg/kg bupropion (Randall et al.
2015). It is not clear why extracellular DA did not increase in the nucleus accumbens shell after
injections of (S)-CE-123, however, DA did substantially increase in the core, and previous work
has shown that the core subregion is a critical site at which effort-based choice is regulated
(Sokolowski and Salamone 1998; Ghods-Sharifi and Floresco 2010; Farrar et al. 2010; Randall
et al. 2012; Nunes et al. 2013).
Several lines of evidence indicate that DAT blockers can have pro-motivational effects in
animal models (Nunes et al. 2013; Randall et al. 2015; Sommer et al. 2014; Yohn et al.
2016a,b,c,d). Although DAT inhibition is a commonly used descriptor for a broad class of drugs,
there is considerable heterogeneity within this group of compounds. For example, amphetamines
such as d-amphetamine and methamphetamine are not only competitive inhibitors of DAT; they
also are substrates that are transported into the neuronal terminal and stimulate release (Ferris et
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al. 2011). Cocaine is a classical DAT inhibitor with a rapid onset and offset of action (Tanda et
al. 2013). Unfortunately, most classical DAT inhibitors and releasing agents have a well
characterized abuse liability (Todtenkopf and Carlezon 2006; Ostlund et al. 2014; Dong et al.
2017), which limits their therapeutic utility for treating motivational dysfunction in psychiatry.
However, not all drugs that bind to the DAT share cocaine’s behavioral profile or have a high
potential for abuse. Over the last several years, atypical DAT inhibitors have been under
development, which have characteristics that differ from cocaine. GBR12909 was developed as a
potential treatment for cocaine addiction (Rothman et al. 2008). GBR12909 blocks many of the
effects of cocaine, and on its own has produced mixed effects in terms of cocaine-like actions; it
did not produce psychostimulant effects in people in the dose ranges tested (Sogaard et al. 1990;
Preti 2000), and although it supported self-administration in primates, its efficacy was lower than
that of cocaine (Woolverton et al. 2001). Although GBR12909 was discontinued as a potential
treatment for cocaine abuse due to its cardiac effects, analogs of GBR12909 have been studied
for their atypical binding characteristics (Rothman et al. 2008). The DAT has multiple functional
conformations, and several benztropine analogs have been shown to bind to the DAT in a
manner that is distinct from that of cocaine (Schmidt et al. 2008; Kohut et al. 2014). Some of
these benztropine analogs have been shown to increase extracellular DA in nucleus accumbens,
albeit over a much longer time course than cocaine (Tanda et al. 2013). Unlike cocaine, these
drugs failed to induce conditioned place preference (Tanda et al. 2013).
(S)-CE-123 is an analog of modafinil, which also binds to the DAT with an atypical
profile (Schmitt and Reith 2011; Cao et al. 2016). Modafinil inhibits DAT and increases
extracellular DA over a broad time course (Mereu et al. 2017), and while this drug has been
shown to have cognitive enhancing and pro-motivational effects, it has a relatively low abuse
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liability (Müller et al. 2013; Mereu et al. 2013). Modafinil has been reported to improve fatigue
symptoms in depressed patients (Lam et al. 2007), and recent studies from our laboratory have
shown that modafinil can reverse the low-effort bias induced by TBZ in rats (Yohn et al. 2016c;
Salamone et al. 2016a). When bound to the DAT, (S)-CE-123 also has an atypical pattern
compared to cocaine, in that it interacts with the negatively charged ASP79 locus (Kristofova et
al., 2018). Moreover, (S)-CE-123 acts as a highly selective atypical inhibitor of DAT relative to
NET and SERT, and is more selective for DAT than modafinil (Kristofova et al. 2018). (S)-CE123 has been shown to enhance cognitive flexibility, improve memory acquisition and retrieval,
and reduce impulsivity in rats (Nikiforuk et al. 2017; Kristofova et al. 2018), and in the present
studies, it reverses the motivational impairments induced by TBZ and increases selection of
high-effort PROG lever pressing.
In the present studies, a partial reversal of the effort-related motivational dysfunction
induced by TBZ was achieved with (S)-CE-123 administration in a dose range of 6.0-24.0
mg/kg. The efficacy of (S)-CE-123 at restoring lever pressing appears to be lower than that of
bupropion, GBR12909, lisdexamfetamine, methylphenidate and modafinil in rats tested on
similar procedures (Nunes et al. 2013; Yohn et al. 2016a,b,c; Salamone et al. 2016a), although
most drugs that block DAT tend to produce only partial reversals of the effects of TBZ (i.e.,
approximately 60-85% restoration of responding). Nevertheless, (S)-CE-123 was highly
efficacious at reversing the TBZ-induced increase in chow intake (Fig. 3.2B), which may
indicate that this drug also has appetite suppressant actions. These potential appetite suppressant
effects of (S)-CE-123 would suggest that the increases in lever pressing seen in the FR5 and
PROG/chow feeding choice studies are not due to an increase in appetite. Drugs that inhibit DAT
bind across a broad range of affinities, which is potentially related to differences in potency seen

112

in behavioral experiments. High affinity drugs such as d-amphetamine, methylphenidate, PRX14040, and GBR12909 have a relatively high potency for reversing the effects of TBZ (Yohn et
al. 2016a,b,c,d; Salamone et al. 2016a). In contrast, compounds with lower DAT binding
affinities such as bupropion, modafinil and (S)-CE-123 tend to be less potent at reversing the
effects of TBZ (i.e., they require higher doses; Nunes et al. 2013; Salamone et al. 2017a; present
studies).
Future studies should examine a larger group of atypical DAT blockers to determine the
overall relation between the neurochemical characteristics of these compounds (e.g. DAT
affinity, selectivity and binding locus, effects on DAT trafficking (Mash et al., 2002; Vaughan et
al., 2013), dynamics of effects on extracellular DA) and their effort-related behavioral effects.
Furthermore, behavioral studies should be extended to include tasks that provide information
about other behavioral effects, including locomotor activity, and most importantly, potential
abuse liability. Drugs such as amphetamine and methylphenidate can increase selection of higheffort activity in humans (Wardle et al. 2011), and can improve motivational function in
depressed patients (Stotz et al. 1999), but they also are well known for their abuse liability. In
contrast, the atypical DAT blocker modafinil has been reported to improve motivational function
in depressed patients (Lam et al. 2007), albeit without a strong abuse liability. The molecular
interactions that occur as a result of the particular functional configuration of the DAT as it binds
to drugs that block its action may be related to the diversity of patterns of abuse potential seen
across multiple drugs (Tanda et al. 2013). Thus, the binding characteristics of drugs like
modafinil and its analogs, such as (S)-CE-123, suggest that novel compounds may ultimately be
identified that are suitable for treating motivational dysfunction, and future studies should
determine if (S)-CE-123 shows signs have having substantial abuse potential.
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8.4 Chapter 4 Discussion:
DAT inhibitors with atypical binding characteristics are being studied for their ability to
ameliorate effort-related symptoms of fatigue and motivational dysfunction in rodents. The
present work focused on the pharmacodynamic, neurochemical, and behavioral profile of the
recently synthesized modafinil analog, (S, S)-CE-158. To determine the selectivity of (S, S)-CE158 for the DAT, in vitro binding and monoamine transporters reuptake inhibition experiments
were conducted using transfected HEK293 cells expressing human isoforms of DAT, NET, and
SERT. In the present study, the IC50 of (S, S)-CE-158 binding to the DAT was reported to be
0.052 µM, while its DAT inhibition was greater than 50-fold selective relative to NET (SERT
reuptake inhibition was undetected; Fig. 4.2, 4.3). These patterns are consistent with results from
inhibition assays measuring the EC50 for inhibition of monoamine transporters of the previously
synthesized compound, (S)-CE-123, which revealed a 30-fold selective inhibition of DAT
relative to NET and more than 400-fold selective compared to SERT (Nikiforuk et al. 2017). By
direct comparison, (S, S)-CE-158 is even more selective for the DAT than (S)-CE-123,
supporting its potential use as a DAT inhibitor with limited off-target effects.
The FR5/chow feeding choice experiment was performed to investigate the effects of (S,
S)-CE-158 for its ability to reverse the effort-related effects of TBZ. Consistent with previous
findings (Nunes et al. 2013; Randall et al. 2014; Yohn et al. 2015a,b,c; Rotolo et al. 2019),
administration of 1.0 mg/kg TBZ shifted choice behavior, decreasing high effort lever pressing
and increasing low-effort chow intake (Fig. 4.4). Previous research has shown that the effects of
TBZ on effort-related choice are not due to actions on the intake of or preference for the two
foods used in the FR5/choice task (Nunes et al. 2013), discrimination of reinforcer magnitude or
reference memory (Yohn et al. 2015a), or sucrose preference or hedonic reactivity (Pardo et al.
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2015). Furthermore, the effects of TBZ on effort-based tasks do not resemble the effects of
reinforcer devaluation by reduction in food motivation, or appetite suppressant drugs (Randall et
al. 2012, 2014; Yang et al. 2020). For these reasons, and also because TBZ induces motivational
symptoms such as fatigue in humans (Chitnis and Karunapuzha, 2009; Frank, 2010; Chen et al.
2012), TBZ was used in the present experiment to provide a challenge to the tendency of rats to
exert physical effort when given a choice.
Co-administration of 8.0 mg/kg (S, S)-CE-158 with TBZ resulted in a significant reversal
of the effects of TBZ on both lever pressing and chow intake. The magnitude of this effect can
be observed by comparing the average number of lever presses at the dose that produced a
significant reversal to the number of lever presses in the vehicle group. Here, the coadministration of 8.0 mg/kg (S, S)-CE-158 with TBZ yielded a lever pressing average which was
85% of the vehicle/vehicle average (Fig. 4.4a), whereas Rotolo et al. (2019) reported only a 40%
restoration of the vehicle/vehicle lever pressing average when the highest dose of (S)-CE-123
(24.0 mg/kg) was co-administered with TBZ. The ability of (S)-CE-123 to only partially reverse
the effects of TBZ was attributed to possible appetite suppressant actions, which were not
observed in the present experiment. Moreover, the efficacy of (S, S)-CE-158 for reversing the
effort-related motivational dysfunction induced by TBZ is comparable to a group of DAT
inhibitors including GBR12909, lisdexamfetamine, and methylphenidate in terms of their
relatively large effects in terms of reversing the effects of TBZ (Salamone et al., 2016a; Yohn et
al., 2016a,b,c).
To measure its effect when administered alone, (S, S)-CE-158 was administered to rats
trained on the concurrent PROG/chow feeding choice task. This task is well suited for assessing
the effects of a drug when administered alone, in terms of increasing the motivation to exert high
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levels of effort on a more highly demanding task. In the present study, (S, S)-CE-158
significantly increased the selection of the high-effort option (lever pressing) and a reduced
selection of the low-effort option (chow intake) at both the 4.0 mg/kg and 8.0 mg/kg doses (Fig.
4.5). These results are consistent with previous experiments demonstrating that DAT inhibitors
such as bupropion, lisdexamfetamine, MRZ-9547, and PRX-14040 significantly increased
PROG lever pressing and decreasing chow consumption (Sommer et al. 2014; Randall et al.,
2015; Yohn et al., 2016b,c,d), whereas drugs that inhibit NET and SERT did not (Yohn et al.
2016d). These results also are consistent with the findings of Cagniard et al. (2006), who
reported that DAT knockdown increased selection of lever pressing in mice tested on an effortbased choice task, and with Wardle et al. (2011), who reported that amphetamine increased
selection of high-effort activity in human participants. Furthermore, it was shown that systemic
administration of (S, S)-CE-158 at a dose of 8.0 mg/kg significantly increased extracellular DA
in the nucleus accumbens core as measured by microdialysis (Fig. 4.6). The peak increase in DA
at 30-90 minutes post-injection is aligned with the time course used for the behavioral
pharmacology experiments (i.e. 30 min injection lead time prior to a 30 min task). Systemic
administration of DAT inhibitors in rodents has been reported to increase extracellular DA in the
nucleus accumbens core, which has been associated with increased motivation (Yohn et al.
2016d; Rotolo et al. 2019) and pro-cognitive effects such as enhanced recognition memory
(Carnats-Perna et al. 2019).
The ability of (S)-CE-123 and (S, S)-CE-158 to increase motivation and ameliorate effortrelated impairments can be seen as complimentary to the known effects of their parent
compound, modafinil. In addition to its prescribed indication as a treatment for narcolepsy,
modafinil is frequently used by many individuals as a nootropic, for off-label effects such as
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cognitive enhancement (Sahakian and Morein-Zamir, 2011; Battleday and Brem, 2015; Sousa
and Dinis-Oliveira, 2020; Teodorini et al. 2020). Memory and cognitive flexibility have been
described as effects of both the S-configuration and the racemic mixture of the thiazolecontaining modafinil analog, CE-123 (Nikiforuk et al. 2017; Kristofova et al. 2018; CarnatsPerna et al. 2019). Interestingly, it has been suggested that modafinil’s effects related to
cognitive processes and task engagement may be dependent on fronto-striatal circuitry, rather
than hippocampal (Müller et al. 2013), which further supports the utility of these drugs as
treatments for effort-related dysfunction. Moreover, it has been suggested that modafinil and its
derivatives possess anti-inflammatory properties in vitro (Jung et al. 2012) and in vivo (Zager et
al. 2017; Han et al. 2018; Brandão et al. 2019), and may reduce multiple sclerosis fatigue in
humans (Shangyan et al. 2018), underlying possible utility of these compounds to attenuate
symptoms of various disorders that are propagated by inflammatory cascades. Therefore, results
from the current studies may be useful to guide future assessments of atypical DAT inhibitors to
expand the clinical indications for modafinil and similar compounds.
In summary, these experiments contributed to the characterization of a recently
developed group of atypical DAT inhibitor compounds, by demonstrating the ability of (S, S)CE-158 to reverse the effort-related effects of TBZ, and increase high-effort responding in tasks
measuring effort-based choice. Additionally, it was shown that systemic administration of (S, S)CE-158 increased extracellular DA in the nucleus accumbens during the behaviorally active time
course. The behavioral assessment of atypical DAT inhibitors such as analogs of benztropine,
GBR12909 and modafinil has led to the discovery that not all inhibitors of DA uptake show
signs of abuse liability to the same extent as the classical DAT inhibitors that are major
psychostimulants such as cocaine (Sogaard et al. 1990; Preti 2000; Woolverton et al. 2001;
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Loland et al. 2008; Schmitt et al. 2008; Esumi et al. 2012; Tanda et al. 2013; Mereu et al. 2013).
These results suggest it is possible that atypical DAT inhibitors may be effective at reducing
motivational impairments with minimal induction of major psychomotor side effects or abuse
liability. Ultimately, this research will guide future studies to advance target identification for
treatments of motivational dysfunction. These and other similar findings could lead to the
development of atypical DA uptake blockers that could potentially treat motivational symptoms
of depression, chronic fatigue syndrome, or other disorders, while reducing undesirable side
effects.

8.5 Chapter 5 Discussion:
Motivational dysfunctions such as anergia, fatigue, and low-effort bias are debilitating
treatment-resistant psychiatric symptoms that span multiple disorders, including MDD, PD,
schizophrenia and MS (Treadway et al. 2012; Yang et al. 2014; Zimmerman et al. 2015; Corfield
et al. 2016; Chong et al. 2016; Barch et al. 2017; Le Heron et al. 2019). In view of data from
animal models and human studies indicating that DA systems regulate behavioral activation and
effort-related function, DAT inhibitors considerable potential as treatment targets. The present
studies showed that the novel compound CT-005404 selectively binds to DAT relative to NET
and SERT (Table 5.1), and also increases extracellular DA with a prolonged time course as
measured by microdialysis (Fig. 5.1). Furthermore, CT-005404 reversed the low-effort bias
induced by the VMAT-2 inhibitor TBZ (Fig. 5.2), as well as the suppression of lever pressing
induced by the pro-inflammatory cytokine IL-1β (Fig. 5.3). When administered alone, CT005404 increased the tendency to select high-effort PROG lever pressing (Fig. 5.4). Taken
together, these results suggest that CT-005404 has the profile of a drug that could be useful for
the treatment of effort-related motivational dysfunctions in humans.
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Consistent with previous studies (Nunes et al. 2013), 1.0 mg/kg TBZ shifted effort-based
choice, significantly decreasing FR5 lever pressing while increasing intake of the concurrently
available chow. The ability of TBZ to induce this effect is not dependent on changes in food
intake or food preference, and does not resemble the effects of appetite suppressant drugs or
reinforcer devaluation on this task (Salamone et al. 1991, 2002; Sink et al. 2008; Nunes et al.
2013). Co-administration of CT-005404 with TBZ led to a significant but partial reversal of the
effects of TBZ. Compared to TBZ alone, rats administered TBZ plus 15.0 and 30.0 mg/kg doses
of CT-005404 showed significant increases in lever pressing and decreases in chow intake (Fig.
5.2). Consistent with the gradual and prolonged elevations in extracellular DA that were seen in
the microdialysis experiment, CT-005404 was able to reverse the effects of TBZ over the period
of 3-4.5 hours after its p.o. administration. The ability of CT-005404 to show positive effects in
the TBZ model is consistent with previously published studies showing that a variety of
compounds that block DAT, including the catecholamine uptake inhibitor bupropion (Nunes et
al. 2013; Yohn et al. 2016b), and the DAT inhibitors lisdexamfetamine, GBR 12909, and PRX14040 (Yohn et al. 2016a,b,c,d), all act to reverse the effort-related effects of TBZ.
Pro-inflammatory cytokines play a significant role in mediating central and peripheral
immune responses, but it has become evident that these proteins also are involved in the
manifestation of psychopathological symptoms including anergia, fatigue, and amotivation
(Dantzer 2001; Dantzer et al. 2009; Felger and Miller 2012; Felger and Treadway 2017).
Increased expression of pro-inflammatory cytokines such as tumor necrosis factor alpha (TNFα), interleukin 6 (IL-6), interferon alpha (IFN-α), and IL-1β in patients with major depression
(Yang et al. 2007; Dantzer et al. 2008; Dowlati et al. 2010; Cattaneo et al. 2013; Rossi et al.
2017). mRNA levels of inflammatory markers including IL-1β, macrophage inhibiting factor,
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and TNF-α, were reported to be negatively correlated with antidepressant treatment response
(Cattaneo et al. 2013). TNF-α, IL-6, and IL-1β are also elevated in patients with MS, and
increased levels of TNF-α and IL-1β are correlated with clinical depression symptom severity in
MS patients (Rossi et al. 2017). IL-1β was shown to decrease lever pressing and slightly increase
chow intake in rats tested on the FR5/chow feeding choice task (Nunes et al. 2014). In the
present studies, IL-1β was used to provide an inflammatory challenge, which may be relevant for
understanding disorders associated with elevated inflammation including MDD and MS. CT005404 was co-administered with IL-1β (4.0 µg/kg) at doses ranging from 7.5-30.0 mg/kg i.p.
IL-1β administration significantly decreased lever pressing, without altering chow intake. The
15.0 and 30 mg/kg doses of CT-005404 partially but significantly reversed the effects of IL-1β,
significantly increasing lever pressing compared to treatment with IL-1β alone (Fig. 5.3).
Evidence indicates that brain DA transmission interacts with the effects of pro-inflammatory
cytokines. Pro-inflammatory cytokine signaling has a modulatory effect on some aspect of
monoamine synthesis and/or transmission (Rossi et al. 2010; Gentile et al. 2015; Felger and
Treadway 2017). Extracellular levels of DA in nucleus accumbens were reduced by
administration of IL-6 in rats at a dose that suppressed lever pressing, and the DAT inhibitor
methylphenidate reversed the lever pressing suppression induced by IL-6 (Yohn et al. 2016),
which is consistent with the ability of CT-005404 to reverse the suppression of lever pressing
induced by IL-1β.
The PROG/chow feeding choice task provides a stronger effort-related challenge than the
FR5/chow choice task, because the lever pressing work requirement gradually increments
throughout the session. This task generates substantial variability in PROG lever pressing output
(Randall et al. 2012, 2014, 2015), which also was observed in the present results. Administration
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of CT-005404 alone led to a significant linear dose-related increase in PROG lever pressing, as
well as a decrease in chow intake. The highest dose of CT-005404 significantly increased PROG
lever pressing and decrease chow intake relative to vehicle (Fig. 5.4), suggesting that the
administration of this novel DAT inhibitor increased the tendency of animals to select the higheffort lever pressing component of the task. This finding is consistent with previous studies
showing that selection of PROG lever pressing relative to chow intake was increased by several
drugs that inhibit DAT, including bupropion, lisdexamfetamine, GBR 12909, and PRX-14040
(Randall et al. 2015; Yohn et al. 2016b,c,d). Taken together, these studies demonstrate that DA
transmission exerts a bi-directional control over effort-based decision making, i.e., that
interference with DA transmission induces a low-effort bias, while augmentation of DA
transmission by blockade of DAT increases selection of high-effort lever pressing. These
findings also are consistent with Wardle et al. (2011), who reported that amphetamine increased
selection of high-effort activity in human participants.
In summary, CT-005404 is a novel DAT inhibitor that binds selectively to DAT
compared to NET and SERT, increases extracellular DA in nucleus accumbens, reverses the
suppression of lever pressing induced by TBZ and IL-1β, and when administered alone,
increases the tendency to select high-effort PROG lever pressing. Thus, CT-005404 has a profile
similar to that shown by bupropion, modafinil, and methylphenidate, which are drugs that have
been shown to improve motivational function in humans. Future research should determine if
CT-005404 shows signs of abuse liability. It is possible that CT-5404 or other novel DAT
inhibitors could ultimately be useful as treatments for motivational dysfunction in humans
suffering from MDD, Parkinsonism, MS, or other disorders.
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8.6 Chapter 6 Discussion:
This experiment was undertaken to develop a modified PROG task to be used for
assessments of effort-based decision making in rats, and to assess the effects of DA depletions on
several measures of high-effort responding during the PROG session. Although most studies
with PROG schedules are relatively open ended in terms of session times, this specific task was
developed in order to obtain break points from animals during a 30-minute session, so that in the
future recording experiments can readily be done during the period of time in which rats show
break points. Although it has sometimes been thought that PROG break points are measures of
“reward” or “reinforcement efficacy”, PROG break points are most directly a measure of how
much work an organism will do to obtain reinforcement (Stewart 1974; Salamone 2006). For
example, increasing the work requirement by increasing the height of the lever has been reported
to decrease progressive ratio break points (Skjoldager, Pierre and Mittlman 1993; Schmelzeis
and Mittleman 1996). Thus, PROG tasks are useful in studying the activational aspects of
motivation and the tendency to work for food reinforcement (Salamone 2006; Salamone and
Correa 2002; Salamone et al. 2016a), and how those the tendency to work for reinforcement is
sensitive to various pharmacological manipulations. Though the PROG/chow feeding choice task
has been used as a reliable model of effort-related choice behavior in animals for a number of
years (Randall et al. 2012, 2014, 2015; Sommer et al. 2014; Yohn et al. 2016b,c,d, 2018), this
study was the first to examine the effects of altering ratio requirements on PROG work output
(e.g. lever pressing, time of last response, and breakpoint ratio) through distinct training phases
in the same cohort of rats over a number of weeks, and the first to examine the effects of TBZ on
high-effort work output on this modified schedule.
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By separating the training into separate phases, we were able to determine the point at
which the parameter modifications were difficult enough to cause the majority of rats to cease
responding, or ‘break’ during a 30-minute session. As depicted in Figure 6.1, the PROG (N=1;
I=4) schedule was chosen as the schedule to be used for the behavioral pharmacology
experiments. A four-day sample of baseline data taken from the ‘N=1; I=4’ training phase
indicated that only three of sixteen rats did not break prior to the end of the 30-minute session. It
was also observed that the rats that demonstrated breakpoints prior to the session end typically
ceased responding within the first three quarters of the session. These data should be used to
inform future studies of effort-related choice, ultimately allowing for direct observations of the
behavioral and electrophysiological changes that are taking place as an animal shifts away from
engaging in a high-effort task.
The behavioral pharmacology experiment assessed the effects of tetrabenazine
administration on total lever presses, time of last response, and break point ratio. Tetrabenazine
administration resulted in significant reductions of all three measures (Fig. 6.2). These findings
indicate that reduced DA transmission causes animals to exert less effort to overcome an
instrumental response cost, effectively modeling the motivational deficits observed in individuals
with neurological or psychiatric disorders. While treatment with DA antagonists or depleting
agents causes animals to shift from choosing high- to low-effort options in tasks motivated by
food, previous research has shown that this is not due to reduced appetite or alterations in
preference or hedonic taste reactivity as the animals’ preference for the high-density arm or high
carbohydrate pellet is still intact (Salamone et al. 1994; Berridge and Robinson, 1998; Randall et
al. 2012, 2014; Nunes et al. 2013; Pardo et al. 2015; Yohn et al. 2015a). Similarly, it is important
to note that humans with depression still maintain preference and the ability to perceive hedonic
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stimuli, but lack the drive to exert the effort required to obtain it (Treadway and Zald, 2011;
Treadway, 2012). When administered a drug that blocked catecholamine synthesis, human
subjects were still able to detect the hedonic properties of cigarette smoking, and still
experienced feelings of craving, but demonstrated lower response break points on the PROG
schedule, indicating a reduced willingness to work for cigarettes (Venugopalan et al. 2011). In
summary, DA depletions cause reductions in rats’ willingness to exert effort on the PROG lever
pressing procedure, which can be compared to human studies of psychopathology related to the
exertion of physical effort. In this regard, it is interesting to note that clinical studies have shown
that willingness to work for monetary reward on a PROG task was impaired in people with
depression and bipolar depression (Hershenberg et al. 2016).
The development of behavioral tasks that requires high levels of effort is critical for
inducing a low-effort bias in animals. The systematic adjustments that were made to the PROG
reinforcement schedule in this study have provided useful information about the effects of
increasing: a) the number of reinforcers delivered at each ratio requirement (N); and b) the
increment at which the ratio requirement increases after N reinforcers are delivered (I). In
addition, the modified PROG task developed here will foster the study of EEG activity in
behaving rats as they shift from high-effort lever pressing to the low-effort alternative, which
will serve as a pre-clinical model of the physiological and neural changes that are relevant in
human fatigue, anergia, and psychomotor slowing. Ultimately, these studies may allow for the
assessment of identifiable patterns of prefrontal/frontal activity that may be relatable to the
exertion of effort.
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8.7 Chapter 7 Discussion:
Our initial studies involving EEG recording have focused on conducting power spectral
density analyses of signals obtained from frontal and parietal cortex, and determining the effects
of TBZ, in untrained freely moving animals. These experiments were intended to be preliminary
studies that allow for the development of EEG and data analysis methods that could lay the
groundwork for future studies performed on trained animals performing on effort-related choice
tasks. Ultimately, this research could allow for the development of EEG markers of effort-based
choice that are translatable to humans. Furthermore, future research will study the behavioral and
EEG effects of pharmacological manipulations that affect effort-based choice in trained animals,
so that we can create larger, more robust variations in approach motivation that will potentially
allow us to identify more sensitive electrophysiological biomarkers.
Results from the Chapter 7 studies identified at least one major difference in relative
frequency band power as a result of TBZ administration, and also focused on inter-hemispheric
coherence based on electrode placements. Data from six rats treated with 1.0 mg/kg TBZ
demonstrated a reduction of power in a range of 7-8 Hz relative to baseline (Fig. 7.1). Although
8 Hz frequency bands can be categorized as within the alpha frequency range, theta oscillations
have been reported within a frequency range of 4-12 Hz (Buzsaki et al. 1983; Penley et al. 2011).
Theta and gamma oscillations originating from hippocampal structures have been implicated in
activities such as locomotion and task engagement in the awake rat (Penley et al. 2011; Hinman
et al. 2013; Jacobson et al. 2013; Schmidt et al. 2013), and thus should be considered as possible
contributors to the cortical EEG signals observed in the present studies. Furthermore, our results
suggested that TBZ did not seem to affect inter-hemispheric coherence of EEG signal from skull
screw electrodes. Pharmacological manipulations and lesion studies have been shown to affect
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relative beta, theta, and gamma frequency power as well as measures of coherence as measured
by EEG and LFP signals in the rat brain (Pálenícek et al. 2011, 2013; Hinman et al. 2013; West
et al. 2018). For example, the DAT inhibitor amphetamine caused an increase in theta and alpha
band coherence and a decrease in beta coherence, which was linked to an increase in locomotion
and extracellular accumbens DA (Pálenícek et al. 2013). These studies emphasize the importance
of studying both intra- and inter-hemispheric coherence in future studies assessing the effects of
TBZ in behaving rats. Nevertheless, the data shown in Figure 7.2 suggest that the position of
electrodes greatly affected the signal coherence, as demonstrated by the strongest signal
coherence between two frontal electrodes positioned on either side of the midline, and two
parietal electrodes positioned on either side of the midline, regardless of drug treatment. Results
from this initial study demonstrate the feasibility of doing recording experiments with a
relatively high degree of spatial resolution (i.e. differentiating prefrontal and parietal cortical
areas) and a notable sensitivity to changes induced by pharmacological manipulations.
Considering that the data reported here reflect EEG activity in an awake rat under
baseline conditions, it is expected that rats behaving on the PROG task will show marked
differences in EEG activity across multiple frequency bands. For example, animals engaging in
high-effort PROG lever pressing may demonstrate lower frontal-frontal coherence, as human
studies have posited a relation between frontal alpha asymmetry and motivated behaviors, as
well as a reduced propensity to exhibit depressive symptoms (Pizzagalli et al. 2005; Nelson et al.
2018; Gheza et al. 2019). Furthermore, changes to beta power may be observed in animals
engaging in the PROG task under baseline (non-drug) conditions and after treatment with TBZ.
Beta oscillations in cortical-basal ganglia circuits have been highlighted as a critical modulator
of movement-related activity (Leventhal et al. 2012; Schmidt and Berke et al. 2017), and
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abnormal beta rhythms have been linked to the motor impairments seen in Parkinson’s disease
(Levy et al. 200l; West et al. 2018) and to pathological motor output in animals during task
engagement (Leventhal et al. 2012). Therefore, the reduction of DA transmission in striatal areas
caused by TBZ may result in alterations in beta power in rats that are correlates of a low-effort
bias during PROG performance. Although TBZ primarily affects subcortical DA transmission in
DA-rich striatal areas (Pettibone et al. 1984; Tanra et al. 1995), a sparse DA innervation also is
present in areas of cortex other than prefrontal regions, with an anterior/posterior gradient (Vitrac
and Benoit-Marand 2017), and thus TBZ may affect cortical DA transmission in ways that have
not yet been elucidated.
The initial step in this study was to establish reliable procedures for recording frontal
cortex EEG signals in awake rats. Now that initial procedures have been established, future work
will aim to record EEG activity while rats are performing on a high-effort lever pressing task
(PROG) under baseline conditions and after pharmacological challenges that produce
motivational deficits. Since PROG responding is characterized by initial periods of responding
followed by a cessation of responding (i.e., “breaking” or ratio strain), a major goal of this future
work will be to determine if there are differences in frontal cortical EEG activity during the
initial period of responding vs. the period during and after the breakpoint. Ideally, this
experiment will involve cohorts of male and female rats that will be trained on the modified
PROG task developed in the studies outlined in Chapter 6. Once sufficiently trained, rats will be
surgically implanted with up to six cortical EEG electrodes adjacent to the frontal cortex and
parietal cortex as additional reference points. After recovery, rats will be tested on their
respective behavioral tasks under baseline (non-drug) conditions and EEG activity will be
recorded throughout the behavioral sessions. Then, rats will be tested on their respective
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behavioral tasks under pharmacological challenge with the VMAT-2 inhibitor TBZ. Additional
studies will involve administration of TBZ to induce lower breakpoints, in order to determine if
the changes in PROG responding induced by TBZ covary with changes in EEG activity. Based
upon the Pizzagalli et al. (2005), Nelson et al. (2018), and Gheza et al. (2019) papers, as well as
the present studies, it is hypothesized that engagement in high-effort lever pressing activity in the
PROG will be marked by changes in frontal EEG activity, and possibly changes in parietal
cortex, and in frequency bands other than alpha, such as theta beta, and gamma, as well.
Furthermore, it is hypothesized that when animals trained on the PROG task reach their break
point ratio, stop lever pressing, and shift to chow consumption, there will be changes in frontal
EEG activity. Lastly, it is hypothesized that TBZ will shift effort-related choice behavior,
decreasing lever pressing and increasing chow intake, which will thus alter the pattern of frontal
cortex EEG activity relative to baseline conditions. These results could lead to a greater
understanding of the circuit mechanisms that underlie effort-based aspects of motivation, while
providing preclinical animal data leading to the development of physiological biomarkers of
exertion of effort that can be easily translatable to human clinical research.

8.8 General Discussion and Conclusions

Effort-related motivational dysfunctions such as anergia, lassitude and fatigue are
hallmark symptoms of depression, parkinsonism, schizophrenia, multiple sclerosis, and other
disorders. Unfortunately, the most commonly prescribed medications do not effectively treat
these symptoms, and can sometimes exacerbate them (Fava et al. 2014). Preclinical models of
effort-based decision making can be used to study the amotivation produced by some of the
conditions associated with depression. The use of behavioral tasks to model specific facets of
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depression and other psychiatric disorders is aligned with the NIMH Research Domain Criteria
(RDoC) initiative, which emphasizes the importance of characterizing the neural processes that
underlie the development of specific psychiatric symptoms. Importantly, tasks that have been
designed to measure effort-related decision making are important in assessing the therapeutic
potential of novel pharmacological compounds for their ability to mitigate effort-related deficits
in animals.
Considerable evidence supports the role of DA in modulating motivational processes.
Drugs that reduce central DA transmission demonstrate a tendency to disturb motivational
functions in animals (Nunes et al. 2013; Randall et al. 2012, 2014; Yohn et al. 2015a,b) and in
humans (Artaloytia et al. 2006; Frank 2009, 2010; Guay, 2010; Chen et al. 2012). Consistent
with previous literature, the DA D2 antagonist haloperidol reduced high-effort responding on the
FR5 feeding task, and shifted rats’ behavior from the high effort (lever pressing) to low effort
(chow intake) alternative on the concurrent FR5/chow feeding choice task (Chapter 2). In several
experiments, the VMAT-2 inhibitor TBZ was shown to alter effort-based choice on the
FR5/chow feeding choice task (Chapters 3-5) and on a PROG lever pressing schedule (Chapter
6). Reductions in lever pressing also were induced by administration of the pro-inflammatory
cytokine IL-1β (Chapter 5). These findings have been validated by clinical studies of effortrelated decision making showing that depressed individuals demonstrate a reduced likelihood of
selecting high effort alternatives (Treadway et al. 2012a; Yang et al. 2014).
Numerous studies have shown that administration of classical DAT inhibitors are able to
reverse the effects of TBZ (Nunes et al. 2013, Yohn et al. 2016a,b; Salamone et al. 2016b) and of
pro-inflammatory cytokines (Yohn et al. 2016c), but these drugs tend to produce undesirable side
effects. Therefore, a novel class of DAT inhibitor compounds was investigated in Chapters 3-5.
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The novel modafinil analogs (S)-CE-123 and (S, S)-CE-158 were able to reverse the motivational
deficits induced by TBZ on the FR5/chow feeding choice task, increase PROG responding, and
increase extracellular accumbens DA as measured by microdialysis (Chapter 3-4). In addition,
the recently synthesized atypical DAT inhibitor CT-005404 reversed a suppression of lever
presses produced by IL-1β, while also demonstrating the ability to reverse the effort-related
effects of TBZ, increase PROG responding, and increase extracellular DA in nucleus accumbens
(Chapter 5). Together, the findings from Chapters 3-5 serve as important preclinical evidence for
atypical DAT inhibitor compounds in support of their potential utility as treatments for
symptoms of fatigue and amotivation seen in depression, schizophrenia, multiple sclerosis, and
other disorders. Future studies need to focus on the potential abuse liability of these compounds.
As discussed above, pharmacological conditions such as the administration of DA
depleting agents or antagonists, or pro-inflammatory cytokines, can induce a low-effort bias in
rats (Salamone et al. 2016a,b,c; Yohn et al. 2016a,b,c), and these effects can be reversed by coadministration of several drugs that facilitate DA transmission (Chapters 3-5). Despite a growing
body of animal work demonstrating that the exertion of effort and selection high-effort options is
dependent upon forebrain circuits that involve mesolimbic DA inputs to nucleus accumbens,
ventral pallidum, amygdala, and prefrontal cortex (Salamone et al. 1991, 1994; 2007, 2016a,b,
2018; Walton et al. 2003; Floresco and Ghods-Sharifi 2007; Mingote et al. 2008; Farrar et al.
2008, 2010; Winstanley and Floresco 2016), potential physiological markers of low effort bias
that can be readily translatable to human clinical research have not been elucidated. In light of
this, Chapters 6-7 experiments employed a novel operant lever pressing task and EEG methods
to aid in the development of physiological markers associated with altered DA transmission and
effort-related dysfunction. In Chapter 6, a PROG task was developed that would require very
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high levels of baseline lever pressing, causing rats to exhibit a breakpoint during a 30-minute
session. TBZ shifted rats away from high-effort responding, reducing total number of lever
presses, time of last response, and breakpoint on the modified PROG schedule (Chapter 6). The
modified PROG lever pressing schedule developed in these experiments will be implemented in
future studies of electrophysiological recordings in awake, behaving rats. In Chapter 7
experiments, cortical EEG was measured in rats under baseline and DA depletion conditions
(i.e., administration of TBZ). Our findings suggested that there are several notable differences in
the cortical EEG markers associated with altered DA transmission in rats, which may ultimately
contribute to our understanding of how DA transmission in the ventral striatum and
striatopallidal circuits modulate cortical functions involved in motivational dysfunctions in
humans.
Finally, the aim of Appendix Experiments 1-3 was to investigate the effects of several
non-dopaminergic drugs on effort-related choice behavior in rodents. Appendix Experiments 1
demonstrated that the SERT inhibitor fluoxetine suppressed FR5/chow lever pressing in male
and female rats. Furthermore, Appendix Experiments 1 and 2 demonstrated that the effort-related
effects induced by drugs such as fluoxetine, haloperidol, tetrabenazine, and risperidone could not
be reversed by reversed by 5-HT2A or 5-HT2C antagonists, or the 5-HT2A inverse agonist
pimavanserin. These findings have been corroborated by recent studies in our lab that have also
shown the negative effects of serotonergic drugs on running wheel choice behavior. Lastly, the
kappa opioid receptor antagonist BT was unable to reverse motivational impairments induced by
tetrabenazine and risperidone on the concurrent FR5/chow feeding choice task. The present
results suggest that there may be limited therapeutic utility for these particular modulators of
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serotonin receptors or kappa opioid receptors in terms of their ability to reverse effort-related
dysfunctions, further emphasizing the importance of DA in regulating effort-related functions.
In summary, the findings from the experiments described above highlight the critical role
of DA in effort-related choice behaviors. DA transmission exerts a bi-directional modulatory
control over exertion of physical effort in rats performing on instrumental tasks. Moreover, the
behavioral paradigms used throughout this body of work have demonstrated their utility as
preclinical tools for studying effort-related motivational impairments and identifying potential
treatments. The conclusions that can be drawn from these experiments will aid in the
development of novel therapeutic strategies for motivational impairments and will contribute to
the growing body of literature on biomarkers related to fatigue and anergia observed in numerous
psychiatric and neurological disorders that can be readily translated to human studies.
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Appendices

Summary of Appendices
Appendix Experiments 1-3 sought to assess the effects of several non-dopaminergic
drugs on effort-related choice in rodents. Appendix Exp 1 demonstrated that the administration
of serotonin (5-HT) transport inhibitors (SERT inhibitors or SSRIs) reduced lever pressing and
did not affect chow intake, but that this effect could not be reversed by the administration of
selective serotonin receptor inhibitors (5-HT2A or 5-HT2C). Appendix Exp 2 examined the
effort-related impairments induced by various pharmacological agents such as fluoxetine,
haloperidol, risperidone, pilocarpine, and tetrabenazine, and showed that the 5-HT2A inverse
agonist pimavanserin was unable to reverse the effort-related effects of any of these drugs.
Appendix Exp 3 examined kappa opioid receptor function in effort-related aspects of motivation
by assessing a kappa opioid receptor antagonist for its ability to reverse the effects of
tetrabenazine, or the effects of risperidone. Taken together, the negative drug reversal results
from Appendix Exp 1-3 emphasize the importance of DA in the regulation of effort-related
behaviors, suggesting the need to focus on dopaminergic manipulations in developing treatments
for the motivational dysfunction seen in depression and other disorders.
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Appendix 1: Investigation of SSRI-induced fatigue in effort-related choice tasks, and of
several selective serotonin receptor antagonists as potential treatment strategies.

1.1 Introduction
Major depressive disorder (MDD) often includes symptoms such as retardation, fatigue,
lassitude, loss of energy and effort-related deficits, which commonly affect motivational and
psychomotor functions (Stahl 2002; Demyttenaere et al. 2005; Salamone et al. 2006; Treadway
and Zald 2011; Treadway et al. 2012a; Fava et al. 2014). The severity of such effort-related
symptoms in depression is highly correlated with problems in social function, employment, and
treatment outcomes (Tylee et al. 1999; Stahl 2002), and it has been observed that these
debilitating symptoms are highly resistant to treatment (Stahl, 2002; Nutt et al. 2007; Fava et al.
2014). In fact, serotonin (5-HT) uptake inhibitors such as fluoxetine (FLX; Prozac) are relatively
ineffective for treating motivational dysfunction, and can induce or exacerbate these symptoms
(Daly et al. 2011; Padala et al. 2012; Stenman and Lilja 2013; Rothschild et al. 2014; Fava et al.
2014). Effort-related motivational symptoms are present in other disorders in addition to
depression, including bipolar disorder, schizophrenia, Parkinsonism, chronic fatigue syndrome
and multiple sclerosis (Salamone et al. 2006, 2010, 2016b; Friedman et al. 2007; Tellez et al.
2008; Green et al. 2015). For these reasons, it is critical to examine the facets of effort-related
dysfunctions in animal models in order to improve upon the currently available treatment options
for these disorders.
The neural basis of the effort-related dysfunctions in psychopathology are still being
characterized, nevertheless, considerable preclinical and clinical evidence implicates central
dopamine (DA), basal ganglia, and related corticolimbic circuits (Rogers et al. 1987; Rampello et
al. 1991; Brown and Gershon 1993; Hickie et al. 1999; Caligiuri and Ellwanger et al. 2000;
Volkow et al. 2001; Schmidt et al. 2001; Brody et al. 2001; Salamone et al. 2006, 2016b; Tellez
et al. 2008; Treadway and Zald 2011; Chong et al. 2015). In addition to DA, other
neurotransmitters such as glutamate, GABA, and 5-HT have also been implicated in the
pathogenesis of MDD (Cowen and Browning 2015; Milak et al. 2016; Zheng et al. 2016;
Belujon and Grace 2017; Pan et al. 2018), but their distinct roles in the regulation of
motivational/psychomotor symptoms have not been fully elucidated. In view of the severe
disease burden presented by depression (Wittchen et al. 2011; Marcus et al. 2012), the
prevalence of motivational symptoms such as anergia and fatigue in depression and other
disorders, and the relative resistance of these motivational/psychomotor symptoms to many
common drug treatments, it seems evident that this line of work will ultimately improve the
outlook for patients suffering from these debilitating symptoms.
Over the past several decades, a considerable body of work has focused on characterizing
the role of various neurotransmitters including dopamine (DA), 5-HT, norepinephrine (NE),
adenosine, and GABA, in the exertion of effort and effort-related decision making (Salamone
and Correa 2002; Salamone et al. 1991, 2002, 2007, 2009a,b). Behavioral tasks have been
developed in animals to study effort-related functions in animals, including operant procedures
with different work requirements, and tests of effort-related decision making that allow animals
to choose between high-effort alternatives that lead to more highly valued rewards vs. low-effort
alternatives that lead to less valued rewards (i.e., less preferred or lower in magnitude). Tests
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involving operant behavior and T-maze performance have demonstrated that low doses of DA
antagonists, as well as DA depletions or antagonism in nucleus accumbens, reduce the exertion
of effort and alter effort-related choice, biasing animals towards low-effort alternatives
(Salamone and Correa 2002, 2012a; Salamone et al. 2007, 2009a,b, 2012). It has been suggested
that tests of effort-based decision making in rodents could be useful as models of the effortrelated motivational symptoms of depression (Salamone et al. 2003, 2006, 2007, 2012, 2015,
2016a,b,c; Salamone and Correa 2012). Reduced selection of high-effort activities in rodents is
induced by manipulations associated with depression, including stress (Shafiei et al. 2012; Bryce
and Floresco 2016), the pro-inflammatory cytokines IL-1β and IL-6 (Nunes et al. 2014; Yohn et
al. 2016c), and the vesicular monoamine transport (VMAT-2) inhibitor tetrabenazine (Nunes et
al. 2013b; Randall et al. 2014; Yohn et al. 2015a,b). These observations are validated by clinical
data demonstrating that people with major depression show a reduced likelihood of selecting
high effort alternatives when assessed in tests of effort-related decision making (Treadway et al.
2012a; Yang et al. 2014).
Recent studies from the Salamone laboratory have focused upon the effort-related effects
of drugs that block the transporters for DA (DAT), NE (NET), and 5-HT (SERT). The effortrelated effects of tetrabenazine can be reversed by co-administration of the antidepressant
bupropion (Nunes et al. 2013b; Randall et al. 2014; Yohn et al. 2015a,c), which blocks DAT and
NET, and also by the DAT blocker GBR12909 (Yohn et al. 2016a). However, the SERT
inhibitors fluoxetine and escitalopram fail to reverse the effort-related effects of tetrabenazine,
and instead tend to exacerbate them (Yohn et al. 2016a,b). Furthermore, evidence indicates that
while DA exerts a bi-directional modulation over effort-related decision making, 5-HT does not.
Increased selection of high-effort choices can be enhanced by augmenting DA transmission with
administration of the catecholamine uptake blockers bupropion (Randall et al. 2015) and
lisdexamfetamine (Yohn et al. 2016b), and the DAT inhibitors MRZ-9547 (Sommer et al. 2014),
PRX-14040 (Yohn et al. 2016d), and GBR12909 (Yohn et al. 2016). In contrast, the SERT
inhibitor fluoxetine reduces selection of high effort lever pressing in rats responding on a
progressive ratio (PROG)/chow feeding choice task at doses that also decrease extracellular DA
in nucleus accumbens (Yohn et al. 2016a,e). This is consistent with studies showing that SERT
inhibitors decrease high-effort physical activities such as voluntary wheel running (Weber et al.
2009; Claghorn et al. 2016).
Although there are several behavioral tasks that have been used for decades to assess the
effects of antidepressant drugs in rodents (e.g. swim test, tail suspension test), none of these
procedures specifically targets effort-related decision making, and therefore they do not seem
suited for studying the effort-related effects of SERT inhibitors. Moreover, since SERT
inhibitors generally yield a positive profile in the traditional behavioral tests related to
depression, yet these drugs are relatively ineffective at treating effort-related motivational
symptoms in depressed people, it underscores the need to have behavioral tests in animals that
specifically focus on the effort-related effects of drugs used to treat depression. Therefore, the
goal of these studies was to determine if the 5-HT2C receptor mediates effort-related effects by
studying the ability of 5-HT2A and 5-HT2C antagonists to reverse the effects of fluoxetine on
effort-related decision making. It was hypothesized that: a) systemic administration of fluoxetine
would induce an effort-related impairment in rats performing on the concurrent FR5/chow
feeding choice task similar to its effects on PROG/chow lever pressing; b) the reduction in
FR5/chow lever pressing induced by fluoxetine would be reversed by antagonism of 5-HT2C
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receptors, but not 5-HT2A receptors; and c) systemic administration of 5-HT2C receptors would
increase high-effort PROG/chow lever pressing.

1.2 Materials and Methods
Animals
Adult male, drug-naïve, Sprague Dawley rats (Envigo, Indianapolis, IN, USA) were
housed in a colony maintained at 23 °C with 12-h light/dark cycles (lights on 07:00). Rats were
obtained weighing 275–299 g at the beginning of the study, and were initially food restricted to
85% of their free-feeding body weight for operant training. Rats were allowed modest weight
gain throughout the experiment. Supplemental chow was provided as needed to maintain body
weights throughout the study, with water available ad libitum. Animal protocols were approved
by the University of Connecticut Animal Care and Use Committee, and followed NIH
guidelines.

Behavioral and Pharmacological Methods
Behavioral sessions were conducted in operant chambers (28 x 23 x 23 cm; Med
Associates, Fairfax, VT). Sessions lasted 30 minutes a day for 5 days/week. First, rats were
trained to lever press on a continuous reinforcement schedule to receive 45 mg highcarbohydrate pellets (Bio-Serv; Frenchtown, NJ, USA) for one week, then were shifted to the
FR5 schedule. After 5 weeks of FR5 training, chow was introduced. During each FR5/chow
feeding choice task session, 15-20 g of lab chow (Laboratory Diet, 5P00 Prolab RMH 3000,
Purina Mills, St. Louis, MO) was concurrently available on the floor of the chamber. Rats were
trained on this FR5/chow feeding choice procedure for 5 weeks, after which drug testing began.
On baseline and drug treatment days, rats consumed all of the operant pellets that were delivered
during each session.
All experiments used a within-groups (i.e., repeated measures) design, in which all
animals received all treatment combinations in a randomly varied order. During the drug
treatment phase, rats were run 5 days per week, with 4 days being baseline days, and one day per
week (either Thursday or Friday) being the drug treatment day. In all of the studies listed below,
fluoxetine (10.0 mg/kg, 12.5 mg/kg, or 15.0 mg/kg IP) was administered 90 min before testing.
Experiment 1 was conducted to establish a dose/response curve for fluoxetine, in which male and
female rats were administered vehicle or one dose of fluoxetine (5.0, 10.0, or 15.0 mg/kg) in a
randomly varied order over the course of four weeks. For the drug reversal studies, in which one
drug is given to induce a behavioral impairment, animals also received a second injection of
various doses of either the 5-HT2A antagonist MDL 100907, or the 5-HT2C antagonist SB 242084
or vehicle to attempt to reverse the effects of fluoxetine. Each reversal study would typically
involve 5 combined drug treatments (e.g. vehicle/vehicle, fluoxetine/vehicle, and fluoxetine plus
3 doses of the 5-HT antagonist).
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List of Drug Experiments:
1. Effect of fluoxetine on effort-related choice.
2. Effect of 5-HT2C antagonist SB 242084 on the effort-related effects of fluoxetine.
3. Effect of 5-HT2A antagonist MDL 100907 on the effort-related effects of fluoxetine.
4. Effect of SB 242084 on performance on the PROG/chow feeding choice task.
5. Effect of MDL 100907 on performance on the PROG/chow feeding choice task.

Data Analyses
Repeated measures analysis of variance (ANOVA) was used to determine the effect of
drug treatment on lever pressing and chow intake in the behavioral pharmacology experiments.
To determine if there were significant reversal effects, nonorthogonal planned comparisons were
performed, using the overall error term to assess differences between each treatment and the
control condition. The number of comparisons was restricted to the number of treatments minus
one (Keppel, 1991).

1.3 Results
FLX (5.0-15.0 mg/kg) was administered to male and female rats prior to performance on
the FR5/chow feeding choice task. In both groups, FLX significantly reduced lever pressing, but
had no significant effect on chow intake. A treatment x sex repeated measures factorial ANOVA
revealed a significant overall main effect of treatment on lever pressing [F(3,42)=29.323,
p<0.001], but no effect of sex on lever pressing (p=n.s.), and no significant treatment x sex
interaction [F(3,42)=0.307, p=n.s.] (Fig. 1A). Due to a non-significant interaction, nonorthogonal planned comparisons were computed collapsed across male and female lever presses.
It was shown that all three doses of FLX significantly reduced lever presses relative to the
vehicle treatment [VEH vs. 5.0 mg/kg FLX, F(1,42)=16.747, p<0.001; VEH vs. 10.0 mg/kg
FLX, F(1,42)=65.577, p<0.001; VEH vs. 15.0 mg/kg FLX, F(1,42)=107.601, p<0.001]. Dose of
FLX had no effect on chow intake (p=n.s.) (Fig. 1B).
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Figure 1. Effects of FLX on performance on the FR5/chow feeding choice task in male and
female rats. Male (n=8) and female (n=8) rats were injected with vehicle or fluoxetine (5.0-15.0
mg/kg IP). (A) Fluoxetine significantly reduced lever pressing at 5.0 mg/kg, 10.0 mg/kg, and
15.0 mg/kg (*p<0.001) and (B) had no effect on chow intake (p=n.s.).

A set of reversal experiments were conducted to investigate the effects of 5-HT2C or 5HT2A receptor antagonists SB 242084 or MDL 100907 on the effort-related impairments induced
by fluoxetine (10.0 mg/kg) in male and female rats. The experiments sought to assess the effects
of SB 242084 (0.25-2.0 mg/kg) on fluoxetine-induced changes in performance on the concurrent
FR5 lever pressing/chow feeding choice task. Repeated measures ANOVA demonstrated a
significant overall main effect of treatment on lever pressing in males [F(5,40)=31.076, p<0.001]
and females [F(5,40)=10.249, p<0.001] (Fig. 2A). Planned comparisons revealed a significant
reduction of lever presses in the FLX plus vehicle condition compared to the vehicle plus vehicle
condition in males [F(1,40)=82.101, p<0.001] and females [F(1,40)=23.883, p<0.001]. Coadministration of FLX with SB 242084 did not produce a significant reversal from the FLX plus
vehicle condition at any of the doses tested (p=n.s.). There was no significant overall effect of
treatment on chow intake (p=n.s.) (Fig. 2B).

138

A

B

#

Figure 2. The effects of SB 242084 on fluoxetine-induced changes in performance on the
concurrent FR5 lever pressing/chow feeding choice procedure in male and female rats. Male
(n=8) and female (n=8) rats were injected with vehicle or fluoxetine (10.0 mg/kg IP) and vehicle
or one of four doses of SB 242084 (0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg IP). (A)
Fluoxetine significantly reduced lever pressing (#p<0.001) and (B) had no effect on chow intake
relative to vehicle, but there was no significant reversal with SB 242084 at any dose.

The second reversal experiment was conducted to investigate the effects of the 5-HT2A
receptor antagonist MDL 100907 on the effort-related impairments induced by fluoxetine (15.0
mg/kg) in male and female rats on the concurrent FR5 lever pressing/chow feeding choice task.
Repeated measures ANOVA demonstrated a significant overall main effect of treatment on lever
pressing in males [F(5,25)=46.214, p<0.001] and females [F(5,25)=19.362, p<0.001] (Fig. 3A).
Planned comparisons revealed a significant reduction of lever presses in the FLX plus vehicle
condition compared to the vehicle plus vehicle condition in males [F(1,25)=46.214, p<0.001]
and females [F(1,25)=55.168, p<0.001]. Co-administration of FLX with SB 242084 at any of the
doses tested did not produce a significant reversal from the FLX plus vehicle condition (p=n.s.).
There was no significant overall effect of treatment on chow intake (p=n.s.) (Fig. 3B).
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Figure 3. The effects of MDL 100907 on fluoxetine-induced changes in performance on the
concurrent FR5 lever pressing/chow feeding choice procedure in male and female rats. Male
(n=6) and female (n=8) rats were injected with vehicle or fluoxetine (15.0 mg/kg IP) and vehicle
or one of four doses of MDL 100907 (0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg IP). (A)
Fluoxetine significantly reduced lever pressing (#p<0.001) and (B) had no effect on chow intake
relative to vehicle, but there was no significant reversal with MDL 100907 at any dose.

Additional experiments investigated the ability of SB 242084 to increase lever pressing
on the PROG/chow feeding choice task in male and female rats. Vehicle or one of four doses of
SB 242084 (0.5-4.0 mg/kg) was administered to rats prior to task performance. Repeated
measures ANOVA revealed that SB 242084 did not have a significant overall effect on lever
pressing in males [F(4,28)=0.742, p=n.s.] or females [F(4,28)=0.514, p=n.s.] (Fig. 4A). In
addition, there was no significant overall effect of treatment on chow intake (p=n.s.). Tests of
between-subjects effects revealed a significant overall difference in chow intake between male
and female rats [F(1,14)=146.536, p<0.001]. (Fig. 4B).
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Figure 4. The effects of SB 242084 on effort-related performance on the concurrent PROG lever
pressing/chow feeding choice procedure in male and female rats. Male (n=8) and female (n=8)
rats were injected with vehicle or one of four doses of SB 242084 (0.5 mg/kg, 1.0 mg/kg, 2.0
mg/kg, 4.0 mg/kg IP). (A) Treatment with SB did not significantly affect lever pressing (p=n.s.)
or (B) chow intake relative to vehicle (p=n.s.). Chow intake significantly differed between male
and female rats (p<0.001).
The fifth experiment in this series assessed the ability of MDL 100907 to increase lever
pressing on the PROG/chow feeding choice task in male and female rats. Vehicle or one of four
doses of MDL 100907 (0.5-4.0 mg/kg) was administered to rats prior to task performance.
Repeated measures ANOVA revealed that MDL 100907 did not have a significant overall effect
on lever pressing in males [F(4,28)=1.253, p=n.s.] or females [F(4,28)=0.802, p=n.s.] (Fig. 5A).
In addition, treatment did not produce a significant effect on chow intake in either group (p=n.s.).
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Tests of between-subjects effects revealed a significant overall difference in chow intake
between male and female rats [F(1,14)=43.131, p<0.001]. (Fig. 5B).
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Figure 5. The effects of MDL 100907 on effort-related performance on the concurrent PROG
lever pressing/chow feeding choice procedure in male and female rats. Male (n=8) and female
(n=8) rats were injected with vehicle or one of four doses of MDL 100907 (0.5 mg/kg, 1.0
mg/kg, 2.0 mg/kg, 4.0 mg/kg IP). (A) MDL did not significantly affect lever pressing (p=n.s.) or
(B) chow intake relative to vehicle at any of the doses tested (p=n.s.). Chow intake significantly
differed between male and female rats (p<0.001).

1.4 Discussion
The purpose of Appendix 1 experiments was to evaluate the effort-related effects of the
SERT inhibitor fluoxetine, and to assess two different selective 5-HT receptor antagonists for
their ability to reverse fluoxetine-induced motivational impairments. Consistent with previous
findings from our laboratory using the PROG/chow feeding choice task (Yohn et al. 2016e),
fluoxetine administration caused a dose-dependent decrease in lever presses on the FR5/chow
feeding choice task. The Yohn et al. (2016e) study was conducted in male rats, while the present
experiment used both males and females. In contrast to the effects of DA antagonists or
depletions on the FR5/chow task performance to produce compensatory increases in chow
consumption, fluoxetine did not have any effect on the amount of chow consumed during the
FR5/chow feeding choice task. Though the lack of compensatory chow intake is thought to be a
result of possible appetite suppression effects, it is important to note that these effects were not
simply due to the use of food reinforcement. Recent studies in our lab demonstrated that
systemic fluoxetine administration dose-dependently decreases both running wheel activity and
chow consumption in choice procedures in male and female rats (Presby et al., in preparation). In
agreement with the data presented here, antagonism of 5-HT2C or 5-HT2A receptors did not
reverse the fluoxetine-induced suppression of wheel running or chow intake, nor did they
increase high-effort responding when administered alone to rats trained on the PROG/chow
procedure. However, the inability of the 5-HT2C receptor antagonist SB 242084 to reverse the
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fluoxetine-induced effects is inconsistent with previous literature demonstrating that SB 242084
blocked the rate decreasing effect of fluoxetine on lever pressing (Bauer et al. 2015), and also
increased lever pressing (Martin et al. 2002). Antagonism of 5-HT2C receptors increased burst
firing in ventral tegmental area (VTA) DA neurons (DiMatteo et al. 1999; DiGiovanni et al.
1999), increased accumbens DA release (Visser et al. 2015), and blocked the decrease in DA
neuron activity induced by the SERT inhibitor citalopram (Dremenecov et al. 2009), which
would have suggested that blocking this receptor might have been able to reverse the effects of
fluoxetine. This inconclusive pattern of effects may be due in part to possible off-target
peripheral actions of fluoxetine and SB 242084 related to systemic administration. Thus, it may
be beneficial to replicate these studies using intracranial administration of selective 5-HT
antagonists into areas of the brain implicated in motivation and mesolimbic DA transmission
such as the VTA. In view of the fact that SERT inhibitors are relatively ineffective at treating
effort-related motivational symptoms of depression, and that these drugs often induce or
exacerbate these debilitating symptoms, ongoing and future work in this area could contribute
significantly to the understanding of the neurotransmitter interactions that underlie the
motivational effects of antidepressants, and could foster the development of agents that would
improve motivational function in people treated with SERT inhibitors.
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Appendix 2: Assessment of pimavanserin in animal models of effort-related choice
behavior: significance for treating motivational dysfunctions.

2.1 Introduction
Behavioral activation and effort-related processes are fundamental aspects of motivation.
Considerable evidence from the basic neuroscience literature indicates that nucleus accumbens
dopamine (DA) is an important component of the neural circuitry that regulates behavioral
activation and effort-related aspects of motivation (Salamone et al. 2007, 2016a,b). Studies of
behavioral activation and effort also are clinically relevant. In humans, symptoms such as
anergia, psychomotor retardation, amotivation and fatigue reflect pathologies in behavioral
activation. These symptoms are fundamental features of depression, Parkinson’s disease and
schizophrenia (Tylee et al. 1999; Stahl 2002; Demyttenaere et al. 2005; Salamone et al. 2006,
2007, 2012; Chong et al. 2015). Within the last few years, rodent procedures assessing effortrelated choice behavior have been developed into formal animal models that are useful for
characterizing the effects of well-known and experimental therapeutic agents.
Tests of effort-based choice behavior allow animals to select between a more preferred
reward that can only be obtained by high exertion of effort vs. a low effort/low reward option. In
our laboratory, several tasks have been developed for assessing effort-related choice behavior in
rats. Our most commonly used task is an operant concurrent choice task that offers rats a choice
between lever pressing to obtain a relatively preferred food (high carbohydrate pellets), vs.
approaching and consuming a less preferred food (lab chow) that is concurrently available.
Under non-drug conditions, rats lever pressing on a fixed ratio 5 (FR5) schedule typically get
most of their food by lever pressing, and they eat only small amounts of chow. With rats
performing on this task, pre-feeding to reduce food motivation was shown to suppress both lever
pressing and chow intake (Salamone et al. 1991). In contrast, low-to-moderate doses of DA
antagonists produced a very different pattern of effects. DA antagonists with varying degrees of
receptor subtype specificity, including cis-flupenthixol, haloperidol, raclopride, eticlopride, SCH
23390, SKF83566 and ecopipam, all decreased lever pressing for food but substantially
increased intake of the concurrently available chow (Salamone et al. 1991, 2002; Nowend et al.
2001; Sink et al. 2008). The low dose of haloperidol that produced this effect (0.1 mg/kg) did not
alter food intake or preference in free-feeding choice tests (Salamone et al. 1991). In addition, it
has been demonstrated that intra-accumbens administration of the muscarinic acetylcholine
receptor agonist pilocarpine shifted rats’ behavior on the FR5/chow task to the low-effort bias,
seen as a reduction of lever presses and increased selection of freely available chow (Nunes et al.
2013b). Although DA antagonists and the muscarinic agonist pilocarpine have been shown to
reduce FR5 lever pressing and increase chow intake, appetite suppressants such as fenfluramine
and cannabinoid CB1 antagonists (Salamone et al., 2002; Sink et al. 2008) do not increase chow
intake at doses that suppress lever pressing.
In addition to the FR5/chow feeding task, a progressive ratio (PROG)/chow feeding
choice task has been developed. With this task, the rats have a choice between lever pressing vs.
approaching and consuming the freely available chow, however, the PROG lever pressing
schedule is more demanding because the ratio requirement gets progressively higher throughout
the session (Randall et al. 2012). Thus, rats tested on this procedure generally press less and each
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chow more than they do on the FR5/choice procedure, because the increasing PROG work
demand makes the animals switch from lever pressing to chow intake once the ratio requirement
gets high enough (Randall et al. 2012). As with the other effort-based tasks, administration of the
DA antagonists haloperidol, ecopipam, and eticlopride all decrease selection of the high-effort
PROG lever pressing at doses that do not impair chow intake (Randall et al. 2012, 2014).
More recently, models have been established that assess the effects of the VMAT-2
inhibitor tetrabenazine. This drug depletes DA by blocking vesicular storage, and tetrabenazine
is useful for animal models because it produces depressive symptoms in people (Guay 2010). At
low doses that reduce extracellular DA and alter DA-related signal transduction in nucleus
accumbens, tetrabenazine also alters effort-based choice in animals responding on multiple tasks,
including the FR5/chow feeding choice task described above (Nunes et al. 2013), the
PROG/chow feeding choice task (Randall et al. 2014), and the T-maze barrier choice task (Yohn
et al. 2015a,b). Tetrabenazine induced these effort-related effects at doses that did not alter food
intake, food preference, sucrose preference, hedonic reactivity to sucrose, or reference memory.
Together with the other results reviewed above, these findings demonstrate that interference with
DA transmission does not simply reduce appetite for food or food-related hedonia, but rather,
alters effort-based choice and produces a bias away from high-effort activity towards low-effort
activity.
Over the last few years, several drugs have been assessed for their ability to improve
effort-related performance in these models. The adenosine A2A receptor antagonists
istradefylline, Lu AA47070, MSX-3 and MSX-4 have all been shown to reverse the effortrelated effects of DA antagonists and tetrabenazine across multiple tasks (Farrar et al. 2007,
2010; Worden et al. 2009; Mott et al. 2009; Salamone et al. 2009; Nunes et al. 2010; Collins et
al. 2011; Nunes et al. 2013; Randall et al. 2014; Yohn et al. 2015a). DA D 1 receptor agonists also
reversed the effort-related effects of DA antagonism and depletion in rats tested on the
FR5/chow feeding choice and T-maze barrier choice tasks (Yohn et al. 2015b). Recent studies
demonstrated that the glycine uptake inhibitor bitopertin was able to reverse the effort-related
effects of haloperidol (Yohn et al. 2017). In addition, several drugs that block DA uptake,
including bupropion, GBR12909, lisdexamfetamine, PRX-14040, methylphenidate, and
modafinil, all were able to reverse the effort-related effects of tetrabenazine (Nunes et al. 2013;
Randall et al. 2014; Yohn et al. 2016a,b,c; Salamone et al. 2016). Moreover, in otherwise
untreated rats that were tested on the PROG/chow feeding choice task, the DA transport
inhibitors bupropion, GBR12909, lisdexamfetamine and PRX-14040 all were shown to increase
selection of the high-effort PROG lever pressing and decrease choice of the low effort option
(chow intake; Randall et al. 2015; Yohn et al. 2016b,c,d). These results demonstrate the
feasibility of using tests of effort-based choice for preclinical characterization of compounds
with different pharmacological profiles, and also emphasize the role of brain DA systems as a
modulator of effort-related functions. This animal research demonstrating the involvement of DA
systems in effort-related aspects of motivation is consistent with studies showing that effortbased decision making in humans is related to DA transmission (Treadway et al. 2011; Wardle et
al. 2012), and that motivational function can be improved in depressed patients by administration
of drugs that increase DA transmission (Stotz et al. 1998; Papakostas et al. 2006). Furthermore,
the use of effort-based tasks in rodents as models of human psychopathology is validated by
studies showing that a low-effort bias on choice tasks is seen in human patients with major
depressive disorder (Treadway et al. 2012b; Yang et al. 2014, 2015), schizophrenia (Gold et al.
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2013, 2015; Reddy et al. 2015) and Parkinson’s disease (Chong et al. 2015). Nevertheless, it is
worth pointing out that these animal models have limitations, and do not directly model effortbased tasks in human subjects suffering from depression, schizophrenia, Parkinson’s disease or
other disorders.
In contrast to the effects of drugs that act to increase DA transmission, drugs that block
serotonin (5-HT) transport, such as the SSRIs fluoxetine and citalopram, failed to reverse the
effects of tetrabenazine on FR5/chow feeding choice performance (Yohn et al. 2016a,b).
Furthermore, fluoxetine and citalopram suppressed lever pressing in rats tested on the FR5/chow
feeding choice task (Yohn et al. 2016a,b), and fluoxetine reduced PROG lever pressing after
both acute and repeated administration (Yohn et al. 2016e). Fluoxetine also was shown to
decrease extracellular DA in nucleus accumbens at a dose that suppressed PROG lever pressing
(Yohn et al. 2016e). These results are consistent with human clinical studies reporting that SSRIs
are relatively poor at treating motivational dysfunctions in depressed people (Papakostas et al.
2006; Bell et al. 2013; Fava et al. 2014; Rothschild et al. 2014; Cooper et al. 2014). In fact, these
drugs can actually worsen effort-related symptoms such as fatigue.
Because of the widespread prevalence of motivational dysfunctions related to problems
with behavioral activation and effort, which are evident across multiple disorders, it is critical to
develop a line of preclinical research for assessing the effects of potential treatments. If
elevations in 5-HT transmission due to uptake blockade are relatively ineffective at restoring
normal motivational function, and in fact can impair effort-related processes, it is critical to study
drugs that blunt 5-HT transmission to determine if they can exert pro-motivational effects. In
view of the ability of pimavanserin to act as an inverse agonist at the 5-HT2A receptor, it is
important to assess the effects of pimavanserin in animal models of effort-related choice
behavior. Pimavanserin (also known as ACP-103) has been approved for human use in treating
hallucinations and delusions associated with Parkinson’s disease (trade name: Nuplazid®).
Previous research has shown that pimavanserin has anti-tremor effects in an animal model of
Parkinsonian tremor (Vanover et al. 2008), but its effects on effort-related motivational processes
are unknown.
This project was undertaken determine if pimavanserin exert effects in animal models of
effort-related choice behavior, and can reverse the effects of the SSRI fluoxetine and the
antipsychotic drugs haloperidol and risperidone, as well as the DA depleting agent tetrabenazine,
on performance of these tasks. In the initial experiments, pimavanserin was assessed for its
ability to reverse the effects of the serotonin transport (SERT) inhibitor fluoxetine in rats tested
on the FR5/chow feeding choice task, and additional experiments studied the ability of
pimavanserin to reverse the effects of the DA D2 antagonist haloperidol, as well as the atypical
antipsychotic risperidone, and the muscarinic agonist pilocarpine, on the FR5/choice procedure.
Finally, pimavanserin and MDL 100907 were tested for their ability to reverse the effort-related
effects of tetrabenazine.
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2.2 Materials and Methods
Animals
Adult male, drug-naïve, Sprague Dawley rats (Envigo, Indianapolis, IN, USA) were
housed in a colony maintained at 23 °C with 12-h light/dark cycles (lights on 07:00). Rats were
obtained weighing 275–299 g at the beginning of the study, and were initially food restricted to
85% of their free-feeding body weight for operant training. Rats were fed supplemental chow to
maintain weight throughout the study, with water available ad libitum. Rats were allowed modest
weight gain throughout the experiment. Animal protocols were approved by the University of
Connecticut Animal Care and Use Committee, and followed NIH guidelines.

Behavioral and Pharmacological Methods
Behavioral sessions were conducted in operant chambers (28 x 23 x 23 cm; Med
Associates, Fairfax, VT). Sessions lasted 30 minutes a day for 5 days/week. First, rats were
trained to lever press on a continuous reinforcement schedule to receive 45 mg highcarbohydrate pellets (Bio-Serv; Frenchtown, NJ, USA) for one week, then were shifted to the
FR5 schedule. After 5 weeks of FR5 training, chow was introduced. During each FR5/chow
feeding choice task session, 15-20 g of lab chow (Laboratory Diet, 5P00 Prolab RMH 3000,
Purina Mills, St. Louis, MO) was concurrently available on the floor of the chamber. Rats were
trained on this FR5/chow feeding choice procedure for 5 weeks, after which drug testing began.
On baseline and drug treatment days, rats consumed all of the operant pellets that were delivered
during each session.
All experiments used a within-groups (i.e., repeated measures) design. Thus, once
animals were trained for a given experiment, all animals received all treatment combinations in a
randomly varied order. During the drug treatment phase, rats were run 5 days per week, with 4
days being baseline (drug-free) days, and one day per week (either Thursday or Friday) being the
drug treatment day. All of the studies listed below (except Exp 3) are drug reversal studies, in
which one drug is given to induce a behavioral impairment (12.5 mg/kg IP fluoxetine 90 min
before testing, 0.1 mg/kg IP haloperidol 50 min before testing, 0.5 mg/kg IP risperidone 30 min
before testing, and 1.0 mg/kg IP tetrabenazine 120 min before testing). Animals also received a
second injection of various doses of pimavanserin or MDL 100907 to attempt to reverse the
effects of the first drug. Each study would typically involve 5 combined drug treatments (e.g.
vehicle/vehicle, haloperidol/vehicle, and haloperidol plus 3 doses of pimavanserin).

List of Drug Experiments
1. FR5/chow feeding with pimavanserin vs. fluoxetine
2. FR5/chow feeding with pimavanserin vs. haloperidol
3. FR5/chow feeding with risperidone (to determine effective dose)
4. FR5/chow feeding with pimavanserin vs. risperidone
5. FR5/chow feeding with pimavanserin vs. pilocarpine
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6. FR5/chow feeding with pimavanserin vs. tetrabenazine
7. FR5/chow feeding with MDL 100907 vs. tetrabenazine

Data Analyses
Repeated measures analysis of variance (ANOVA) was used to determine the effect of
drug treatment on lever pressing and chow intake in the behavioral pharmacology experiments.
To determine if there were significant reversal effects, nonorthogonal planned comparisons were
performed, using the overall error term to assess differences between each treatment and the
control condition. The number of comparisons was restricted to the number of treatments minus
one (Keppel, 1991).

2.3 Results
A series of experiments were conducted to investigate the effects of the 5-HT2A inverse
agonist pimavanserin on the effort-related impairments induced by various pharmacological
challenges. The first set of experiments sought to assess the effects of pimavanserin on
fluoxetine-induced changes in performance on the concurrent FR5 lever pressing/chow feeding
choice task. Repeated measures ANOVA demonstrated a significant overall main effect of
treatment on lever pressing [F(4,24)=25.603, p<0.001] (Fig. 1A), [F(4,20)=16.527, p<0.001]
(Fig. 1C). There was no overall effect of drug treatment on chow intake in either experiment.
Planned comparisons indicated that fluoxetine (12.5 mg/kg) significantly reduced lever pressing
compared to the vehicle condition (p<0.001; Fig. 1A and 1C), but had no effect on chow intake
(Fig. 1B, 1D). There was no significant reversal of lever pressing when pimavanserin was coadministered at any dose. Furthermore, the route of administration (subcutaneous vs.
intraperitoneal) had no effect on the ability of pimavanserin to reverse the fluoxetine-induced
suppression of lever pressing.
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Figure 1. The effects of pimavanserin on fluoxetine-induced changes in performance on the
concurrent FR5 lever pressing/chow feeding choice procedure. (A,B) Fluoxetine and
pimavanserin (subcutaneous; SC). Rats (n=7) were injected with vehicle or fluoxetine (12.5
mg/kg IP) and vehicle or one of three doses of pimavanserin (1.0, 5.0, or 10.0 mg/kg SC). (A)
Fluoxetine significantly reduced lever pressing (*p<0.001) and (B) had no effect on chow intake,
but there was no significant reversal with pimavanserin at any dose. (C,D) Fluoxetine and
pimavanserin (intraperitoneal; IP). Rats (n=6) were injected with vehicle or fluoxetine (12.5
mg/kg IP) and vehicle or one of three doses of pimavanserin (1.0, 5.0, or 10.0 mg/kg IP). (C)
Fluoxetine significantly reduced lever pressing (*p<0.001) from vehicle, and (D) had no effect
on chow intake, but there was no significant reversal with pimavanserin at any dose.

Figure 2 shows the effects of pimavanserin on haloperidol-induced changes in
performance on the concurrent FR5 lever pressing/chow feeding choice procedure. Repeated
measures ANOVA revealed a significant overall main effect of treatment on lever pressing and
chow intake in all three experiments (Fig. 2A: [F(4,28)=13.575, p<0.001]; Fig. 2B:
[F(4,28)=5.079, p<0.05]; Fig. 2C: [F(4,28)=22.012, p<0.001]; Fig. 2D: [F(4,28)=13.653,
p<0.001]; Fig. 2E: [F(3,21)=66.199, p<0.001]; Fig. 2F: [F(3,21)=25.642, p<0.001]. Planned
comparisons were performed and showed that haloperidol (0.1 mg/kg) significantly reduced
lever pressing (p<0.001) and increased chow intake (p<0.001) in all three experiments (Fig. 2).
There was no significant reversal of the haloperidol-induced effort-related effects on lever
pressing or chow intake by pimavanserin at any dose, regardless of route of administration.
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Figure 2. The effects of pimavanserin on haloperidol-induced changes in performance on the
concurrent FR5 lever pressing/chow feeding choice procedure. (A,B) Haloperidol and
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pimavanserin (subcutaneous; SC). Rats (n=8) were injected with vehicle or haloperidol (0.1
mg/kg IP) and vehicle or one of three doses of pimavanserin (1.0, 5.0, or 10.0 mg/kg SC). (A)
Haloperidol significantly reduced lever pressing (*p<0.001) and (B) increased chow intake
(*p<0.001) from vehicle, but there was no significant reversal with pimavanserin at any dose.
(C,D) Haloperidol and pimavanserin (intraperitoneal; IP). Rats (n=8) were injected with vehicle
or haloperidol (0.1 mg/kg IP) and vehicle or one of three doses of pimavanserin (1.0, 5.0, or 10.0
mg/kg IP). (C) Haloperidol significantly reduced lever pressing (*p<0.001) and (D) increased
chow intake from vehicle, but there was no significant reversal with pimavanserin. (E,F)
Haloperidol and pimavanserin (IP vs. SC) at a higher dose. Rats (n=8) were injected with
vehicle or haloperidol (0.1 mg/kg IP) and vehicle or pimavanserin (20 mg/kg IP or SC). (E)
Haloperidol significantly reduced lever pressing (*p<0.001) and (F) increased chow intake
(*p<0.001) from vehicle, but there was no significant reversal with pimavanserin using either IP
or SC routes of administration.

The antipsychotic drug risperidone was administered to rats trained on the FR5/chow
feeding choice procedure to evaluate its effects effort-related choice behavior, and to determine
the effective dose to be used to induce a motivational deficit in pharmacological challenge
reversal experiments. Repeated measures ANOVA showed a significant effect of treatment on
lever pressing [F(5,35)=25.758, p<0.001] and chow intake [F(5,35)=11.525, p<0.001]. When
administered alone, risperidone significantly reduced lever pressing at 0.25 mg/kg (p<0.001) and
0.5 mg/kg (p<0.001) (Fig. 3A), and significantly increased chow intake at 0.5 mg/kg (p<0.001)
(Fig. 3B).
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Figure 3. The effects of risperidone when administered alone to rats on the concurrent FR5 lever
pressing/chow feeding choice procedure. Rats (n=8) were injected with vehicle or risperidone
(0.0313-0.5 mg/kg IP). (A) Risperidone significantly reduced lever presses at 0.25 mg/kg
(*p<0.001) and 0.5 mg/kg (*p<0.001). (B) Risperidone significantly increased chow intake at 0.5
mg/kg (*p<0.001).
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In a fourth experiment, pimavanserin was assessed for its ability to reverse the
suppression of lever pressing caused by risperidone. There was a significant overall main effect
of drug treatment on lever pressing [F(4,60)=53.847, p<0.001], but no significant effect of drug
treatment on chow intake [F(4,60)=0.636, n.s.]. Risperidone induced a significant reduction of
lever pressing on the FR5/chow feeding choice task compared to the vehicle/vehicle condition
(Fig. 4A), but had no effect on chow intake (Fig. 4B). Co-administration of pimavanserin (1.010.0 mg/kg) with risperidone did not produce a significant reversal of the reduction in lever
pressing at any dose.
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Figure 4. The effects of pimavanserin on risperidone-induced changes in performance on the
concurrent FR5 lever pressing/chow feeding choice procedure. Rats (n=16) were injected with
vehicle or risperidone (0.5 mg/kg IP) and vehicle or one of three doses of pimavanserin (1.0, 5.0,
or 10.0 mg/kg SC). (A) Risperidone significantly reduced lever pressing from vehicle/vehicle
(*p<0.001) but there was no significant reversal with pimavanserin at any dose. (B) There was
no significant effect of risperidone or pimavanserin on chow intake.

Figure 5 shows the effects of pimavanserin on pilocarpine-induced changes in
performance on the concurrent FR5 lever pressing/chow feeding choice task. There was a
significant overall main effect of treatment on lever pressing [F(3,21)=28.287, p<0.001], and no
effect of drug treatment on chow intake [F(3,21)=0.656, n.s.]. Pilocarpine administration caused
a reduction in lever pressing (p<0.001) (Fig. 5A), but did not affect chow intake (Fig. 5B).
Pimavanserin did not cause a reversal of pilocarpine-induced suppression of lever pressing at
either dose.
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Figure 5. The effects of pimavanserin on pilocarpine-induced changes in performance on the
concurrent FR5 lever pressing/chow feeding choice procedure. Rats (n=8) were injected with
vehicle or pilocarpine (1.0 mg/kg IP) and vehicle or one of two doses of pimavanserin (1.0 or
10.0 mg/kg SC). (A) Pilocarpine significantly reduced lever pressing from vehicle/vehicle
(*p<0.001) and (B) had no effect on chow intake. There was no significant reversal of the
pilocarpine-induced suppression of lever pressing with pimavanserin at any dose.

The DA-depleting agent tetrabenazine was used to induce an effort-related impairment in
rats on the FR5/chow feeding choice task in the final two experiments. As shown in Figure 6, a
repeated measures ANOVA demonstrated a significant overall main effect of drug treatment on
lever pressing [F(4,60)=45.831, p<0.001] and on chow intake [F(4,60)=16.782, p<0.001].
Tetrabenazine significantly reduced lever presses (p<0.001) (Fig. 6A) and increased chow intake
(Fig. 6B) compared to the vehicle treatment. These effects were not attenuated by pimavanserin
at any dose.
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Figure 6. The effects of pimavanserin on tetrabenazine (TBZ)-induced changes in performance
on the concurrent FR5 lever pressing/chow feeding choice procedure. Rats (n=16) were injected
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with vehicle or tetrabenazine (1.0 mg/kg IP) and vehicle or one of three doses of pimavanserin
(1.0, 5.0 mg/kg, or 10.0 mg/kg SC). (A) Tetrabenazine significantly reduced lever pressing
(*p<0.001) and (B) increased chow intake (*p<0.001) from vehicle/vehicle, but there was no
significant reversal of the tetrabenazine-induced effects on lever pressing or chow intake with
pimavanserin at any dose.

The last experiment of the series assessed whether the tetrabenazine-induced effects on
lever pressing and chow intake could be reversed by the co-administration of MDL 100907. A
one-way ANOVA revealed a significant reduction of lever presses when tetrabenazine and MDL
were co-administered compared to the tetrabenazine plus vehicle treatment group
[F(1,31)=4.458, *p<0.05] (Fig. 7A). Co-administration of tetrabenazine and MDL did not differ
from the tetrabenazine plus vehicle treatment condition (Fig. 7B).
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Figure 7. The effects of MDL 100907 on tetrabenazine-induced changes in performance on the
concurrent FR5 lever pressing/chow feeding choice procedure. Rats (n=16) were injected with
tetrabenazine (1.0 mg/kg IP) and MDL 100907 (1.0 mg/kg IP). (A) One-way ANOVA revealed a
significant reduction of lever presses when TBZ and MDL were co-administered compared to
the TBZ plus vehicle treatment group [F(1,31)=4.458, *p<0.05]. (B) Chow intake was unaffected
[F(1,31)=0.753, n.s.].

2.4 Discussion
Across all 6 reversal experiments, pimavanserin showed no signs of reversing the effects
of fluoxetine, haloperidol, risperidone, pilocarpine, or tetrabenazine. It seems unlikely that these
negative results were due a lack of range of doses tested, because depending upon the
experiment, pimavanserin doses ranging from 1.0 mg/kg up to 20.0 mg/kg were used.
Furthermore, it was determined that the route of drug administration did not have an effect on the
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results. These results are consistent with other data (Rotolo Ph.D. Dissertation Appendix 1)
indicating that the selective 5-HT2A antagonist MDL 100907 and the 5-HT2B antagonist SB
242084 also were ineffective in at improving performance in fluoxetine-treated rats tested on
effort-based choice procedures. Experiment 7 showed that MDL 100907 also was unable to
reverse the effects of tetrabenazine. Taken together, these results suggest that the tested drugs
that act upon 5-HT2 family receptors were ineffective at reversing any of the drug-induced
impairments in effort-based choice induced by a variety of different drugs with distinct
pharmacological profiles (e.g. SERT inhibitor, DA antagonists, DA depleting agent, muscarinic
agonist). The present results should be put into context by recognizing the limitations of the
methods being used. The effort-based choice models employed may not predict accurately the
effects of serotonergic drugs in human subjects suffering from psychiatric disorders like
Parkinson’s disease, schizophrenia or depression. Nevertheless, these negative results serve to
emphasize the important role that dopaminergic drugs have in modulating effort-based choice
behavior (e.g. Rotolo et al. 2019).
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Appendix 3: Assessment of the role of kappa opioid receptor function in animal models of
effort-related choice behavior: significance for treating motivational dysfunctions.

3.1 Introduction
Individuals that suffer from major depressive disorder (MDD) and other psychiatric
disorders often experience an array of symptoms affecting mood, cognition, and motivation. The
most commonly used antidepressant drug therapies include selective serotonin reuptake
inhibitors (SSRIs) and tricyclic antidepressants, but these drugs do not mitigate some of the most
debilitating symptoms, and are often accompanied by negative side effects (Montgomery et al.
1994; Li et al. 2016). Moreover, individuals that are treated with DA antagonists or depleting
agents often experience effects such as depression, anergia and motivational dysfunctions (Frank
2009, 2010; Guay, 2010; Chen et al. 2012; Kennedy et al. 2014). Drugs that inhibit the uptake of
the dopamine (DA) transporter (DAT) have demonstrated clinical efficacy in reducing some of
the physical symptoms of depression, but can be accompanied by adverse effects such as
psychostimulant effects, psychosis, and abuse liability, limiting their therapeutic use. The
drawbacks of the currently approved pharmacological treatments beg the need for the
investigation of an alternative class of drugs that will more effectively treat symptoms of
amotivation in humans.
Since most of the widely prescribed antidepressants affect some aspect of monoamine
transmission, there may be utility in assessing compounds in a distinct category for their safety
and efficacy as treatments for depression. Recently, it has been noted that the endogenous opioid
system has been implicated in some regulatory aspects of MDD symptoms. There are several
different modulators of the endogenous opioid system that have been characterized by distinct
structures and patterns of functional activity (Waldhoer et al. 2004; Guerrero et al. 2019). The
kappa opioid receptor (KOR) has been identified as a key central nervous system modulator and
is distributed throughout the brain, including in areas relevant in disorders such as depression
and schizophrenia (Simonin et al. 1995; Mague et al. 2003; Carlezon et al. 2006; Ranganathan et
al. 2012). Some preclinical and clinical evidence suggests that KOR antagonists have therapeutic
value for stress- and mood-related symptoms of depression and anxiety disorders (Mague et al.
2003; Shippenberg 2009; Lalanne et al. 2014), but the ability of this class of drugs to ameliorate
symptoms of motivational dysfunction and fatigue have not been explored.
Animal studies of effort-related choice behavior are being used to model effort-related
motivational dysfunctions in humans. Our laboratory has developed several behavioral tasks in
rodents that assess the role of DA, serotonin (5-HT), adenosine, and GABA in the exertion of
effort and effort-related decision making (Salamone and Correa 2002; Salamone et al. 1991,
2012). With these procedures, animals are offered a choice between high effort instrumental
actions leading to highly valued reinforcers vs. low effort/low reward options. Several previous
studies have shown that DAT inhibitors, including GBR12909, lisdexamfetamine,
methylphenidate, and PRX-14040, can reverse the effort-related effects of the vesicular
monoamine transport inhibitor tetrabenazine, which blocks DA storage (Nunes et al. 2013, Yohn
et al. 2016a,b,d; Salamone et al. 2016b). Other studies have demonstrated that SERT inhibitors
such as fluoxetine (Prozac) and citalopram (Lexapro) are not effective at treating fatigue and
anergia, and can even exacerbate them (Cooper et al. 2014; Yohn et al. 2016a,b,d). Because
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many drugs that block DAT or SERT produce a number of undesirable side effects, there is a
need to investigate novel alternative or adjunctive drug therapies, such as modulators of the
endogenous opioid system, to aid in the treatment of effort-related symptoms.
The purpose of these studies was to investigate the function of the KOR in effort-related
aspects of motivation. Initial experiments sought to determine if a novel KOR antagonist
(BlackThorn Therapeutics) can reverse impairments in effort-related choice behavior induced by
the dopamine (DA) storage blocker tetrabenazine and the DA D2 receptor antagonist/5-HT2A
receptor inverse agonist risperidone. Additional experiments investigated the effects of the
benzodiazepine inverse agonist FG-7142 on effort-based choice as a comparison to the effects
induced by DA depletion or antagonism. Finally, the ability of the KOR antagonist to reverse the
effects of FG-7142 was assessed.

3.2 Materials and Methods
Animals
Adult male, drug-naïve, Sprague Dawley rats (Envigo, Indianapolis, IN, USA) were
housed in a colony maintained at 23 °C with 12-h light/dark cycles (lights on 07:00). Rats were
obtained weighing 275–299 g at the beginning of the study, and were initially food restricted to
85% of their free-feeding body weight for operant training. Rats were fed supplemental chow to
maintain weight throughout the study, with water available ad libitum. Rats were allowed modest
weight gain throughout the experiment. Animal protocols were approved by the University of
Connecticut Animal Care and Use Committee, and followed NIH guidelines.

Behavioral and Pharmacological Methods
Behavioral sessions were conducted in operant chambers (28 x 23 x 23 cm; Med
Associates, Fairfax, VT). Sessions lasted 30 minutes a day for 5 days/week. First, rats were
trained to lever press on a continuous reinforcement schedule to receive 45 mg highcarbohydrate pellets (Bio-Serv; Frenchtown, NJ, USA) for one week, then were shifted to the
FR5 schedule. After 5 weeks of FR5 training, chow was introduced. During each FR5/chow
feeding choice task session, 15-20 g of lab chow (Laboratory Diet, 5P00 Prolab RMH 3000,
Purina Mills, St. Louis, MO) was concurrently available on the floor of the chamber. Rats were
trained on this FR5/chow feeding choice procedure for 5 weeks, after which drug testing began.
On baseline and drug treatment days, rats consumed all of the operant pellets that were delivered
during each session.
All experiments used a within-groups (i.e., repeated measures) design. Thus, once
animals were trained for a given experiment, all animals received all treatment combinations in a
randomly varied order. During the drug treatment phase, rats were run 5 days per week, with 4
days being baseline (drug-free) days, and one day per week (either Thursday or Friday) being the
drug treatment day. Three of the studies listed below (Experiments 1, 2, and 4) are drug reversal
studies, in which one drug is given to induce a behavioral impairment (1.0 mg/kg IP
tetrabenazine 120 min before testing, 0.5 mg/kg IP risperidone 30 min before testing, and 6.0
mg/kg IP FG-7142 30 min before testing). Animals also received a second injection of various
doses of vehicle or the KOR antagonist (3.0, 10.0, or 30.0 mg/kg P.O. 120 min before testing) to
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attempt to reverse the effects of the first drug. Each study would typically involve 5 combined
drug treatments (e.g. vehicle/vehicle, tetrabenazine/vehicle, and tetrabenazine plus 3 doses of
KOR antagonist). Experiment 3 was conducted to establish a dose/response curve for the FG7142, in which animals were administered vehicle or one dose of FG-7142 (2.0, 4.0, 6.0, or 8.0
mg/kg) in a randomly varied order over the course of five weeks.

List of Drug Experiments:
1. Effect of KOR antagonist on the effort-related effects of tetrabenazine.
2. Effect of KOR antagonist on the effort-related effects of risperidone.
3. Effect of FG-7142 on effort-related choice.
4. Reversal of the effort-related effects of the benzodiazepine inverse agonist FG-7142 by KOR
antagonist.

Data Analyses
Repeated measures analysis of variance (ANOVA) was used to determine the effect of
drug treatment on lever pressing and chow intake in the behavioral pharmacology experiments.
To determine if there were significant reversal effects, nonorthogonal planned comparisons were
performed, using the overall error term to assess differences between each treatment and the
control condition. The number of comparisons was restricted to the number of treatments minus
one (Keppel, 1991).

3.3 Results
1. Effect of KOR antagonist on the effort-related effects of tetrabenazine. A series of
experiments were conducted to investigate the effects of a recently synthesized KOR antagonist
(BlackThorn Therapeutics) on the effort-related impairments induced by various
pharmacological challenges. The first experiment sought to assess the effects of the KOR
antagonist on tetrabenazine-induced changes in performance on the concurrent FR5 lever
pressing/chow feeding choice task. Repeated measures ANOVA demonstrated a significant
overall main effect of treatment on lever pressing [F(4,56)=48.295, p<0.001] (Fig. 1A) and on
chow intake [F(4,56)=21.927, p<0.001] (Fig. 1B). Planned comparisons indicated that
tetrabenazine (1.0 mg/kg) significantly reduced lever pressing (p<0.001; Fig. 1A), and
significantly increased chow intake (Fig. 1B) compared to the vehicle condition. There was no
significant reversal of lever pressing when the KOR antagonist was co-administered at any dose,
though chow intake at the two highest doses was significantly lower than tetrabenazine alone.
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Figure 1. The effects of the KOR antagonist (BT) on tetrabenazine-induced changes in
performance on the concurrent FR5 lever pressing/chow feeding choice procedure. Rats (n=15)
were injected with vehicle or tetrabenazine (1.0 mg/kg IP) and vehicle or one of three doses of
the KOR antagonist (3.0, 10.0, or 30.0 mg/kg P.O.). (A) Tetrabenazine significantly reduced
lever pressing (#p<0.001) from vehicle. The KOR antagonist BT did not reverse the lever
pressing impairment at any dose. (B) Tetrabenazine plus vehicle significantly increased chow
intake compared to vehicle (#p<0.001). Planned comparisons indicated that when coadministered, the KOR antagonist BT significantly reduced chow intake from tetrabenazine plus
vehicle at 10.0 mg/kg (*p<0.05) and 30.0 mg/kg (**p<0.001).
2. Effect of KOR antagonist on the effort-related effects of risperidone. Figure 2 shows
the effects of the KOR antagonist on risperidone-induced changes in performance on the
concurrent FR5 lever pressing/chow feeding choice procedure. Repeated measures ANOVA
revealed a significant overall main effect of treatment on lever pressing [F(4,60)=27.824,
p<0.001] (Fig. 2A) and chow intake [F(4,60)=17.350, p<0.001] (Fig. 2B). Planned comparisons
were performed and showed that risperidone (0.5 mg/kg) significantly reduced lever pressing
(p<0.001) and increased chow intake (p<0.001) compared to vehicle. There was no significant
reversal of the risperidone-induced effort-related effects on lever pressing or chow intake by the
KOR antagonist at any dose, although there was a trend towards a reversal at 10.0 mg/kg. BT did
produce a dose-related reduction in chow intake relative to tetrabenazine alone.

158

A

B

Figure 2. The effects of the KOR antagonist (BT) on risperidone-induced changes in
performance on the concurrent FR5 lever pressing/chow feeding choice procedure. Rats (n=16)
were injected with vehicle or risperidone (0.5 mg/kg IP) and vehicle or one of three doses of the
KOR antagonist (3.0, 10.0, or 30.0 mg/kg P.O.). (A) Risperidone significantly reduced lever
pressing (#p<0.001) from vehicle. The KOR antagonist BT did not significantly reverse the lever
pressing impairment at any dose, however, co-administration of 10.0 mg/kg BT and risperidone
approached significance (†0.05<p<0.1). (B) Tetrabenazine plus vehicle significantly increased
chow intake compared to vehicle (#p<0.001). Planned comparisons indicated that when coadministered, the KOR antagonist BT significantly reduced chow intake from tetrabenazine plus
vehicle at 10.0 mg/kg (*p<0.05) and 30.0 mg/kg (**p<0.001).

3. Effect of FG-7142 on effort-related choice. The benzodiazepine inverse agonist FG7142 was assessed for its effects on the FR5/chow feeding choice procedure (Fig. 3). Repeated
measures ANOVA demonstrated a statistically significant overall effect of treatment on lever
pressing [F(4,60)=80.872, p<0.001] (Fig. 3A). Planned comparisons revealed a significant
reduction in lever presses compared to vehicle at all four doses of FG-7142 (2.0-8.0 mg/kg)
(p<0.001). Repeated measures ANOVA was also used to assess the effect of FG-7142 on chow
intake. Treatment with FG-7142 produced an overall significant effect on chow intake
[F(4,60)=2.544, p<0.05]. (Fig. 3B).
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Figure 3. The effects of the benzodiazepine inverse agonist FG-7142 on effort-related choice
behavior in rats. Rats (n=16) were injected with vehicle or FG-7142 (2.0-8.0 mg/kg IP) prior to
performing on the concurrent FR5 lever pressing/chow feeding choice procedure. (A) FG-7142
significantly reduced lever pressing (*p<0.001) from vehicle at all four doses. (B) FG-7142
produced a significant overall effect on chow intake (p<0.05). Treatment with 2.0 mg/kg and 8.0
mg/kg significantly increased chow intake relative to vehicle (**p<0.01, *p<0.05).

4. Reversal of the effort-related effects of the benzodiazepine inverse agonist FG-7142 by
KOR antagonist. In the fourth experiment, the KOR antagonist was assessed for its ability to
reverse the effort-related performance effects of the benzodiazepine inverse agonist FG-7142 in
rats performing on the FR5/chow task (Fig. 4). Repeated measures ANOVA revealed a
significant overall effect of treatment on lever pressing [F(4,60)=43.362, p<0.001] (Fig. 4A). A
significant reduction in lever presses was produced by co-administration of 6.0 mg/kg FG-7142
plus vehicle, compared to the vehicle plus vehicle condition. None of the three doses of the KOR
antagonist were able to significantly reverse the FG-7142-induced suppression of lever presses.
Drug treatment did not have a significant overall effect on chow intake (Fig. 4B).
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Figure 4. Effects of the KOR antagonist (BT) on FG-7142-induced changes in performance on
the concurrent FR5 lever pressing/chow feeding choice procedure. Rats (n=16) were injected
with vehicle or FG-7142 (6.0 mg/kg IP) and vehicle or one of three doses of the KOR antagonist
(3.0, 10.0, or 30.0 mg/kg P.O.). (A) FG-7142 significantly reduced lever pressing (#p<0.001)
from vehicle. The KOR antagonist BT did not significantly reverse the lever pressing impairment
at any dose (p=n.s.). (B) Drug treatment did not have an overall effect on chow intake (p=n.s.).

3.4 Discussion
The concurrent FR5/chow feeding choice task was useful for assessing the ability of the
novel KOR antagonist to reverse the effects of the DA depleting agent tetrabenazine, the DA
D2/5-HT2A inverse agonist risperidone, and the benzodiazepine inverse agonist FG-7142. In
order to assess the effect of the KOR BT on FG-7142, it also was necessary to determine if FG7142 induced effort-related effects in rats performing on this task. In summary, the KOR
antagonist was unable to reverse the suppression in lever pressing caused by tetrabenazine,
risperidone, although it did reverse the increase in chow intake produced by these drugs. BT also
failed to reverse the suppression of lever pressing induced by FG-7142. These data suggest that
the KOR antagonist is not an effective treatment of effort-related dysfunction when administered
on its own as measured by the FR5/chow feeding choice task. Nevertheless, it is possible that it
could be tested in the future as a potential adjunct therapy in combination with dopaminergic
compounds. Furthermore, previous research has demonstrated that the effects of other KOR
antagonists can take up to hours or days (Guerrero et al. 2019), so it is possible that the time
course of this more recently synthesized compound may need to be further elucidated in in vivo
behavioral experiments.
The third experiment provided the first examination of the effects of FG-7142 using a
task that assesses effort-based choice. FG-7142 is a benzodiazepine inverse agonist that acts as
an anxiogenic drug and produces signs of the stress response. Preclinical studies of the role of
stressors in modulating aspects of motivational performance are important, because stress is
generally seen as a factor in several psychopathologies. Previous research has shown that
restraint stress or administration of the stress-related hormones corticosterone or corticotropin161

releasing hormone can produce a low effort bias in tests of effort-based choice (Shafiei et al.
2012; Bryce and Floresco, 2016; Dieterich et al. 2020). In the present studies, FG-7142
substantially decreased lever pressing, but did not significantly increase chow intake in the dose
range tested. Nevertheless, and examination of the dose response curve for FG-7142 indicates
that the lowest dose (2.0 mg/kg) produced a substantial reduction in lever pressing, and at that
dose there was a tendency for most rats to show an increase in chow intake. Thus, future research
should explore the possibility that low doses in the range of 1.0-3.0 mg/kg would in fact produce
a significant shift from lever pressing to chow intake.
Taken together, these experiments provide critical preclinical research that address the
feasibility of using KOR antagonists to improve effort-related aspects of motivation in people
with depression, Parkinson’s disease, or schizophrenia.
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